diff --git "a/test_predictions.txt" "b/test_predictions.txt"
new file mode 100644--- /dev/null
+++ "b/test_predictions.txt"
@@ -0,0 +1,32304 @@
+A O
+novel O
+SCN5A O
+mutation O
+manifests O
+as O
+a O
+malignant O
+form O
+of O
+long O
+QT O
+syndrome O
+with O
+perinatal O
+onset O
+of O
+tachycardia O
+/ O
+bradycardia O
+. O
+
+OBJECTIVE O
+: O
+Congenital O
+long O
+QT O
+syndrome O
+( O
+LQTS O
+) O
+with O
+in O
+utero O
+onset O
+of O
+the O
+rhythm O
+disturbances O
+is O
+associated O
+with O
+a O
+poor O
+prognosis O
+. O
+
+In O
+this O
+study O
+we O
+investigated O
+a O
+newborn O
+patient O
+with O
+fetal O
+bradycardia O
+, O
+2 O
+: O
+1 O
+atrioventricular O
+block O
+and O
+ventricular O
+tachycardia O
+soon O
+after O
+birth O
+. O
+
+METHODS O
+: O
+Mutational O
+analysis O
+and O
+DNA O
+sequencing O
+were O
+conducted O
+in O
+a O
+newborn O
+. O
+
+The O
+2 O
+: O
+1 O
+atrioventricular O
+block O
+improved O
+to O
+1 O
+: O
+1 O
+conduction O
+only O
+after O
+intravenous O
+lidocaine B
+infusion O
+or O
+a O
+high O
+dose O
+of O
+mexiletine B
+, O
+which O
+also O
+controlled O
+the O
+ventricular O
+tachycardia O
+. O
+
+RESULTS O
+: O
+A O
+novel O
+, O
+spontaneous O
+LQTS O
+- O
+3 O
+mutation O
+was O
+identified O
+in O
+the O
+transmembrane O
+segment O
+6 O
+of O
+domain O
+IV O
+of O
+the O
+Na O
+( O
+v O
+) O
+1 O
+. O
+5 O
+cardiac O
+sodium O
+channel O
+, O
+with O
+a O
+G O
+--> O
+A O
+substitution O
+at O
+codon O
+1763 O
+, O
+which O
+changed O
+a O
+valine O
+( O
+GTG O
+) O
+to O
+a O
+methionine O
+( O
+ATG O
+). O
+
+The O
+proband O
+was O
+heterozygous O
+but O
+the O
+mutation O
+was O
+absent O
+in O
+the O
+parents O
+and O
+the O
+sister O
+. O
+
+Expression O
+of O
+this O
+mutant O
+channel O
+in O
+tsA201 O
+mammalian O
+cells O
+by O
+site O
+- O
+directed O
+mutagenesis O
+revealed O
+a O
+persistent O
+tetrodotoxin B
+- O
+sensitive O
+but O
+lidocaine B
+- O
+resistant O
+current O
+that O
+was O
+associated O
+with O
+a O
+positive O
+shift O
+of O
+the O
+steady O
+- O
+state O
+inactivation O
+curve O
+, O
+steeper O
+activation O
+curve O
+and O
+faster O
+recovery O
+from O
+inactivation O
+. O
+
+We O
+also O
+found O
+a O
+similar O
+electrophysiological O
+profile O
+for O
+the O
+neighboring O
+V1764M O
+mutant O
+. O
+
+But O
+, O
+the O
+other O
+neighboring O
+I1762A O
+mutant O
+had O
+no O
+persistent O
+current O
+and O
+was O
+still O
+associated O
+with O
+a O
+positive O
+shift O
+of O
+inactivation O
+. O
+
+CONCLUSIONS O
+: O
+These O
+findings O
+suggest O
+that O
+the O
+Na O
+( O
+v O
+) O
+1 O
+. O
+5 O
+/ O
+V1763M O
+channel O
+dysfunction O
+and O
+possible O
+neighboring O
+mutants O
+contribute O
+to O
+a O
+persistent O
+inward O
+current O
+due O
+to O
+altered O
+inactivation O
+kinetics O
+and O
+clinically O
+congenital O
+LQTS O
+with O
+perinatal O
+onset O
+of O
+arrhythmias O
+that O
+responded O
+to O
+lidocaine B
+and O
+mexiletine B
+. O
+
+
+Allelic O
+expression O
+imbalance O
+of O
+human O
+mu O
+opioid O
+receptor O
+( O
+OPRM1 O
+) O
+caused O
+by O
+variant O
+A118G O
+. O
+
+As O
+a O
+primary O
+target O
+for O
+opioid B
+drugs O
+and O
+peptides O
+, O
+the O
+mu O
+opioid O
+receptor O
+( O
+OPRM1 O
+) O
+plays O
+a O
+key O
+role O
+in O
+pain O
+perception O
+and O
+addiction O
+. O
+
+Genetic O
+variants O
+of O
+OPRM1 O
+have O
+been O
+implicated O
+in O
+predisposition O
+to O
+drug O
+addiction O
+, O
+in O
+particular O
+the O
+single O
+nucleotide O
+polymorphism O
+A118G O
+, O
+leading O
+to O
+an O
+N40D O
+substitution O
+, O
+with O
+an O
+allele O
+frequency O
+of O
+10 O
+- O
+32 O
+%, O
+and O
+uncertain O
+functions O
+. O
+
+We O
+have O
+measured O
+allele O
+- O
+specific O
+mRNA O
+expression O
+of O
+OPRM1 O
+in O
+human O
+autopsy O
+brain O
+tissues O
+, O
+using O
+A118G O
+as O
+a O
+marker O
+. O
+
+In O
+8 O
+heterozygous O
+samples O
+measured O
+, O
+the O
+A118 O
+mRNA O
+allele O
+was O
+1 O
+. O
+5 O
+- O
+2 O
+. O
+5 O
+- O
+fold O
+more O
+abundant O
+than O
+the O
+G118 O
+allele O
+. O
+
+Transfection O
+into O
+Chinese O
+hamster O
+ovary O
+cells O
+of O
+a O
+cDNA O
+representing O
+only O
+the O
+coding O
+region O
+of O
+OPRM1 O
+, O
+carrying O
+adenosine B
+, O
+guanosine O
+, O
+cytidine O
+, O
+and O
+thymidine O
+in O
+position O
+118 O
+, O
+resulted O
+in O
+1 O
+. O
+5 O
+- O
+fold O
+lower O
+mRNA O
+levels O
+only O
+for O
+OPRM1 O
+- O
+G118 O
+, O
+and O
+more O
+than O
+10 O
+- O
+fold O
+lower O
+OPRM1 O
+protein O
+levels O
+, O
+measured O
+by O
+Western O
+blotting O
+and O
+receptor O
+binding O
+assay O
+. O
+
+After O
+transfection O
+and O
+inhibition O
+of O
+transcription O
+with O
+actinomycin B
+D I
+, O
+analysis O
+of O
+mRNA O
+turnover O
+failed O
+to O
+reveal O
+differences O
+in O
+mRNA O
+stability O
+between O
+A118 O
+and O
+G118 O
+alleles O
+, O
+indicating O
+a O
+defect O
+in O
+transcription O
+or O
+mRNA O
+maturation O
+. O
+
+These O
+results O
+indicate O
+that O
+OPRM1 O
+- O
+G118 O
+is O
+a O
+functional O
+variant O
+with O
+deleterious O
+effects O
+on O
+both O
+mRNA O
+and O
+protein O
+yield O
+. O
+
+Clarifying O
+the O
+functional O
+relevance O
+of O
+polymorphisms O
+associated O
+with O
+susceptibility O
+to O
+a O
+complex O
+disorder O
+such O
+as O
+drug O
+addiction O
+provides O
+a O
+foundation O
+for O
+clinical O
+association O
+studies O
+. O
+
+
+Genetic O
+polymorphisms O
+in O
+the O
+carbonyl O
+reductase O
+3 O
+gene O
+CBR3 O
+and O
+the O
+NAD O
+( O
+P O
+) O
+H O
+: O
+quinone O
+oxidoreductase O
+1 O
+gene O
+NQO1 O
+in O
+patients O
+who O
+developed O
+anthracycline B
+- O
+related O
+congestive O
+heart O
+failure O
+after O
+childhood O
+cancer O
+. O
+
+BACKGROUND O
+: O
+Exposure O
+to O
+anthracyclines B
+as O
+part O
+of O
+cancer O
+therapy O
+has O
+been O
+associated O
+with O
+the O
+development O
+of O
+congestive O
+heart O
+failure O
+( O
+CHF O
+). O
+
+The O
+potential O
+role O
+of O
+genetic O
+risk O
+factors O
+in O
+anthracycline B
+- O
+related O
+CHF O
+remains O
+to O
+be O
+defined O
+. O
+
+Thus O
+, O
+in O
+this O
+study O
+, O
+the O
+authors O
+examined O
+whether O
+common O
+polymorphisms O
+in O
+candidate O
+genes O
+involved O
+in O
+the O
+pharmacodynamics O
+of O
+anthracyclines B
+( O
+in O
+particular O
+, O
+the O
+nicotinamide O
+adenine O
+dinucleotide O
+phosphate O
+: O
+quinone O
+oxidoreductase O
+1 O
+gene O
+NQO1 O
+and O
+the O
+carbonyl O
+reductase O
+3 O
+gene O
+CBR3 O
+) O
+had O
+an O
+impact O
+on O
+the O
+risk O
+of O
+anthracycline B
+- O
+related O
+CHF O
+. O
+
+METHODS O
+: O
+A O
+nested O
+case O
+- O
+control O
+study O
+was O
+conducted O
+within O
+a O
+cohort O
+of O
+1979 O
+patients O
+enrolled O
+in O
+the O
+Childhood O
+Cancer O
+Survivor O
+Study O
+who O
+received O
+treatment O
+with O
+anthracyclines B
+and O
+had O
+available O
+DNA O
+. O
+
+Thirty O
+patients O
+with O
+CHF O
+( O
+cases O
+) O
+and O
+115 O
+matched O
+controls O
+were O
+genotyped O
+for O
+polymorphisms O
+in O
+NQO1 O
+( O
+NQO1 O
+* O
+2 O
+) O
+and O
+CBR3 O
+( O
+the O
+CBR3 O
+valine O
+[ O
+V O
+] O
+to O
+methionine O
+[ O
+M O
+] O
+substitution O
+at O
+position O
+244 O
+[ O
+V244M O
+]). O
+
+Enzyme O
+activity O
+assays O
+with O
+recombinant O
+CBR3 O
+isoforms O
+( O
+CBR3 O
+V244 O
+and O
+CBR3 O
+M244 O
+) O
+and O
+the O
+anthracycline B
+substrate O
+doxorubicin B
+were O
+used O
+to O
+investigate O
+the O
+functional O
+impact O
+of O
+the O
+CBR3 O
+V244M O
+polymorphism O
+. O
+
+RESULTS O
+: O
+Multivariate O
+analyses O
+adjusted O
+for O
+sex O
+and O
+primary O
+disease O
+recurrence O
+were O
+used O
+to O
+test O
+for O
+associations O
+between O
+the O
+candidate O
+genetic O
+polymorphisms O
+( O
+NQO1 O
+* O
+2 O
+and O
+CBR3 O
+V244M O
+) O
+and O
+the O
+risk O
+of O
+CHF O
+. O
+
+Analyses O
+indicated O
+no O
+association O
+between O
+the O
+NQO1 O
+* O
+2 O
+polymorphism O
+and O
+the O
+risk O
+of O
+anthracycline B
+- O
+related O
+CHF O
+( O
+odds O
+ratio O
+[ O
+OR O
+], O
+1 O
+. O
+4 O
+; O
+P O
+=. O
+97 O
+). O
+
+There O
+was O
+a O
+trend O
+toward O
+an O
+association O
+between O
+the O
+CBR3 O
+V244M O
+polymorphism O
+and O
+the O
+risk O
+of O
+CHF O
+( O
+OR O
+, O
+8 O
+. O
+16 O
+; O
+P O
+=. O
+56 O
+for O
+G O
+/ O
+G O
+vs O
+A O
+/ O
+A O
+; O
+OR O
+, O
+5 O
+. O
+44 O
+; O
+P O
+=. O
+92 O
+for O
+G O
+/ O
+A O
+vs O
+A O
+/ O
+A O
+). O
+
+In O
+line O
+, O
+recombinant O
+CBR3 O
+V244 O
+( O
+G O
+allele O
+) O
+synthesized O
+2 O
+. O
+6 O
+- O
+fold O
+more O
+cardiotoxic O
+doxorubicinol B
+per O
+unit O
+of O
+time O
+than O
+CBR3 O
+M244 O
+( O
+A O
+allele O
+; O
+CBR3 O
+V244 O
+[ O
+8 O
+. O
+26 O
++/- O
+3 O
+. O
+57 O
+nmol O
+/ O
+hour O
+. O
+mg O
+] O
+vs O
+CBR3 O
+M244 O
+[ O
+3 O
+. O
+22 O
++/- O
+0 O
+. O
+67 O
+nmol O
+/ O
+hour O
+. O
+mg O
+]; O
+P O
+=. O
+1 O
+). O
+
+CONCLUSIONS O
+: O
+The O
+functional O
+CBR3 O
+V244M O
+polymorphism O
+may O
+have O
+an O
+impact O
+on O
+the O
+risk O
+of O
+anthracycline B
+- O
+related O
+CHF O
+among O
+childhood O
+cancer O
+survivors O
+by O
+modulating O
+the O
+intracardiac O
+formation O
+of O
+cardiotoxic O
+anthracycline B
+alcohol I
+metabolites O
+. O
+
+Larger O
+confirmatory O
+case O
+- O
+control O
+studies O
+are O
+warranted O
+. O
+
+
+Debrisoquine B
+phenotype O
+and O
+the O
+pharmacokinetics O
+and O
+beta O
+- O
+2 O
+receptor O
+pharmacodynamics O
+of O
+metoprolol B
+and O
+its O
+enantiomers O
+. O
+
+The O
+metabolism O
+of O
+the O
+cardioselective O
+beta O
+- O
+blocker O
+metoprolol B
+is O
+under O
+genetic O
+control O
+of O
+the O
+debrisoquine B
+/ O
+sparteine B
+type O
+. O
+
+The O
+two O
+metabolic O
+phenotypes O
+, O
+extensive O
+( O
+EM O
+) O
+and O
+poor O
+metabolizers O
+( O
+PM O
+), O
+show O
+different O
+stereoselective O
+metabolism O
+, O
+resulting O
+in O
+apparently O
+higher O
+beta O
+- O
+1 O
+adrenoceptor O
+antagonistic O
+potency O
+of O
+racemic O
+metoprolol B
+in O
+EMs O
+. O
+
+We O
+investigated O
+if O
+the O
+latter O
+also O
+applies O
+to O
+the O
+beta O
+- O
+2 O
+adrenoceptor O
+antagonism O
+by O
+metoprolol B
+. O
+
+The O
+drug O
+effect O
+studied O
+was O
+the O
+antagonism O
+by O
+metoprolol B
+of O
+terbutaline B
+- O
+induced O
+hypokalemia O
+. O
+
+By O
+using O
+pharmacokinetic O
+pharmacodynamic O
+modeling O
+the O
+pharmacodynamics O
+of O
+racemic O
+metoprolol B
+and O
+the O
+active O
+S O
+- O
+isomer O
+, O
+were O
+quantitated O
+in O
+EMs O
+and O
+PMs O
+in O
+terms O
+of O
+IC50 O
+values O
+, O
+representing O
+metoprolol B
+plasma O
+concentrations O
+resulting O
+in O
+half O
+- O
+maximum O
+receptor O
+occupancy O
+. O
+
+Six O
+EMs O
+received O
+0 O
+. O
+5 O
+mg O
+of O
+terbutaline B
+s O
+. O
+c O
+. O
+
+on O
+two O
+different O
+occasions O
+: O
+1 O
+) O
+1 O
+hr O
+after O
+administration O
+of O
+a O
+placebo O
+and O
+2 O
+) O
+1 O
+hr O
+after O
+150 O
+mg O
+of O
+metoprolol B
+p O
+. O
+o O
+. O
+
+Five O
+PMs O
+were O
+studied O
+according O
+to O
+the O
+same O
+protocol O
+, O
+except O
+for O
+a O
+higher O
+terbutaline B
+dose O
+( O
+0 O
+. O
+75 O
+mg O
+) O
+on O
+day O
+2 O
+. O
+
+Blood O
+samples O
+for O
+the O
+analysis O
+of O
+plasma O
+potassium B
+, O
+terbutaline B
+, O
+metoprolol B
+( O
+racemic O
+, O
+R O
+- O
+and O
+S O
+- O
+isomer O
+), O
+and O
+alpha O
+- O
+hydroxymetoprolol O
+concentrations O
+were O
+taken O
+at O
+regular O
+time O
+intervals O
+, O
+during O
+8 O
+hr O
+after O
+metoprolol B
+. O
+
+In O
+PMs O
+, O
+metoprolol B
+increased O
+the O
+terbutaline B
+area O
+under O
+the O
+plasma O
+concentration O
+vs O
+. O
+
+time O
+curve O
+(+ O
+67 O
+%). O
+
+Higher O
+metoprolol B
+/ O
+alpha B
+- I
+hydroxymetoprolol I
+ratios O
+in O
+PMs O
+were O
+predictive O
+for O
+higher O
+R O
+-/ O
+S O
+- O
+isomer O
+ratios O
+of O
+unchanged O
+drug O
+. O
+
+There O
+was O
+a O
+difference O
+in O
+metoprolol B
+potency O
+with O
+higher O
+racemic O
+metoprolol B
+IC50 O
+values O
+in O
+PMs O
+( O
+72 O
++/- O
+7 O
+ng O
+. O
+ml O
+- O
+1 O
+) O
+than O
+EMs O
+( O
+42 O
++/- O
+8 O
+ng O
+. O
+ml O
+- O
+1 O
+, O
+P O
+less O
+than O
+. O
+1 O
+). O
+
+( O
+ABSTRACT O
+TRUNCATED O
+AT O
+250 O
+WORDS O
+) O
+
+
+The O
+first O
+founder O
+DGUOK O
+mutation O
+associated O
+with O
+hepatocerebral O
+mitochondrial O
+DNA O
+depletion O
+syndrome O
+. O
+
+Deoxyguanosine O
+kinase O
+( O
+dGK O
+) O
+deficiency O
+is O
+a O
+frequent O
+cause O
+of O
+mitochondrial O
+DNA O
+depletion O
+associated O
+with O
+a O
+hepatocerebral O
+phenotype O
+. O
+
+In O
+this O
+study O
+, O
+we O
+describe O
+a O
+new O
+splice O
+site O
+mutation O
+in O
+the O
+DGUOK O
+gene O
+and O
+the O
+clinical O
+, O
+radiologic O
+, O
+and O
+genetic O
+features O
+of O
+these O
+DGUOK O
+patients O
+. O
+
+This O
+new O
+DGUOK O
+homozygous O
+mutation O
+( O
+c O
+. O
+444 O
+- O
+62C O
+> O
+A O
+) O
+was O
+identified O
+in O
+three O
+patients O
+from O
+two O
+North O
+- O
+African O
+consanguineous O
+families O
+with O
+combined O
+respiratory O
+chain O
+deficiencies O
+and O
+mitochondrial O
+DNA O
+depletion O
+in O
+the O
+liver O
+. O
+
+Brain O
+MRIs O
+are O
+normal O
+in O
+DGUOK O
+patients O
+in O
+the O
+literature O
+. O
+
+Interestingly O
+, O
+we O
+found O
+subtentorial O
+abnormal O
+myelination O
+and O
+moderate O
+hyperintensity O
+in O
+the O
+bilateral O
+pallidi O
+in O
+our O
+patients O
+. O
+
+This O
+new O
+mutation O
+creates O
+a O
+cryptic O
+splice O
+site O
+in O
+intron O
+3 O
+( O
+in O
+position O
+- O
+62 O
+) O
+and O
+is O
+predicted O
+to O
+result O
+in O
+a O
+larger O
+protein O
+with O
+an O
+in O
+- O
+frame O
+insertion O
+of O
+20 O
+amino O
+acids O
+. O
+
+In O
+silico O
+analysis O
+of O
+the O
+putative O
+impact O
+of O
+the O
+insertion O
+shows O
+serious O
+clashes O
+in O
+protein O
+conformation O
+: O
+this O
+insertion O
+disrupts O
+the O
+alpha5 O
+helix O
+of O
+the O
+dGK O
+kinase O
+domain O
+, O
+rendering O
+the O
+protein O
+unable O
+to O
+bind O
+purine O
+deoxyribonucleosides B
+. O
+
+In O
+addition O
+, O
+a O
+common O
+haplotype O
+that O
+segregated O
+with O
+the O
+disease O
+in O
+both O
+families O
+was O
+detected O
+by O
+haplotype O
+reconstruction O
+with O
+10 O
+markers O
+( O
+microsatellites O
+and O
+SNPs O
+), O
+which O
+span O
+4 O
+. O
+6 O
+Mb O
+of O
+DNA O
+covering O
+the O
+DGUOK O
+locus O
+. O
+
+In O
+conclusion O
+, O
+we O
+report O
+a O
+new O
+DGUOK O
+splice O
+site O
+mutation O
+that O
+provide O
+insight O
+into O
+a O
+critical O
+protein O
+domain O
+( O
+dGK O
+kinase O
+domain O
+) O
+and O
+the O
+first O
+founder O
+mutation O
+in O
+a O
+North O
+- O
+African O
+population O
+. O
+
+
+Adenosine O
+A O
+( O
+2A O
+) O
+receptor O
+gene O
+( O
+ADORA2A O
+) O
+variants O
+may O
+increase O
+autistic O
+symptoms O
+and O
+anxiety O
+in O
+autism O
+spectrum O
+disorder O
+. O
+
+Autism O
+spectrum O
+disorders O
+( O
+ASDs O
+) O
+are O
+heterogeneous O
+disorders O
+presenting O
+with O
+increased O
+rates O
+of O
+anxiety O
+. O
+
+The O
+adenosine O
+A O
+( O
+2A O
+) O
+receptor O
+gene O
+( O
+ADORA2A O
+) O
+is O
+associated O
+with O
+panic O
+disorder O
+and O
+is O
+located O
+on O
+chromosome O
+22q11 O
+. O
+23 O
+. O
+
+Its O
+gene O
+product O
+, O
+the O
+adenosine O
+A O
+( O
+2A O
+) O
+receptor O
+, O
+is O
+strongly O
+expressed O
+in O
+the O
+caudate O
+nucleus O
+, O
+which O
+also O
+is O
+involved O
+in O
+ASD O
+. O
+
+As O
+autistic O
+symptoms O
+are O
+increased O
+in O
+individuals O
+with O
+22q11 O
+. O
+2 O
+deletion O
+syndrome O
+, O
+and O
+large O
+22q11 O
+. O
+2 O
+deletions O
+and O
+duplications O
+have O
+been O
+observed O
+in O
+ASD O
+individuals O
+, O
+in O
+this O
+study O
+, O
+98 O
+individuals O
+with O
+ASD O
+and O
+234 O
+control O
+individuals O
+were O
+genotyped O
+for O
+eight O
+single O
+- O
+nucleotide O
+polymorphisms O
+in O
+ADORA2A O
+. O
+
+Nominal O
+association O
+with O
+the O
+disorder O
+was O
+observed O
+for O
+rs2236624 O
+- O
+CC O
+, O
+and O
+phenotypic O
+variability O
+in O
+ASD O
+symptoms O
+was O
+influenced O
+by O
+rs3761422 O
+, O
+rs5751876 O
+and O
+rs35320474 O
+. O
+
+In O
+addition O
+, O
+association O
+of O
+ADORA2A O
+variants O
+with O
+anxiety O
+was O
+replicated O
+for O
+individuals O
+with O
+ASD O
+. O
+
+Findings O
+point O
+toward O
+a O
+possible O
+mediating O
+role O
+of O
+ADORA2A O
+variants O
+on O
+phenotypic O
+expression O
+in O
+ASD O
+that O
+need O
+to O
+be O
+replicated O
+in O
+a O
+larger O
+sample O
+. O
+
+
+High O
+frequency O
+of O
+lamivudine B
+resistance O
+mutations O
+in O
+Brazilian O
+patients O
+co O
+- O
+infected O
+with O
+HIV O
+and O
+hepatitis O
+B O
+. O
+
+This O
+study O
+analyzed O
+the O
+genotype O
+distribution O
+and O
+frequency O
+of O
+lamivudine B
+( O
+LAM B
+) O
+and O
+tenofovir B
+( O
+TDF O
+) O
+resistance O
+mutations O
+in O
+a O
+group O
+of O
+patients O
+co O
+- O
+infected O
+with O
+HIV O
+and O
+hepatitis O
+B O
+virus O
+( O
+HBV O
+). O
+
+A O
+cross O
+- O
+sectional O
+study O
+of O
+847 O
+patients O
+with O
+HIV O
+was O
+conducted O
+. O
+
+Patients O
+provided O
+blood O
+samples O
+for O
+HBsAg B
+detection O
+. O
+
+The O
+load O
+of O
+HBV O
+was O
+determined O
+using O
+an O
+in O
+- O
+house O
+real O
+- O
+time O
+polymerase O
+chain O
+reaction O
+. O
+
+HBV O
+genotypes O
+/ O
+subgenotypes O
+, O
+antiviral O
+resistance O
+, O
+basal O
+core O
+promoter O
+( O
+BCP O
+), O
+and O
+precore O
+mutations O
+were O
+detected O
+by O
+DNA O
+sequencing O
+. O
+
+Twenty O
+- O
+eight O
+patients O
+with O
+co O
+- O
+infection O
+were O
+identified O
+. O
+
+The O
+distribution O
+of O
+HBV O
+genotypes O
+among O
+these O
+patients O
+was O
+A O
+( O
+n O
+= O
+9 O
+; O
+50 O
+%), O
+D O
+( O
+n O
+= O
+4 O
+; O
+22 O
+. O
+2 O
+%), O
+G O
+( O
+n O
+= O
+3 O
+; O
+16 O
+. O
+7 O
+%), O
+and O
+F O
+( O
+n O
+= O
+2 O
+; O
+11 O
+. O
+1 O
+%). O
+
+Eighteen O
+patients O
+were O
+treated O
+with O
+LAM B
+and O
+six O
+patients O
+were O
+treated O
+with O
+LAM B
+plus O
+TDF O
+. O
+
+The O
+length O
+of O
+exposure O
+to O
+LAM B
+and O
+TDF O
+varied O
+from O
+4 O
+to O
+216 O
+months O
+. O
+
+LAM B
+resistance O
+substitutions O
+( O
+rtL180M O
++ O
+rtM204V O
+) O
+were O
+detected O
+in O
+10 O
+( O
+50 O
+%) O
+of O
+the O
+20 O
+patients O
+with O
+viremia O
+. O
+
+This O
+pattern O
+and O
+an O
+accompanying O
+rtV173L O
+mutation O
+was O
+found O
+in O
+four O
+patients O
+. O
+
+Three O
+patients O
+with O
+the O
+triple O
+polymerase O
+substitution O
+pattern O
+( O
+rtV173L O
++ O
+rtL180M O
++ O
+rtM204V O
+) O
+had O
+associated O
+changes O
+in O
+the O
+envelope O
+gene O
+( O
+sE164D O
++ O
+sI195M O
+). O
+
+Mutations O
+in O
+the O
+BCP O
+region O
+( O
+A1762T O
+, O
+G1764A O
+) O
+and O
+in O
+the O
+precore O
+region O
+( O
+G1896A O
+, O
+G1899A O
+) O
+were O
+also O
+found O
+. O
+
+No O
+putative O
+TDF O
+resistance O
+substitution O
+was O
+detected O
+. O
+
+The O
+data O
+suggest O
+that O
+prolonged O
+LAM B
+use O
+is O
+associated O
+with O
+the O
+emergence O
+of O
+particular O
+changes O
+in O
+the O
+HBV O
+genome O
+, O
+including O
+substitutions O
+that O
+may O
+elicit O
+a O
+vaccine O
+escape O
+phenotype O
+. O
+
+No O
+putative O
+TDF O
+resistance O
+change O
+was O
+detected O
+after O
+prolonged O
+use O
+of O
+TDF O
+. O
+
+
+Identification O
+of O
+a O
+novel O
+FBN1 O
+gene O
+mutation O
+in O
+a O
+Chinese O
+family O
+with O
+Marfan O
+syndrome O
+. O
+
+PURPOSE O
+: O
+To O
+identify O
+the O
+mutation O
+in O
+the O
+fibrillin O
+- O
+1 O
+gene O
+( O
+FBN1 O
+) O
+in O
+a O
+Chinese O
+family O
+with O
+Marfan O
+syndrome O
+( O
+MFS O
+). O
+
+METHODS O
+: O
+Patients O
+and O
+family O
+members O
+were O
+given O
+complete O
+physical O
+, O
+ophthalmic O
+, O
+and O
+cardiovascular O
+examinations O
+. O
+
+Genomic O
+DNA O
+was O
+extracted O
+from O
+leukocytes O
+of O
+venous O
+blood O
+of O
+six O
+individuals O
+in O
+the O
+family O
+and O
+170 O
+healthy O
+Chinese O
+individuals O
+. O
+
+All O
+of O
+the O
+65 O
+coding O
+exons O
+and O
+their O
+flanking O
+intronic O
+boundaries O
+of O
+FBN1 O
+were O
+amplified O
+in O
+the O
+proband O
+by O
+polymerase O
+chain O
+reaction O
+and O
+followed O
+by O
+direct O
+sequencing O
+. O
+
+The O
+mutation O
+identified O
+in O
+the O
+proband O
+was O
+screened O
+in O
+the O
+other O
+family O
+members O
+and O
+the O
+170 O
+healthy O
+Chinese O
+individuals O
+by O
+direct O
+sequencing O
+. O
+
+Protein O
+conservation O
+analysis O
+was O
+performed O
+in O
+six O
+species O
+using O
+an O
+online O
+ClustalW O
+tool O
+. O
+
+Protein O
+structure O
+was O
+modeled O
+based O
+on O
+the O
+Protein O
+data O
+bank O
+and O
+mutated O
+in O
+DeepView O
+v4 O
+. O
+0 O
+. O
+1 O
+to O
+predict O
+the O
+functional O
+consequences O
+of O
+the O
+mutation O
+. O
+
+RESULTS O
+: O
+A O
+novel O
+heterozygous O
+c O
+. O
+3703T O
+> O
+C O
+change O
+in O
+exon O
+29 O
+of O
+FBN1 O
+was O
+detected O
+in O
+the O
+proband O
+, O
+which O
+resulted O
+in O
+the O
+substitution O
+of O
+serine O
+by O
+proline O
+at O
+codon O
+1235 O
+( O
+p O
+. O
+S1235P O
+). O
+
+This O
+mutation O
+was O
+also O
+present O
+in O
+two O
+family O
+members O
+but O
+absent O
+in O
+the O
+other O
+, O
+unaffected O
+family O
+members O
+and O
+the O
+170 O
+healthy O
+Chinese O
+individuals O
+. O
+
+The O
+mutant O
+residue O
+located O
+in O
+the O
+calcium B
+binding O
+epidermal O
+growth O
+factor O
+- O
+like O
+# O
+15 O
+domain O
+is O
+highly O
+conserved O
+among O
+mammalian O
+species O
+and O
+could O
+probably O
+induce O
+conformation O
+change O
+of O
+the O
+domain O
+. O
+
+CONCLUSIONS O
+: O
+We O
+indentified O
+a O
+novel O
+p O
+. O
+S1235P O
+mutation O
+in O
+FBN1 O
+, O
+which O
+is O
+the O
+causative O
+mutation O
+for O
+MFS O
+in O
+this O
+family O
+. O
+
+Our O
+result O
+expands O
+the O
+mutation O
+spectrum O
+of O
+FBN1 O
+and O
+contributes O
+to O
+the O
+study O
+of O
+the O
+molecular O
+pathogenesis O
+of O
+Marfan O
+syndrome O
+. O
+
+
+Molecular O
+and O
+phenotypic O
+analysis O
+of O
+patients O
+with O
+deletions O
+within O
+the O
+deletion O
+- O
+rich O
+region O
+of O
+the O
+Duchenne O
+muscular O
+dystrophy O
+( O
+DMD O
+) O
+gene O
+. O
+
+Eighty O
+unrelated O
+individuals O
+with O
+Duchenne O
+muscular O
+dystrophy O
+( O
+DMD O
+) O
+or O
+Becker O
+muscular O
+dystrophy O
+( O
+BMD O
+) O
+were O
+found O
+to O
+have O
+deletions O
+in O
+the O
+major O
+deletion O
+- O
+rich O
+region O
+of O
+the O
+DMD O
+locus O
+. O
+
+This O
+region O
+includes O
+the O
+last O
+five O
+exons O
+detected O
+by O
+cDNA5b O
+- O
+7 O
+, O
+all O
+exons O
+detected O
+by O
+cDNA8 O
+, O
+and O
+the O
+first O
+two O
+exons O
+detected O
+by O
+cDNA9 O
+. O
+
+These O
+80 O
+individuals O
+account O
+for O
+approximately O
+75 O
+% O
+of O
+109 O
+deletions O
+of O
+the O
+gene O
+, O
+detected O
+among O
+181 O
+patients O
+analyzed O
+with O
+the O
+entire O
+dystrophin O
+cDNA O
+. O
+
+Endpoints O
+for O
+many O
+of O
+these O
+deletions O
+were O
+further O
+characterized O
+using O
+two O
+genomic O
+probes O
+, O
+p20 O
+( O
+DXS269 O
+; O
+Wapenaar O
+et O
+al O
+.) O
+
+and O
+GMGX11 O
+( O
+DXS239 O
+; O
+present O
+paper O
+). O
+
+Clinical O
+findings O
+are O
+presented O
+for O
+all O
+80 O
+patients O
+allowing O
+a O
+correlation O
+of O
+phenotypic O
+severity O
+with O
+the O
+genotype O
+. O
+
+Thirty O
+- O
+eight O
+independent O
+patients O
+were O
+old O
+enough O
+to O
+be O
+classified O
+as O
+DMD O
+, O
+BMD O
+, O
+or O
+intermediate O
+phenotype O
+and O
+had O
+deletions O
+of O
+exons O
+with O
+sequenced O
+intron O
+/ O
+exon O
+boundaries O
+. O
+
+Of O
+these O
+, O
+eight O
+BMD O
+patients O
+and O
+one O
+intermediate O
+patient O
+had O
+gene O
+deletions O
+predicted O
+to O
+leave O
+the O
+reading O
+frame O
+intact O
+, O
+while O
+21 O
+DMD O
+patients O
+, O
+7 O
+intermediate O
+patients O
+, O
+and O
+1 O
+BMD O
+patient O
+had O
+gene O
+deletions O
+predicted O
+to O
+disrupt O
+the O
+reading O
+frame O
+. O
+
+Thus O
+, O
+with O
+two O
+exceptions O
+, O
+frameshift O
+deletions O
+of O
+the O
+gene O
+resulted O
+in O
+more O
+severe O
+phenotype O
+than O
+did O
+in O
+- O
+frame O
+deletions O
+. O
+
+This O
+is O
+in O
+agreement O
+with O
+recent O
+findings O
+by O
+Baumbach O
+et O
+al O
+. O
+
+and O
+Koenig O
+et O
+al O
+. O
+
+but O
+is O
+in O
+contrast O
+to O
+findings O
+, O
+by O
+Malhotra O
+et O
+al O
+. O
+
+at O
+the O
+5 O
+' O
+end O
+of O
+the O
+gene O
+. O
+
+
+Absence O
+of O
+PKC O
+- O
+alpha O
+attenuates O
+lithium B
+- O
+induced O
+nephrogenic O
+diabetes O
+insipidus O
+. O
+
+Lithium B
+, O
+an O
+effective O
+antipsychotic B
+, O
+induces O
+nephrogenic O
+diabetes O
+insipidus O
+( O
+NDI O
+) O
+in O
+40 O
+% O
+of O
+patients O
+. O
+
+The O
+decreased O
+capacity O
+to O
+concentrate O
+urine O
+is O
+likely O
+due O
+to O
+lithium B
+acutely O
+disrupting O
+the O
+cAMP B
+pathway O
+and O
+chronically O
+reducing O
+urea O
+transporter O
+( O
+UT O
+- O
+A1 O
+) O
+and O
+water O
+channel O
+( O
+AQP2 O
+) O
+expression O
+in O
+the O
+inner O
+medulla O
+. O
+
+Targeting O
+an O
+alternative O
+signaling O
+pathway O
+, O
+such O
+as O
+PKC O
+- O
+mediated O
+signaling O
+, O
+may O
+be O
+an O
+effective O
+method O
+of O
+treating O
+lithium B
+- O
+induced O
+polyuria O
+. O
+
+PKC O
+- O
+alpha O
+null O
+mice O
+( O
+PKCa O
+KO O
+) O
+and O
+strain O
+- O
+matched O
+wild O
+type O
+( O
+WT O
+) O
+controls O
+were O
+treated O
+with O
+lithium B
+for O
+0 O
+, O
+3 O
+or O
+5 O
+days O
+. O
+
+WT O
+mice O
+had O
+increased O
+urine O
+output O
+and O
+lowered O
+urine O
+osmolality O
+after O
+3 O
+and O
+5 O
+days O
+of O
+treatment O
+whereas O
+PKCa O
+KO O
+mice O
+had O
+no O
+change O
+in O
+urine O
+output O
+or O
+concentration O
+. O
+
+Western O
+blot O
+analysis O
+revealed O
+that O
+AQP2 O
+expression O
+in O
+medullary O
+tissues O
+was O
+lowered O
+after O
+3 O
+and O
+5 O
+days O
+in O
+WT O
+mice O
+; O
+however O
+, O
+AQP2 O
+was O
+unchanged O
+in O
+PKCa O
+KO O
+. O
+
+Similar O
+results O
+were O
+observed O
+with O
+UT O
+- O
+A1 O
+expression O
+. O
+
+Animals O
+were O
+also O
+treated O
+with O
+lithium B
+for O
+6 O
+weeks O
+. O
+
+Lithium B
+- O
+treated O
+WT O
+mice O
+had O
+19 O
+- O
+fold O
+increased O
+urine O
+output O
+whereas O
+treated O
+PKCa O
+KO O
+animals O
+had O
+a O
+4 O
+- O
+fold O
+increase O
+in O
+output O
+. O
+
+AQP2 O
+and O
+UT O
+- O
+A1 O
+expression O
+was O
+lowered O
+in O
+6 O
+week O
+lithium B
+- O
+treated O
+WT O
+animals O
+whereas O
+in O
+treated O
+PKCa O
+KO O
+mice O
+, O
+AQP2 O
+was O
+only O
+reduced O
+by O
+2 O
+- O
+fold O
+and O
+UT O
+- O
+A1 O
+expression O
+was O
+unaffected O
+. O
+
+Urinary O
+sodium B
+, O
+potassium B
+and O
+calcium B
+were O
+elevated O
+in O
+lithium B
+- O
+fed O
+WT O
+but O
+not O
+in O
+lithium B
+- O
+fed O
+PKCa O
+KO O
+mice O
+. O
+
+Our O
+data O
+show O
+that O
+ablation O
+of O
+PKCa O
+preserves O
+AQP2 O
+and O
+UT O
+- O
+A1 O
+protein O
+expression O
+and O
+localization O
+in O
+lithium B
+- O
+induced O
+NDI O
+, O
+and O
+prevents O
+the O
+development O
+of O
+the O
+severe O
+polyuria O
+associated O
+with O
+lithium B
+therapy O
+. O
+
+
+Decreased O
+Whole O
+- O
+Body O
+Fat O
+Mass O
+Produced O
+by O
+Chronic O
+Alcohol B
+Consumption O
+is O
+Associated O
+with O
+Activation O
+of O
+S6K1 O
+- O
+Mediated O
+Protein O
+Synthesis O
+and O
+Increased O
+Autophagy O
+in O
+Epididymal O
+White O
+Adipose O
+Tissue O
+. O
+
+BACKGROUND O
+: O
+Chronic O
+alcohol B
+consumption O
+leads O
+to O
+a O
+loss O
+of O
+white O
+adipose O
+tissue O
+( O
+WAT O
+) O
+but O
+the O
+underlying O
+mechanisms O
+for O
+this O
+lipodystrophy O
+are O
+not O
+fully O
+elucidated O
+. O
+
+This O
+study O
+tested O
+the O
+hypothesis O
+that O
+the O
+reduction O
+in O
+WAT O
+mass O
+in O
+chronic O
+alcohol B
+- O
+fed O
+mice O
+is O
+associated O
+with O
+a O
+decreased O
+protein O
+synthesis O
+specifically O
+related O
+to O
+impaired O
+function O
+of O
+mammalian O
+target O
+of O
+rapamycin O
+( O
+mTOR O
+). O
+
+METHODS O
+: O
+Adult O
+male O
+mice O
+were O
+provided O
+an O
+alcohol B
+- O
+containing O
+liquid O
+diet O
+for O
+24 O
+weeks O
+or O
+an O
+isonitrogenous O
+isocaloric O
+control O
+diet O
+. O
+
+In O
+vivo O
+protein O
+synthesis O
+was O
+determined O
+at O
+this O
+time O
+and O
+thereafter O
+epididymal O
+WAT O
+( O
+eWAT O
+) O
+was O
+excised O
+for O
+analysis O
+of O
+signal O
+transduction O
+pathways O
+central O
+to O
+controling O
+protein O
+synthesis O
+and O
+degradation O
+. O
+
+RESULTS O
+: O
+While O
+chronic O
+alcohol B
+feeding O
+decreased O
+whole O
+- O
+body O
+and O
+eWAT O
+mass O
+, O
+this O
+was O
+associated O
+with O
+a O
+discordant O
+increase O
+in O
+protein O
+synthesis O
+in O
+eWAT O
+. O
+
+This O
+increase O
+was O
+not O
+associated O
+with O
+a O
+change O
+in O
+mTOR O
+, O
+4E O
+- O
+BP1 O
+, O
+Akt O
+, O
+or O
+PRAS40 O
+phosphorylation O
+. O
+
+Instead O
+, O
+a O
+selective O
+increase O
+in O
+phosphorylation O
+of O
+S6K1 O
+and O
+its O
+downstream O
+substrates O
+, O
+S6 O
+and O
+eIF4B O
+was O
+detected O
+in O
+alcohol B
+- O
+fed O
+mice O
+. O
+
+Alcohol B
+also O
+increased O
+eEF2K O
+phosphorylation O
+and O
+decreased O
+eEF2 O
+phosphorylation O
+consistent O
+with O
+increased O
+translation O
+elongation O
+. O
+
+Alcohol B
+increased O
+Atg12 O
+- O
+5 O
+, O
+LC3B O
+- O
+I O
+and O
+- O
+II O
+, O
+and O
+ULK1 O
+S555 O
+phosphorylation O
+, O
+suggesting O
+increased O
+autophagy O
+, O
+while O
+markers O
+of O
+apoptosis O
+( O
+cleaved O
+caspase O
+- O
+3 O
+and O
+- O
+9 O
+, O
+and O
+PARP O
+) O
+were O
+unchanged O
+. O
+
+Lipolytic O
+enzymes O
+( O
+ATGL O
+and O
+HSL O
+phosphorylation O
+) O
+were O
+increased O
+and O
+lipogenic O
+regulators O
+( O
+PPARgamma O
+and O
+C O
+/ O
+EBPalpha O
+) O
+were O
+decreased O
+in O
+eWAT O
+by O
+alcohol B
+. O
+
+Although O
+alcohol B
+increased O
+TNF O
+- O
+alpha O
+, O
+IL O
+- O
+6 O
+, O
+and O
+IL O
+- O
+1beta O
+mRNA O
+, O
+no O
+change O
+in O
+key O
+components O
+of O
+the O
+NLRP3 O
+inflammasome O
+( O
+NLRP3 O
+, O
+ACS O
+, O
+and O
+cleaved O
+caspase O
+- O
+1 O
+) O
+was O
+detected O
+suggesting O
+alcohol B
+did O
+not O
+increase O
+pyroptosis O
+. O
+
+Plasma O
+insulin B
+did O
+not O
+differ O
+between O
+groups O
+. O
+
+CONCLUSIONS O
+: O
+These O
+results O
+demonstrate O
+that O
+the O
+alcohol B
+- O
+induced O
+decrease O
+in O
+whole O
+- O
+body O
+fat O
+mass O
+resulted O
+in O
+part O
+from O
+activation O
+of O
+autophagy O
+in O
+eWAT O
+as O
+protein O
+synthesis O
+was O
+increased O
+and O
+mediated O
+by O
+the O
+specific O
+increase O
+in O
+the O
+activity O
+of O
+S6K1 O
+. O
+
+
+Nefiracetam B
+( O
+DM B
+- I
+9384 I
+) O
+reverses O
+apomorphine B
+- O
+induced O
+amnesia O
+of O
+a O
+passive O
+avoidance O
+response O
+: O
+delayed O
+emergence O
+of O
+the O
+memory O
+retention O
+effects O
+. O
+
+Nefiracetam B
+is O
+a O
+novel O
+pyrrolidone B
+derivative I
+which O
+attenuates O
+scopolamine B
+- O
+induced O
+learning O
+and O
+post O
+- O
+training O
+consolidation O
+deficits O
+. O
+
+Given O
+that O
+apomorphine B
+inhibits O
+passive O
+avoidance O
+retention O
+when O
+given O
+during O
+training O
+or O
+in O
+a O
+defined O
+10 O
+- O
+12h O
+post O
+- O
+training O
+period O
+, O
+we O
+evaluated O
+the O
+ability O
+of O
+nefiracetam B
+to O
+attenuate O
+amnesia O
+induced O
+by O
+dopaminergic B
+agonism O
+. O
+
+A O
+step O
+- O
+down O
+passive O
+avoidance O
+paradigm O
+was O
+employed O
+and O
+nefiracetam B
+( O
+3 O
+mg O
+/ O
+kg O
+) O
+and O
+apomorphine B
+( O
+0 O
+. O
+5 O
+mg O
+/ O
+kg O
+) O
+were O
+given O
+alone O
+or O
+in O
+combination O
+during O
+training O
+and O
+at O
+the O
+10 O
+- O
+12h O
+post O
+- O
+training O
+period O
+of O
+consolidation O
+. O
+
+Co O
+- O
+administration O
+of O
+nefiracetam B
+and O
+apomorphine B
+during O
+training O
+or O
+10h O
+thereafter O
+produced O
+no O
+significant O
+anti O
+- O
+amnesic O
+effect O
+. O
+
+However O
+, O
+administration O
+of O
+nefiracetam B
+during O
+training O
+completely O
+reversed O
+the O
+amnesia O
+induced O
+by O
+apomorphine B
+at O
+the O
+10h O
+post O
+- O
+training O
+time O
+and O
+the O
+converse O
+was O
+also O
+TRUE O
+. O
+
+These O
+effects O
+were O
+not O
+mediated O
+by O
+a O
+dopaminergic O
+mechanism O
+as O
+nefiracetam B
+, O
+at O
+millimolar O
+concentrations O
+, O
+failed O
+to O
+displace O
+either O
+[ B
+3H I
+] I
+SCH I
+23390 I
+or O
+[ B
+3H I
+] I
+spiperone I
+binding O
+from O
+D1 O
+or O
+D2 O
+dopamine O
+receptor O
+subtypes O
+, O
+respectively O
+. O
+
+It O
+is O
+suggested O
+that O
+nefiracetam B
+augments O
+molecular O
+processes O
+in O
+the O
+early O
+stages O
+of O
+events O
+which O
+ultimately O
+lead O
+to O
+consolidation O
+of O
+memory O
+. O
+
+
+Pethidine B
+- O
+associated O
+seizure O
+in O
+a O
+healthy O
+adolescent O
+receiving O
+pethidine B
+for O
+postoperative O
+pain O
+control O
+. O
+
+A O
+healthy O
+17 O
+- O
+year O
+- O
+old O
+male O
+received O
+standard O
+intermittent O
+doses O
+of O
+pethidine B
+via O
+a O
+patient O
+- O
+controlled O
+analgesia O
+( O
+PCA O
+) O
+pump O
+for O
+management O
+of O
+postoperative O
+pain O
+control O
+. O
+
+Twenty O
+- O
+three O
+h O
+postoperatively O
+he O
+developed O
+a O
+brief O
+self O
+- O
+limited O
+seizure O
+. O
+
+Both O
+plasma O
+pethidine B
+and O
+norpethidine B
+were O
+elevated O
+in O
+the O
+range O
+associated O
+with O
+clinical O
+manifestations O
+of O
+central O
+nervous O
+system O
+excitation O
+. O
+
+No O
+other O
+risk O
+factors O
+for O
+CNS O
+toxicity O
+were O
+identified O
+. O
+
+This O
+method O
+allowed O
+frequent O
+self O
+- O
+dosing O
+of O
+pethidine B
+at O
+short O
+time O
+intervals O
+and O
+rapid O
+accumulation O
+of O
+pethidine B
+and O
+norpethidine B
+. O
+
+The O
+routine O
+use O
+of O
+pethidine B
+via O
+PCA O
+even O
+for O
+a O
+brief O
+postoperative O
+analgesia O
+should O
+be O
+reconsidered O
+. O
+
+
+Recovery O
+of O
+tacrolimus B
+- O
+associated O
+brachial O
+neuritis O
+after O
+conversion O
+to O
+everolimus B
+in O
+a O
+pediatric O
+renal O
+transplant O
+recipient O
+-- O
+case O
+report O
+and O
+review O
+of O
+the O
+literature O
+. O
+
+TAC O
+has O
+been O
+shown O
+to O
+be O
+a O
+potent O
+immunosuppressive O
+agent O
+for O
+solid O
+organ O
+transplantation O
+in O
+pediatrics O
+. O
+
+Neurotoxicity O
+is O
+a O
+potentially O
+serious O
+toxic O
+effect O
+. O
+
+It O
+is O
+characterized O
+by O
+encephalopathy O
+, O
+headaches O
+, O
+seizures O
+, O
+or O
+neurological O
+deficits O
+. O
+
+Here O
+, O
+we O
+describe O
+an O
+eight O
+- O
+and O
+- O
+a O
+- O
+half O
+- O
+yr O
+- O
+old O
+male O
+renal O
+transplant O
+recipient O
+with O
+right O
+BN O
+. O
+
+MRI O
+demonstrated O
+hyperintense O
+T2 O
+signals O
+in O
+the O
+cervical O
+cord O
+and O
+right O
+brachial O
+plexus O
+roots O
+indicative O
+of O
+both O
+myelitis O
+and O
+right O
+brachial O
+plexitis O
+. O
+
+Symptoms O
+persisted O
+for O
+three O
+months O
+despite O
+TAC O
+dose O
+reduction O
+, O
+administration O
+of O
+IVIG O
+and O
+four O
+doses O
+of O
+methylprednisolone B
+pulse O
+therapy O
+. O
+
+Improvement O
+and O
+eventually O
+full O
+recovery O
+only O
+occurred O
+after O
+TAC O
+was O
+completely O
+discontinued O
+and O
+successfully O
+replaced O
+by O
+everolimus B
+. O
+
+
+MOL1 O
+is O
+required O
+for O
+cambium O
+homeostasis O
+in O
+Arabidopsis O
+. O
+
+Plants O
+maintain O
+pools O
+of O
+pluripotent O
+stem O
+cells O
+which O
+allow O
+them O
+to O
+constantly O
+produce O
+new O
+tissues O
+and O
+organs O
+. O
+
+Stem O
+cell O
+homeostasis O
+in O
+shoot O
+and O
+root O
+tips O
+depends O
+on O
+negative O
+regulation O
+by O
+ligand O
+- O
+receptor O
+pairs O
+of O
+the O
+CLE O
+peptide O
+and O
+leucine O
+- O
+rich O
+repeat O
+receptor O
+- O
+like O
+kinase O
+( O
+LRR O
+- O
+RLK O
+) O
+families O
+. O
+
+However O
+, O
+regulation O
+of O
+the O
+cambium O
+, O
+the O
+stem O
+cell O
+niche O
+required O
+for O
+lateral O
+growth O
+of O
+shoots O
+and O
+roots O
+, O
+is O
+poorly O
+characterized O
+. O
+
+Here O
+we O
+show O
+that O
+the O
+LRR O
+- O
+RLK O
+MOL1 O
+is O
+necessary O
+for O
+cambium O
+homeostasis O
+in O
+Arabidopsis O
+thaliana O
+. O
+
+By O
+employing O
+promoter O
+reporter O
+lines O
+, O
+we O
+reveal O
+that O
+MOL1 O
+is O
+active O
+in O
+a O
+domain O
+that O
+is O
+distinct O
+from O
+the O
+domain O
+of O
+the O
+positively O
+acting O
+CLE41 O
+/ O
+PXY O
+signaling O
+module O
+. O
+
+In O
+particular O
+, O
+we O
+show O
+that O
+MOL1 O
+acts O
+in O
+an O
+opposing O
+manner O
+to O
+the O
+CLE41 O
+/ O
+PXY O
+module O
+and O
+that O
+changing O
+the O
+domain O
+or O
+level O
+of O
+MOL1 O
+expression O
+both O
+result O
+in O
+disturbed O
+cambium O
+organization O
+. O
+
+Underlining O
+discrete O
+roles O
+of O
+MOL1 O
+and O
+PXY O
+, O
+both O
+LRR O
+- O
+RLKs O
+are O
+not O
+able O
+to O
+replace O
+each O
+other O
+when O
+their O
+expression O
+domains O
+are O
+interchanged O
+. O
+
+Furthermore O
+, O
+MOL1 O
+but O
+not O
+PXY O
+is O
+able O
+to O
+rescue O
+CLV1 O
+deficiency O
+in O
+the O
+shoot O
+apical O
+meristem O
+. O
+
+By O
+identifying O
+genes O
+mis O
+- O
+expressed O
+in O
+mol1 O
+mutants O
+, O
+we O
+demonstrate O
+that O
+MOL1 O
+represses O
+genes O
+associated O
+with O
+stress O
+- O
+related O
+ethylene O
+and O
+jasmonic O
+acid O
+hormone O
+signaling O
+pathways O
+which O
+have O
+known O
+roles O
+in O
+coordinating O
+lateral O
+growth O
+of O
+the O
+Arabidopsis O
+stem O
+. O
+
+Our O
+findings O
+provide O
+evidence O
+that O
+common O
+regulatory O
+mechanisms O
+in O
+different O
+plant O
+stem O
+cell O
+niches O
+are O
+adapted O
+to O
+specific O
+niche O
+anatomies O
+and O
+emphasize O
+the O
+importance O
+of O
+a O
+complex O
+spatial O
+organization O
+of O
+intercellular O
+signaling O
+cascades O
+for O
+a O
+strictly O
+bidirectional O
+tissue O
+production O
+. O
+
+
+In O
+vivo O
+evidences O
+suggesting O
+the O
+role O
+of O
+oxidative O
+stress O
+in O
+pathogenesis O
+of O
+vancomycin B
+- O
+induced O
+nephrotoxicity O
+: O
+protection O
+by O
+erdosteine B
+. O
+
+The O
+aims O
+of O
+this O
+study O
+were O
+to O
+examine O
+vancomycin B
+( O
+VCM B
+)- O
+induced O
+oxidative O
+stress O
+that O
+promotes O
+production O
+of O
+reactive B
+oxygen I
+species I
+( O
+ROS B
+) O
+and O
+to O
+investigate O
+the O
+role O
+of O
+erdosteine B
+, O
+an O
+expectorant B
+agent O
+, O
+which O
+has O
+also O
+antioxidant O
+properties O
+, O
+on O
+kidney O
+tissue O
+against O
+the O
+possible O
+VCM B
+- O
+induced O
+renal O
+impairment O
+in O
+rats O
+. O
+
+Rats O
+were O
+divided O
+into O
+three O
+groups O
+: O
+sham O
+, O
+VCM O
+and O
+VCM O
+plus O
+erdosteine B
+. O
+
+VCM B
+was O
+administrated O
+intraperitoneally O
+( O
+i O
+. O
+p O
+.) O
+
+with O
+200mgkg O
+(- O
+1 O
+) O
+twice O
+daily O
+for O
+7 O
+days O
+. O
+
+Erdosteine B
+was O
+administered O
+orally O
+. O
+
+VCM O
+administration O
+to O
+control O
+rats O
+significantly O
+increased O
+renal O
+malondialdehyde B
+( O
+MDA B
+) O
+and O
+urinary O
+N O
+- O
+acetyl O
+- O
+beta O
+- O
+d O
+- O
+glucosaminidase O
+( O
+NAG O
+, O
+a O
+marker O
+of O
+renal O
+tubular O
+injury O
+) O
+excretion O
+but O
+decreased O
+superoxide O
+dismutase O
+( O
+SOD O
+) O
+and O
+catalase O
+( O
+CAT O
+) O
+activities O
+. O
+
+Erdosteine B
+administration O
+with O
+VCM B
+injections O
+caused O
+significantly O
+decreased O
+renal O
+MDA B
+and O
+urinary O
+NAG B
+excretion O
+, O
+and O
+increased O
+SOD O
+activity O
+, O
+but O
+not O
+CAT O
+activity O
+in O
+renal O
+tissue O
+when O
+compared O
+with O
+VCM B
+alone O
+. O
+
+Erdosteine B
+showed O
+histopathological O
+protection O
+against O
+VCM B
+- O
+induced O
+nephrotoxicity O
+. O
+
+There O
+were O
+a O
+significant O
+dilatation O
+of O
+tubular O
+lumens O
+, O
+extensive O
+epithelial O
+cell O
+vacuolization O
+, O
+atrophy O
+, O
+desquamation O
+, O
+and O
+necrosis O
+in O
+VCM B
+- O
+treated O
+rats O
+more O
+than O
+those O
+of O
+the O
+control O
+and O
+the O
+erdosteine B
+groups O
+. O
+
+Erdosteine B
+caused O
+a O
+marked O
+reduction O
+in O
+the O
+extent O
+of O
+tubular O
+damage O
+. O
+
+It O
+is O
+concluded O
+that O
+oxidative O
+tubular O
+damage O
+plays O
+an O
+important O
+role O
+in O
+the O
+VCM O
+- O
+induced O
+nephrotoxicity O
+and O
+the O
+modulation O
+of O
+oxidative O
+stress O
+with O
+erdosteine B
+reduces O
+the O
+VCM O
+- O
+induced O
+kidney O
+damage O
+both O
+at O
+the O
+biochemical O
+and O
+histological O
+levels O
+. O
+
+
+Mutation O
+screening O
+of O
+the O
+GUCA1B O
+gene O
+in O
+patients O
+with O
+autosomal O
+dominant O
+cone O
+and O
+cone O
+rod O
+dystrophy O
+. O
+
+Background O
+: O
+Heterozygous O
+mutations O
+in O
+GUCA1A O
+( O
+MIM O
+# O
+600364 O
+) O
+have O
+been O
+identified O
+to O
+cause O
+autosomal O
+dominantly O
+inherited O
+cone O
+dystrophy O
+, O
+cone O
+rod O
+dystrophy O
+and O
+macular O
+dystrophy O
+. O
+
+However O
+, O
+the O
+role O
+of O
+GUCA1B O
+gene O
+mutations O
+in O
+inherited O
+retinal O
+disease O
+has O
+been O
+controversial O
+. O
+
+We O
+therefore O
+performed O
+a O
+mutation O
+analysis O
+of O
+the O
+GUCA1B O
+gene O
+in O
+a O
+clinically O
+well O
+characterized O
+group O
+of O
+patients O
+of O
+European O
+and O
+North O
+- O
+American O
+geographical O
+origin O
+with O
+autosomal O
+dominantly O
+inherited O
+cone O
+dystrophy O
+and O
+cone O
+rod O
+dystrophy O
+. O
+
+Material O
+and O
+Methods O
+: O
+Twenty O
+- O
+four O
+unrelated O
+patients O
+diagnosed O
+with O
+cone O
+dystrophy O
+or O
+cone O
+rod O
+dystrophy O
+according O
+to O
+standard O
+diagnostic O
+criteria O
+and O
+a O
+family O
+history O
+consistent O
+with O
+an O
+autosomal O
+dominant O
+mode O
+of O
+inheritance O
+were O
+included O
+in O
+the O
+study O
+. O
+
+Mutation O
+analysis O
+of O
+all O
+coding O
+exons O
+of O
+the O
+GUCA1B O
+gene O
+was O
+performed O
+by O
+polymerase O
+chain O
+reaction O
+amplification O
+of O
+genomic O
+DNA O
+and O
+subsequent O
+DNA O
+sequencing O
+. O
+
+Results O
+: O
+Three O
+different O
+sequence O
+variants O
+, O
+c O
+.- O
+17T O
+> O
+C O
+, O
+c O
+. O
+171T O
+> O
+C O
+, O
+c O
+. O
+465G O
+> O
+T O
+were O
+identified O
+. O
+
+The O
+sequence O
+variant O
+c O
+. O
+465G O
+> O
+T O
+encodes O
+a O
+conservative O
+amino O
+acid O
+substitution O
+, O
+p O
+. O
+Glu155Asp O
+, O
+located O
+in O
+EF O
+- O
+hand O
+4 O
+, O
+the O
+calcium B
+binding O
+site O
+of O
+GCAP2 O
+protein O
+. O
+
+All O
+sequence O
+variants O
+were O
+previously O
+reported O
+in O
+healthy O
+subjects O
+. O
+
+Conclusion O
+: O
+The O
+absence O
+of O
+clearly O
+pathogenic O
+mutations O
+in O
+the O
+selected O
+patient O
+group O
+suggests O
+that O
+the O
+GUCA1B O
+gene O
+is O
+a O
+minor O
+cause O
+for O
+retinal O
+degenerations O
+in O
+Europeans O
+or O
+North O
+- O
+Americans O
+. O
+
+
+Cardioprotective O
+effect O
+of O
+tincture O
+of O
+Crataegus O
+on O
+isoproterenol B
+- O
+induced O
+myocardial O
+infarction O
+in O
+rats O
+. O
+
+Tincture O
+of O
+Crataegus O
+( O
+TCR O
+), O
+an O
+alcoholic O
+extract O
+of O
+the O
+berries O
+of O
+hawthorn O
+( O
+Crataegus O
+oxycantha O
+), O
+is O
+used O
+in O
+herbal O
+and O
+homeopathic O
+medicine O
+. O
+
+The O
+present O
+study O
+was O
+done O
+to O
+investigate O
+the O
+protective O
+effect O
+of O
+TCR B
+on O
+experimentally O
+induced O
+myocardial O
+infarction O
+in O
+rats O
+. O
+
+Pretreatment O
+of O
+TCR B
+, O
+at O
+a O
+dose O
+of O
+0 O
+. O
+5 O
+mL O
+/ O
+100 O
+g O
+bodyweight O
+per O
+day O
+, O
+orally O
+for O
+30 O
+days O
+, O
+prevented O
+the O
+increase O
+in O
+lipid B
+peroxidation O
+and O
+activity O
+of O
+marker O
+enzymes O
+observed O
+in O
+isoproterenol B
+- O
+induced O
+rats O
+( O
+85 O
+mg O
+kg O
+(- O
+1 O
+) O
+s O
+. O
+c O
+. O
+for O
+2 O
+days O
+at O
+an O
+interval O
+of O
+24 O
+h O
+). O
+
+TCR O
+prevented O
+the O
+isoproterenol B
+- O
+induced O
+decrease O
+in O
+antioxidant O
+enzymes O
+in O
+the O
+heart O
+and O
+increased O
+the O
+rate O
+of O
+ADP B
+- O
+stimulated O
+oxygen B
+uptake O
+and O
+respiratory O
+coupling O
+ratio O
+. O
+
+TCR O
+protected O
+against O
+pathological O
+changes O
+induced O
+by O
+isoproterenol B
+in O
+rat O
+heart O
+. O
+
+The O
+results O
+show O
+that O
+pretreatment O
+with O
+TCR O
+may O
+be O
+useful O
+in O
+preventing O
+the O
+damage O
+induced O
+by O
+isoproterenol B
+in O
+rat O
+heart O
+. O
+
+
+A O
+novel O
+splicing O
+mutation O
+in O
+SLC12A3 O
+associated O
+with O
+Gitelman O
+syndrome O
+and O
+idiopathic O
+intracranial O
+hypertension O
+. O
+
+We O
+report O
+a O
+case O
+of O
+Gitelman O
+syndrome O
+( O
+GS O
+) O
+in O
+a O
+dizygotic O
+twin O
+who O
+presented O
+at O
+12 O
+years O
+of O
+age O
+with O
+growth O
+delay O
+, O
+metabolic O
+alkalosis O
+, O
+hypomagnesemia O
+and O
+hypokalemia O
+with O
+inappropriate O
+kaliuresis O
+, O
+and O
+idiopathic O
+intracranial O
+hypertension O
+with O
+bilateral O
+papilledema O
+( O
+pseudotumor O
+cerebri O
+). O
+
+The O
+patient O
+, O
+her O
+twin O
+sister O
+, O
+and O
+her O
+mother O
+also O
+presented O
+with O
+cerebral O
+cavernous O
+malformations O
+. O
+
+Based O
+on O
+the O
+early O
+onset O
+and O
+normocalciuria O
+, O
+Bartter O
+syndrome O
+was O
+diagnosed O
+first O
+. O
+
+However O
+, O
+mutation O
+analysis O
+showed O
+that O
+the O
+proband O
+is O
+a O
+compound O
+heterozygote O
+for O
+2 O
+mutations O
+in O
+SLC12A3 O
+: O
+a O
+substitution O
+of O
+serine O
+by O
+leucine O
+at O
+amino O
+acid O
+position O
+555 O
+( O
+p O
+. O
+Ser555Leu O
+) O
+and O
+a O
+novel O
+guanine O
+to O
+cytosine O
+transition O
+at O
+the O
+5 O
+' O
+splice O
+site O
+of O
+intron O
+22 O
+( O
+c O
+. O
+2633 O
++ O
+1G O
+> O
+C O
+), O
+providing O
+the O
+molecular O
+diagnosis O
+of O
+GS O
+. O
+
+These O
+mutations O
+were O
+not O
+detected O
+in O
+200 O
+normal O
+chromosomes O
+and O
+cosegregated O
+within O
+the O
+family O
+. O
+
+Analysis O
+of O
+complementary O
+DNA O
+showed O
+that O
+the O
+heterozygous O
+nucleotide O
+change O
+c O
+. O
+2633 O
++ O
+1G O
+> O
+C O
+caused O
+the O
+appearance O
+of O
+2 O
+RNA O
+molecules O
+, O
+1 O
+normal O
+transcript O
+and O
+1 O
+skipping O
+the O
+entire O
+exon O
+22 O
+( O
+r O
+. O
+2521_2634del O
+). O
+
+Supplementation O
+with O
+potassium B
+and O
+magnesium B
+improved O
+clinical O
+symptoms O
+and O
+resulted O
+in O
+catch O
+- O
+up O
+growth O
+, O
+but O
+vision O
+remained O
+impaired O
+. O
+
+Three O
+similar O
+associations O
+of O
+Bartter O
+syndrome O
+/ O
+GS O
+with O
+pseudotumor O
+cerebri O
+were O
+found O
+in O
+the O
+literature O
+, O
+suggesting O
+that O
+electrolyte O
+abnormalities O
+and O
+secondary O
+aldosteronism O
+may O
+have O
+a O
+role O
+in O
+idiopathic O
+intracranial O
+hypertension O
+. O
+
+This O
+study O
+provides O
+further O
+evidence O
+for O
+the O
+phenotypical O
+heterogeneity O
+of O
+GS O
+and O
+its O
+association O
+with O
+severe O
+manifestations O
+in O
+children O
+. O
+
+It O
+also O
+shows O
+the O
+independent O
+segregation O
+of O
+familial O
+cavernomatosis O
+and O
+GS O
+. O
+
+
+Association O
+between O
+polymorphisms O
+in O
+SLC30A8 O
+, O
+HHEX O
+, O
+CDKN2A O
+/ O
+B O
+, O
+IGF2BP2 O
+, O
+FTO O
+, O
+WFS1 O
+, O
+CDKAL1 O
+, O
+KCNQ1 O
+and O
+type O
+2 O
+diabetes O
+in O
+the O
+Korean O
+population O
+. O
+
+According O
+to O
+recent O
+genome O
+- O
+wide O
+association O
+studies O
+, O
+a O
+number O
+of O
+single O
+nucleotide O
+polymorphisms O
+( O
+SNPs O
+) O
+are O
+reported O
+to O
+be O
+associated O
+with O
+type O
+2 O
+diabetes O
+mellitus O
+( O
+T2DM O
+). O
+
+The O
+aim O
+of O
+the O
+present O
+study O
+was O
+to O
+investigate O
+the O
+association O
+among O
+the O
+polymorphisms O
+of O
+SLC30A8 O
+, O
+HHEX O
+, O
+CDKN2A O
+/ O
+B O
+, O
+IGF2BP2 O
+, O
+FTO O
+, O
+WFS1 O
+, O
+CDKAL1 O
+and O
+KCNQ1 O
+and O
+the O
+risk O
+of O
+T2DM O
+in O
+the O
+Korean O
+population O
+. O
+
+This O
+study O
+was O
+based O
+on O
+a O
+multicenter O
+case O
+- O
+control O
+study O
+, O
+including O
+908 O
+patients O
+with O
+T2DM O
+and O
+502 O
+non O
+- O
+diabetic O
+controls O
+. O
+
+We O
+genotyped O
+rs13266634 O
+, O
+rs1111875 O
+, O
+rs10811661 O
+, O
+rs4402960 O
+, O
+rs8050136 O
+, O
+rs734312 O
+, O
+rs7754840 O
+and O
+rs2237892 O
+and O
+measured O
+the O
+body O
+weight O
+, O
+body O
+mass O
+index O
+and O
+fasting O
+plasma O
+glucose B
+in O
+all O
+patients O
+and O
+controls O
+. O
+
+The O
+strongest O
+association O
+was O
+found O
+in O
+a O
+variant O
+of O
+CDKAL1 O
+[ O
+rs7754840 O
+, O
+odds O
+ratio O
+( O
+OR O
+) O
+= O
+1 O
+. O
+77 O
+, O
+95 O
+% O
+CI O
+= O
+1 O
+. O
+50 O
+- O
+2 O
+. O
+10 O
+, O
+p O
+= O
+5 O
+. O
+0 O
+x O
+10 O
+(- O
+11 O
+)]. O
+
+The O
+G O
+allele O
+of O
+rs1111875 O
+( O
+OR O
+= O
+1 O
+. O
+43 O
+, O
+95 O
+% O
+CI O
+= O
+1 O
+. O
+18 O
+- O
+1 O
+. O
+72 O
+, O
+p O
+= O
+1 O
+. O
+8 O
+x O
+10 O
+(- O
+4 O
+)) O
+in O
+HHEX O
+), O
+the O
+T O
+allele O
+of O
+rs10811661 O
+( O
+OR O
+= O
+1 O
+. O
+47 O
+, O
+95 O
+% O
+CI O
+= O
+1 O
+. O
+23 O
+- O
+1 O
+. O
+75 O
+, O
+p O
+= O
+2 O
+. O
+1 O
+x O
+10 O
+(- O
+5 O
+)) O
+in O
+CDKN2A O
+/ O
+B O
+) O
+and O
+the O
+C O
+allele O
+of O
+rs2237892 O
+( O
+OR O
+= O
+1 O
+. O
+31 O
+, O
+95 O
+% O
+
+CI O
+= O
+1 O
+. O
+10 O
+- O
+1 O
+. O
+56 O
+, O
+p O
+= O
+0 O
+. O
+3 O
+) O
+in O
+KCNQ1 O
+showed O
+significant O
+associations O
+with O
+T2DM O
+. O
+
+Rs13266634 O
+( O
+OR O
+= O
+1 O
+. O
+19 O
+, O
+95 O
+% O
+CI O
+= O
+1 O
+. O
+0 O
+- O
+1 O
+. O
+42 O
+, O
+p O
+= O
+0 O
+. O
+45 O
+) O
+in O
+SLC30A8 O
+showed O
+a O
+nominal O
+association O
+with O
+the O
+risk O
+of O
+T2DM O
+, O
+whereas O
+SNPs O
+in O
+IGF2BP2 O
+, O
+FTO O
+and O
+WFS1 O
+were O
+not O
+associated O
+. O
+
+In O
+conclusion O
+, O
+we O
+have O
+shown O
+that O
+SNPs O
+in O
+HHEX O
+, O
+CDKN2A O
+/ O
+B O
+, O
+CDKAL1 O
+, O
+KCNQ1 O
+and O
+SLC30A8 O
+confer O
+a O
+risk O
+of O
+T2DM O
+in O
+the O
+Korean O
+population O
+. O
+
+
+Serotonin O
+6 O
+receptor O
+gene O
+is O
+associated O
+with O
+methamphetamine B
+- O
+induced O
+psychosis O
+in O
+a O
+Japanese O
+population O
+. O
+
+BACKGROUND O
+: O
+Altered O
+serotonergic O
+neural O
+transmission O
+is O
+hypothesized O
+to O
+be O
+a O
+susceptibility O
+factor O
+for O
+psychotic O
+disorders O
+such O
+as O
+schizophrenia O
+. O
+
+The O
+serotonin O
+6 O
+( O
+5 O
+- O
+HT6 O
+) O
+receptor O
+is O
+therapeutically O
+targeted O
+by O
+several O
+second O
+generation O
+antipsychotics B
+, O
+such O
+as O
+clozapine B
+and O
+olanzapine B
+, O
+and O
+d B
+- I
+amphetamine I
+- O
+induced O
+hyperactivity O
+in O
+rats O
+is O
+corrected O
+with O
+the O
+use O
+of O
+a O
+selective O
+5 O
+- O
+HT6 O
+receptor O
+antagonist O
+. O
+
+In O
+addition O
+, O
+the O
+disrupted O
+prepulse O
+inhibition O
+induced O
+by O
+d B
+- I
+amphetamine I
+or O
+phencyclidine B
+was O
+restored O
+by O
+5 O
+- O
+HT6 O
+receptor O
+antagonist O
+in O
+an O
+animal O
+study O
+using O
+rats O
+. O
+
+These O
+animal O
+models O
+were O
+considered O
+to O
+reflect O
+the O
+positive O
+symptoms O
+of O
+schizophrenia O
+, O
+and O
+the O
+above O
+evidence O
+suggests O
+that O
+altered O
+5 O
+- O
+HT6 O
+receptors O
+are O
+involved O
+in O
+the O
+pathophysiology O
+of O
+psychotic O
+disorders O
+. O
+
+The O
+symptoms O
+of O
+methamphetamine B
+( O
+METH B
+)- O
+induced O
+psychosis O
+are O
+similar O
+to O
+those O
+of O
+paranoid O
+type O
+schizophrenia O
+. O
+
+Therefore O
+, O
+we O
+conducted O
+an O
+analysis O
+of O
+the O
+association O
+of O
+the O
+5 O
+- O
+HT6 O
+gene O
+( O
+HTR6 O
+) O
+with O
+METH B
+- O
+induced O
+psychosis O
+. O
+
+METHOD O
+: O
+Using O
+five O
+tagging O
+SNPs O
+( O
+rs6693503 O
+, O
+rs1805054 O
+, O
+rs4912138 O
+, O
+rs3790757 O
+and O
+rs9659997 O
+), O
+we O
+conducted O
+a O
+genetic O
+association O
+analysis O
+of O
+case O
+- O
+control O
+samples O
+( O
+197 O
+METH B
+- O
+induced O
+psychosis O
+patients O
+and O
+337 O
+controls O
+) O
+in O
+the O
+Japanese O
+population O
+. O
+
+The O
+age O
+and O
+sex O
+of O
+the O
+control O
+subjects O
+did O
+not O
+differ O
+from O
+those O
+of O
+the O
+methamphetamine B
+dependence O
+patients O
+. O
+
+RESULTS O
+: O
+rs6693503 O
+was O
+associated O
+with O
+METH B
+- O
+induced O
+psychosis O
+patients O
+in O
+the O
+allele O
+/ O
+genotype O
+- O
+wise O
+analysis O
+. O
+
+Moreover O
+, O
+this O
+association O
+remained O
+significant O
+after O
+Bonferroni O
+correction O
+. O
+
+In O
+the O
+haplotype O
+- O
+wise O
+analysis O
+, O
+we O
+detected O
+an O
+association O
+between O
+two O
+markers O
+( O
+rs6693503 O
+and O
+rs1805054 O
+) O
+and O
+three O
+markers O
+( O
+rs6693503 O
+, O
+rs1805054 O
+and O
+rs4912138 O
+) O
+in O
+HTR6 O
+and O
+METH B
+- O
+induced O
+psychosis O
+patients O
+, O
+respectively O
+. O
+
+CONCLUSION O
+: O
+HTR6 O
+may O
+play O
+an O
+important O
+role O
+in O
+the O
+pathophysiology O
+of O
+METH B
+- O
+induced O
+psychosis O
+in O
+the O
+Japanese O
+population O
+. O
+
+
+Reciprocal O
+effects O
+of O
+NNK O
+and O
+SLURP O
+- O
+1 O
+on O
+oncogene O
+expression O
+in O
+target O
+epithelial O
+cells O
+. O
+
+AIMS O
+: O
+To O
+elucidate O
+how O
+the O
+nicotinic O
+acetylcholine O
+receptors O
+expressed O
+on O
+bronchial O
+and O
+oral O
+epithelial O
+cells O
+targeted O
+by O
+the O
+tobacco O
+nitrosamine I
+( O
+4 B
+-( I
+methylnitrosamino I
+)- I
+1 I
+-( I
+3 I
+- I
+pyridyl I
+)- I
+1 I
+- I
+butanone I
+) O
+( O
+NNK B
+) O
+facilitate O
+carcinogenic O
+transformation O
+. O
+
+MAIN O
+METHODS O
+: O
+Since O
+NNK O
+- O
+dependent O
+transformation O
+can O
+be O
+abolished O
+by O
+the O
+nicotinergic O
+secreted O
+mammalian O
+Ly O
+- O
+6 O
+/ O
+urokinase O
+plasminogen O
+activator O
+receptor O
+related O
+protein O
+- O
+1 O
+( O
+SLURP O
+- O
+1 O
+), O
+we O
+compared O
+effects O
+of O
+NNK O
+and O
+recombinant O
+( O
+r O
+) O
+SLURP O
+- O
+1 O
+on O
+the O
+expression O
+of O
+genes O
+related O
+to O
+tumorigenesis O
+in O
+human O
+immortalized O
+bronchial O
+and O
+oral O
+epithelial O
+cell O
+lines O
+BEP2D O
+and O
+Het O
+- O
+1A O
+, O
+respectively O
+. O
+
+KEY O
+FINDINGS O
+: O
+NNK O
+stimulated O
+expression O
+of O
+oncogenic O
+genes O
+, O
+including O
+MYB O
+and O
+PIK3CA O
+in O
+BEP2D O
+, O
+ETS1 O
+, O
+NRAS O
+and O
+SRC O
+in O
+Het O
+- O
+1A O
+, O
+and O
+AKT1 O
+, O
+KIT O
+and O
+RB1 O
+in O
+both O
+cell O
+types O
+, O
+which O
+could O
+be O
+abolished O
+in O
+the O
+presence O
+of O
+rSLURP O
+- O
+1 O
+. O
+
+Other O
+cancer O
+- O
+related O
+genes O
+whose O
+upregulation O
+by O
+NNK O
+was O
+abolishable O
+by O
+rSLURP O
+- O
+1 O
+were O
+the O
+growth O
+factors O
+EGF O
+in O
+BEP2D O
+cells O
+and O
+HGF O
+in O
+Het O
+- O
+1A O
+cells O
+, O
+and O
+the O
+transcription O
+factors O
+CDKN2A O
+and O
+STAT3 O
+( O
+Het O
+- O
+1A O
+only O
+). O
+
+NNK O
+also O
+upregulated O
+the O
+anti O
+- O
+apoptotic O
+BCL2 O
+( O
+Het O
+- O
+1A O
+) O
+and O
+downregulated O
+the O
+pro O
+- O
+apoptotic O
+TNF O
+( O
+Het O
+- O
+1A O
+), O
+BAX O
+and O
+CASP8 O
+( O
+BEP2D O
+), O
+all O
+of O
+which O
+could O
+be O
+abolished O
+, O
+in O
+part O
+, O
+by O
+rSLURP O
+- O
+1 O
+. O
+
+NNK O
+decreased O
+expression O
+of O
+the O
+CTNNB1 O
+gene O
+encoding O
+the O
+intercellular O
+adhesion O
+molecule O
+beta O
+- O
+catenin O
+( O
+BEP2D O
+), O
+as O
+well O
+as O
+tumor O
+suppressors O
+CDKN3 O
+and O
+FOXD3 O
+in O
+BEP2D O
+cells O
+and O
+SERPINB5 O
+in O
+Het O
+- O
+1A O
+cells O
+. O
+
+These O
+pro O
+- O
+oncogenic O
+effects O
+of O
+NNK O
+were O
+abolished O
+by O
+rSLURP O
+- O
+1 O
+that O
+also O
+upregulated O
+RUNX3 O
+. O
+
+SIGNIFICANCE O
+: O
+The O
+obtained O
+results O
+identified O
+target O
+genes O
+for O
+both O
+NNK O
+and O
+SLURP O
+- O
+1 O
+and O
+shed O
+light O
+on O
+the O
+molecular O
+mechanism O
+of O
+their O
+reciprocal O
+effects O
+on O
+tumorigenic O
+transformation O
+of O
+bronchial O
+and O
+oral O
+epithelial O
+cells O
+. O
+
+
+Long O
+- O
+term O
+exposure O
+of O
+MCF O
+- O
+7 O
+breast O
+cancer O
+cells O
+to O
+ethanol B
+stimulates O
+oncogenic O
+features O
+. O
+
+Alcohol B
+consumption O
+is O
+a O
+risk O
+factor O
+for O
+breast O
+cancer O
+. O
+
+Little O
+is O
+known O
+regarding O
+the O
+mechanism O
+, O
+although O
+it O
+is O
+assumed O
+that O
+acetaldehyde B
+or O
+estrogen O
+mediated O
+pathways O
+play O
+a O
+role O
+. O
+
+We O
+previously O
+showed O
+that O
+long O
+- O
+term O
+exposure O
+to O
+2 O
+. O
+5 O
+mM O
+ethanol B
+( O
+blood O
+alcohol B
+~ O
+0 O
+. O
+12 O
+%) O
+of O
+MCF O
+- O
+12A O
+, O
+a O
+human O
+normal O
+epithelial O
+breast O
+cell O
+line O
+, O
+induced O
+epithelial O
+mesenchymal O
+transition O
+( O
+EMT O
+) O
+and O
+oncogenic O
+transformation O
+. O
+
+In O
+this O
+study O
+, O
+we O
+investigated O
+in O
+the O
+human O
+breast O
+cancer O
+cell O
+line O
+MCF O
+- O
+7 O
+, O
+whether O
+a O
+similar O
+exposure O
+to O
+ethanol B
+at O
+concentrations O
+ranging O
+up O
+to O
+peak O
+blood O
+levels O
+in O
+heavy O
+drinkers O
+would O
+increase O
+malignant O
+progression O
+. O
+
+Short O
+- O
+term O
+( O
+1 O
+- O
+week O
+) O
+incubation O
+to O
+ethanol B
+at O
+as O
+low O
+as O
+1 O
+- O
+5 O
+mM O
+( O
+corresponding O
+to O
+blood O
+alcohol I
+concentration O
+of O
+~ O
+0 O
+. O
+48 O
+- O
+0 O
+. O
+24 O
+%) O
+upregulated O
+the O
+stem O
+cell O
+related O
+proteins O
+4-Oct O
+and O
+Nanog O
+, O
+but O
+they O
+were O
+reduced O
+after O
+exposure O
+at O
+25 O
+mM O
+. O
+
+Long O
+- O
+term O
+( O
+4 O
+- O
+week O
+) O
+exposure O
+to O
+25 O
+mM O
+ethanol B
+upregulated O
+the O
+4-Oct O
+and O
+Nanog O
+proteins O
+, O
+as O
+well O
+as O
+the O
+malignancy O
+marker O
+Ceacam6 O
+. O
+
+DNA O
+microarray O
+analysis O
+in O
+cells O
+exposed O
+for O
+1 O
+week O
+showed O
+upregulated O
+expression O
+of O
+metallothionein O
+genes O
+, O
+particularly O
+MT1X O
+. O
+
+Long O
+- O
+term O
+exposure O
+upregulated O
+expression O
+of O
+some O
+malignancy O
+related O
+genes O
+( O
+STEAP4 O
+, O
+SERPINA3 O
+, O
+SAMD9 O
+, O
+GDF15 O
+, O
+KRT15 O
+, O
+ITGB6 O
+, O
+TP63 O
+, O
+and O
+PGR O
+, O
+as O
+well O
+as O
+the O
+CEACAM O
+, O
+interferon O
+related O
+, O
+and O
+HLA O
+gene O
+families O
+). O
+
+Some O
+of O
+these O
+findings O
+were O
+validated O
+by O
+RT O
+- O
+PCR O
+. O
+
+A O
+similar O
+treatment O
+also O
+modulated O
+numerous O
+microRNAs O
+( O
+miRs O
+) O
+including O
+one O
+regulator O
+of O
+4-Oct O
+as O
+well O
+as O
+miRs O
+involved O
+in O
+oncogenesis O
+and O
+/ O
+or O
+malignancy O
+, O
+with O
+only O
+a O
+few O
+estrogen B
+- O
+induced O
+miRs O
+. O
+
+Long O
+- O
+term O
+25 O
+mM O
+ethanol B
+also O
+induced O
+a O
+5 O
+. O
+6 O
+- O
+fold O
+upregulation O
+of O
+anchorage O
+- O
+independent O
+growth O
+, O
+an O
+indicator O
+of O
+malignant O
+- O
+like O
+features O
+. O
+
+Exposure O
+to O
+acetaldehyde B
+resulted O
+in O
+little O
+or O
+no O
+effect O
+comparable O
+to O
+that O
+of O
+ethanol B
+. O
+
+The O
+previously O
+shown O
+alcohol B
+induction O
+of O
+oncogenic O
+transformation O
+of O
+normal O
+breast O
+cells O
+is O
+now O
+complemented O
+by O
+the O
+current O
+results O
+suggesting O
+alcohol B
+' O
+s O
+potential O
+involvement O
+in O
+malignant O
+progression O
+of O
+breast O
+cancer O
+. O
+
+
+Large O
+contiguous O
+gene O
+deletions O
+in O
+Sjogren O
+- O
+Larsson O
+syndrome O
+. O
+
+Sjogren O
+- O
+Larsson O
+syndrome O
+( O
+SLS O
+) O
+is O
+an O
+autosomal O
+recessive O
+disorder O
+characterized O
+by O
+ichthyosis O
+, O
+mental O
+retardation O
+, O
+spasticity O
+and O
+mutations O
+in O
+the O
+ALDH3A2 O
+gene O
+for O
+fatty O
+aldehyde O
+dehydrogenase O
+, O
+an O
+enzyme O
+that O
+catalyzes O
+the O
+oxidation O
+of O
+fatty B
+aldehyde I
+to O
+fatty B
+acid I
+. O
+
+More O
+than O
+70 O
+mutations O
+have O
+been O
+identified O
+in O
+SLS O
+patients O
+, O
+including O
+small O
+deletions O
+or O
+insertions O
+, O
+missense O
+mutations O
+, O
+splicing O
+defects O
+and O
+complex O
+nucleotide O
+changes O
+. O
+
+We O
+now O
+describe O
+2 O
+SLS O
+patients O
+whose O
+disease O
+is O
+caused O
+by O
+large O
+contiguous O
+gene O
+deletions O
+of O
+the O
+ALDH3A2 O
+locus O
+on O
+17p11 O
+. O
+2 O
+. O
+
+The O
+deletions O
+were O
+defined O
+using O
+long O
+distance O
+inverse O
+PCR O
+and O
+microarray O
+- O
+based O
+comparative O
+genomic O
+hybridization O
+. O
+
+A O
+24 O
+- O
+year O
+- O
+old O
+SLS O
+female O
+was O
+homozygous O
+for O
+a O
+352 O
+- O
+kb O
+deletion O
+involving O
+ALDH3A2 O
+and O
+4 O
+contiguous O
+genes O
+including O
+ALDH3A1 O
+, O
+which O
+codes O
+for O
+the O
+major O
+soluble O
+protein O
+in O
+cornea O
+. O
+
+Although O
+lacking O
+corneal O
+disease O
+, O
+she O
+showed O
+severe O
+symptoms O
+of O
+SLS O
+with O
+uncommon O
+deterioration O
+in O
+oral O
+motor O
+function O
+and O
+loss O
+of O
+ambulation O
+. O
+
+The O
+other O
+19 O
+- O
+month O
+- O
+old O
+female O
+patient O
+was O
+a O
+compound O
+heterozygote O
+for O
+a O
+1 O
+. O
+44 O
+- O
+Mb O
+contiguous O
+gene O
+deletion O
+and O
+a O
+missense O
+mutation O
+( O
+c O
+. O
+407C O
+> O
+T O
+, O
+P136L O
+) O
+in O
+ALDH3A2 O
+. O
+
+These O
+studies O
+suggest O
+that O
+large O
+gene O
+deletions O
+may O
+account O
+for O
+up O
+to O
+5 O
+% O
+of O
+the O
+mutant O
+alleles O
+in O
+SLS O
+. O
+
+Geneticists O
+should O
+consider O
+the O
+possibility O
+of O
+compound O
+heterozygosity O
+for O
+large O
+deletions O
+in O
+patients O
+with O
+SLS O
+and O
+other O
+inborn O
+errors O
+of O
+metabolism O
+, O
+which O
+has O
+implications O
+for O
+carrier O
+testing O
+and O
+prenatal O
+diagnosis O
+. O
+
+
+Serum O
+Amyloid O
+A O
+Induces O
+Inflammation O
+, O
+Proliferation O
+and O
+Cell O
+Death O
+in O
+Activated O
+Hepatic O
+Stellate O
+Cells O
+. O
+
+Serum O
+amyloid O
+A O
+( O
+SAA O
+) O
+is O
+an O
+evolutionary O
+highly O
+conserved O
+acute O
+phase O
+protein O
+that O
+is O
+predominantly O
+secreted O
+by O
+hepatocytes O
+. O
+
+However O
+, O
+its O
+role O
+in O
+liver O
+injury O
+and O
+fibrogenesis O
+has O
+not O
+been O
+elucidated O
+so O
+far O
+. O
+
+In O
+this O
+study O
+, O
+we O
+determined O
+the O
+effects O
+of O
+SAA B
+on O
+hepatic O
+stellate O
+cells O
+( O
+HSCs O
+), O
+the O
+main O
+fibrogenic O
+cell O
+type O
+of O
+the O
+liver O
+. O
+
+Serum O
+amyloid O
+A O
+potently O
+activated O
+IkappaB O
+kinase O
+, O
+c O
+- O
+Jun O
+N O
+- O
+terminal O
+kinase O
+( O
+JNK O
+), O
+Erk O
+and O
+Akt O
+and O
+enhanced O
+NF O
+- O
+kappaB O
+- O
+dependent O
+luciferase O
+activity O
+in O
+primary O
+human O
+and O
+rat O
+HSCs O
+. O
+
+Serum O
+amyloid O
+A O
+induced O
+the O
+transcription O
+of O
+MCP O
+- O
+1 O
+, O
+RANTES O
+and O
+MMP9 O
+in O
+an O
+NF O
+- O
+kappaB O
+- O
+and O
+JNK O
+- O
+dependent O
+manner O
+. O
+
+Blockade O
+of O
+NF O
+- O
+kappaB O
+revealed O
+cytotoxic O
+effects O
+of O
+SAA B
+in O
+primary O
+HSCs O
+with O
+signs O
+of O
+apoptosis O
+such O
+as O
+caspase O
+3 O
+and O
+PARP O
+cleavage O
+and O
+Annexin O
+V O
+staining O
+. O
+
+Serum O
+amyloid O
+A O
+induced O
+HSC O
+proliferation O
+, O
+which O
+depended O
+on O
+JNK O
+, O
+Erk O
+and O
+Akt O
+activity O
+. O
+
+In O
+primary O
+hepatocytes O
+, O
+SAA B
+also O
+activated O
+MAP O
+kinases O
+, O
+but O
+did O
+not O
+induce O
+relevant O
+cell O
+death O
+after O
+NF O
+- O
+kappaB O
+inhibition O
+. O
+
+In O
+two O
+models O
+of O
+hepatic O
+fibrogenesis O
+, O
+CCl4 O
+treatment O
+and O
+bile O
+duct O
+ligation O
+, O
+hepatic O
+mRNA O
+levels O
+of O
+SAA1 O
+and O
+SAA3 O
+were O
+strongly O
+increased O
+. O
+
+In O
+conclusion O
+, O
+SAA B
+may O
+modulate O
+fibrogenic O
+responses O
+in O
+the O
+liver O
+in O
+a O
+positive O
+and O
+negative O
+fashion O
+by O
+inducing O
+inflammation O
+, O
+proliferation O
+and O
+cell O
+death O
+in O
+HSCs O
+. O
+
+
+Influence O
+of O
+interleukin O
+12B O
+( O
+IL12B O
+) O
+polymorphisms O
+on O
+spontaneous O
+and O
+treatment O
+- O
+induced O
+recovery O
+from O
+hepatitis O
+C O
+virus O
+infection O
+. O
+
+BACKGROUND O
+/ O
+AIMS O
+: O
+Interleukin O
+- O
+12 O
+( O
+IL O
+- O
+12 O
+) O
+governs O
+the O
+Th1 O
+- O
+type O
+immune O
+response O
+, O
+affecting O
+the O
+spontaneous O
+and O
+treatment O
+- O
+induced O
+recovery O
+from O
+HCV O
+- O
+infection O
+. O
+
+We O
+investigated O
+whether O
+the O
+IL12B O
+polymorphisms O
+within O
+the O
+promoter O
+region O
+( O
+4 O
+bp O
+insertion O
+/ O
+deletion O
+) O
+and O
+the O
+3 O
+'- O
+UTR O
+( O
+1188 O
+- O
+A O
+/ O
+C O
+), O
+which O
+have O
+been O
+reported O
+to O
+influence O
+IL O
+- O
+12 O
+synthesis O
+, O
+are O
+associated O
+with O
+the O
+outcome O
+of O
+HCV O
+infection O
+. O
+
+METHODS O
+: O
+We O
+analyzed O
+186 O
+individuals O
+with O
+spontaneous O
+HCV O
+clearance O
+, O
+501 O
+chronically O
+HCV O
+infected O
+patients O
+, O
+and O
+217 O
+healthy O
+controls O
+. O
+
+IL12B O
+3 O
+'- O
+UTR O
+and O
+promoter O
+genotyping O
+was O
+performed O
+by O
+Taqman O
+- O
+based O
+assays O
+with O
+allele O
+- O
+specific O
+oligonucleotide O
+probes O
+and O
+PCR O
+- O
+based O
+allele O
+- O
+specific O
+DNA O
+- O
+amplification O
+, O
+respectively O
+. O
+
+RESULTS O
+: O
+The O
+proportion O
+of O
+IL12B O
+promoter O
+and O
+3 O
+'- O
+UTR O
+genotypes O
+did O
+not O
+differ O
+significantly O
+between O
+the O
+different O
+cohorts O
+. O
+
+However O
+, O
+HCV O
+genotype O
+1 O
+- O
+infected O
+patients O
+with O
+high O
+baseline O
+viremia O
+carrying O
+the O
+IL12B O
+3 O
+'- O
+UTR O
+1188 O
+- O
+C O
+- O
+allele O
+showed O
+significantly O
+higher O
+sustained O
+virologic O
+response O
+( O
+SVR O
+) O
+rates O
+( O
+25 O
+. O
+3 O
+% O
+vs O
+. O
+
+46 O
+% O
+vs O
+. O
+
+54 O
+. O
+5 O
+% O
+for O
+A O
+/ O
+A O
+, O
+A O
+/ O
+C O
+and O
+C O
+/ O
+C O
+) O
+due O
+to O
+reduced O
+relapse O
+rates O
+( O
+24 O
+. O
+2 O
+% O
+vs O
+. O
+
+12 O
+% O
+vs O
+. O
+
+zero O
+% O
+for O
+A O
+/ O
+A O
+, O
+A O
+/ O
+C O
+and O
+C O
+/ O
+C O
+). O
+
+CONCLUSIONS O
+: O
+IL12B O
+3 O
+'- O
+UTR O
+1188 O
+- O
+C O
+- O
+allele O
+carriers O
+appear O
+to O
+be O
+capable O
+of O
+responding O
+more O
+efficiently O
+to O
+antiviral O
+combination O
+therapy O
+as O
+a O
+consequence O
+of O
+a O
+reduced O
+relapse O
+rate O
+. O
+
+No O
+association O
+of O
+IL12B O
+polymorphisms O
+and O
+self O
+- O
+limited O
+HCV O
+infection O
+could O
+be O
+demonstrated O
+. O
+
+
+No O
+Evidence O
+for O
+BRAF O
+as O
+a O
+melanoma O
+/ O
+nevus O
+susceptibility O
+gene O
+. O
+
+Somatic O
+mutations O
+of O
+BRAF O
+have O
+been O
+identified O
+in O
+both O
+melanoma O
+tumors O
+and O
+benign O
+nevi O
+. O
+
+Germ O
+line O
+mutations O
+in O
+BRAF O
+have O
+not O
+been O
+identified O
+as O
+causal O
+in O
+families O
+predisposed O
+to O
+melanoma O
+. O
+
+However O
+, O
+a O
+recent O
+study O
+suggested O
+that O
+a O
+BRAF O
+haplotype O
+was O
+associated O
+with O
+risk O
+of O
+sporadic O
+melanoma O
+in O
+men O
+. O
+
+Polymorphisms O
+or O
+other O
+variants O
+in O
+the O
+BRAF O
+gene O
+may O
+therefore O
+act O
+as O
+candidate O
+low O
+- O
+penetrance O
+genes O
+for O
+nevus O
+/ O
+melanoma O
+susceptibility O
+. O
+
+We O
+hypothesized O
+that O
+promoter O
+variants O
+would O
+be O
+the O
+most O
+likely O
+candidates O
+for O
+determinants O
+of O
+risk O
+. O
+
+Using O
+denaturing O
+high O
+- O
+pressure O
+liquid O
+chromatography O
+and O
+sequencing O
+, O
+we O
+screened O
+peripheral O
+blood O
+DNA O
+from O
+184 O
+familial O
+melanoma O
+cases O
+for O
+BRAF O
+promoter O
+variants O
+. O
+
+We O
+identified O
+a O
+promoter O
+insertion O
+/ O
+deletion O
+in O
+linkage O
+disequilibrium O
+with O
+the O
+previously O
+described O
+BRAF O
+polymorphism O
+in O
+intron O
+11 O
+( O
+rs1639679 O
+) O
+reported O
+to O
+be O
+associated O
+with O
+melanoma O
+susceptibility O
+in O
+males O
+. O
+
+We O
+therefore O
+investigated O
+the O
+contribution O
+of O
+this O
+BRAF O
+polymorphism O
+to O
+melanoma O
+susceptibility O
+in O
+581 O
+consecutively O
+recruited O
+incident O
+cases O
+, O
+258 O
+incident O
+cases O
+in O
+a O
+study O
+of O
+late O
+relapse O
+, O
+673 O
+female O
+general O
+practitioner O
+controls O
+, O
+and O
+the O
+184 O
+familial O
+cases O
+. O
+
+We O
+found O
+no O
+statistically O
+significant O
+difference O
+in O
+either O
+genotype O
+or O
+allele O
+frequencies O
+between O
+cases O
+and O
+controls O
+overall O
+or O
+between O
+male O
+and O
+female O
+cases O
+for O
+the O
+BRAF O
+polymorphism O
+in O
+the O
+two O
+incident O
+case O
+series O
+. O
+
+Our O
+results O
+therefore O
+suggest O
+that O
+the O
+BRAF O
+polymorphism O
+is O
+not O
+significantly O
+associated O
+with O
+melanoma O
+and O
+the O
+promoter O
+insertion O
+/ O
+deletion O
+linked O
+with O
+the O
+polymorphism O
+is O
+not O
+a O
+causal O
+variant O
+. O
+
+In O
+addition O
+, O
+we O
+found O
+that O
+there O
+was O
+no O
+association O
+between O
+the O
+BRAF O
+genotype O
+and O
+mean O
+total O
+number O
+of O
+banal O
+or O
+atypical O
+nevi O
+in O
+either O
+the O
+cases O
+or O
+controls O
+. O
+
+
+CFI O
+- O
+rs7356506 O
+polymorphisms O
+associated O
+with O
+Vogt O
+- O
+Koyanagi O
+- O
+Harada O
+syndrome O
+. O
+
+PURPOSE O
+: O
+Complement O
+factor O
+I O
+( O
+CFI O
+) O
+plays O
+an O
+important O
+role O
+in O
+complement O
+activation O
+pathways O
+and O
+is O
+known O
+to O
+affect O
+the O
+development O
+of O
+uveitis O
+. O
+
+The O
+present O
+study O
+was O
+performed O
+to O
+investigate O
+the O
+existence O
+of O
+an O
+association O
+between O
+CFI O
+genetic O
+polymorphisms O
+and O
+Vogt O
+- O
+Koyanagi O
+- O
+Harada O
+( O
+VKH O
+) O
+syndrome O
+. O
+
+METHODS O
+: O
+A O
+total O
+of O
+100 O
+patients O
+diagnosed O
+with O
+VKH O
+syndrome O
+and O
+300 O
+healthy O
+controls O
+were O
+recruited O
+for O
+the O
+study O
+. O
+
+Two O
+milliliters O
+of O
+peripheral O
+blood O
+were O
+collected O
+in O
+a O
+sterile O
+anticoagulative O
+tube O
+. O
+
+CFI O
+- O
+rs7356506 O
+polymorphisms O
+were O
+genotyped O
+using O
+Sequenom O
+MassARRAY O
+technology O
+. O
+
+Allele O
+and O
+genotype O
+frequencies O
+were O
+compared O
+between O
+patients O
+and O
+controls O
+using O
+a O
+X O
+( O
+2 O
+) O
+test O
+. O
+
+The O
+analyses O
+were O
+stratified O
+for O
+recurrent O
+status O
+, O
+complicated O
+cataract O
+status O
+, O
+and O
+steroid B
+- O
+sensitive O
+status O
+. O
+
+RESULTS O
+: O
+No O
+significant O
+association O
+was O
+found O
+between O
+CFI O
+- O
+rs7356506 O
+polymorphisms O
+and O
+VKH O
+syndrome O
+. O
+
+However O
+, O
+patients O
+with O
+recurrent O
+VKH O
+syndrome O
+had O
+lower O
+frequencies O
+of O
+the O
+G O
+allele O
+and O
+GG O
+homozygosity O
+in O
+CFI O
+- O
+rs7356506 O
+when O
+compared O
+to O
+the O
+controls O
+( O
+p O
+= O
+0 O
+. O
+16 O
+, O
+odds O
+ratio O
+[ O
+OR O
+]= O
+0 O
+. O
+429 O
+, O
+95 O
+% O
+confidence O
+interval O
+[ O
+CI O
+]= O
+0 O
+. O
+212 O
+- O
+0 O
+. O
+871 O
+; O
+p O
+= O
+0 O
+. O
+14 O
+, O
+OR O
+= O
+0 O
+. O
+364 O
+, O
+95 O
+% O
+CI O
+= O
+0 O
+. O
+158 O
+- O
+0 O
+. O
+837 O
+, O
+respectively O
+). O
+
+Furthermore O
+, O
+there O
+were O
+significant O
+decreases O
+in O
+the O
+frequencies O
+of O
+the O
+G O
+allele O
+and O
+GG O
+homozygosity O
+in O
+CFI O
+- O
+rs7356506 O
+in O
+patients O
+with O
+VKH O
+syndrome O
+with O
+complicated O
+cataract O
+compared O
+to O
+the O
+controls O
+( O
+p O
+< O
+0 O
+. O
+1 O
+, O
+OR O
+= O
+0 O
+. O
+357 O
+, O
+95 O
+% O
+CI O
+= O
+0 O
+. O
+197 O
+- O
+0 O
+. O
+648 O
+; O
+p O
+< O
+0 O
+. O
+1 O
+, O
+OR O
+= O
+0 O
+. O
+273 O
+, O
+95 O
+% O
+CI O
+= O
+0 O
+. O
+135 O
+- O
+0 O
+. O
+551 O
+, O
+respectively O
+). O
+
+Nevertheless O
+, O
+no O
+significant O
+association O
+with O
+patients O
+with O
+VKH O
+syndrome O
+in O
+steroid B
+- O
+sensitive O
+statuses O
+was O
+detected O
+for O
+CFI O
+- O
+rs7356506 O
+polymorphisms O
+. O
+
+CONCLUSIONS O
+: O
+Our O
+results O
+indicate O
+that O
+CFI O
+polymorphisms O
+are O
+not O
+significantly O
+associated O
+with O
+VKH O
+syndrome O
+; O
+nevertheless O
+, O
+we O
+identified O
+a O
+trend O
+for O
+the O
+association O
+of O
+CFI O
+- O
+7356506 O
+with O
+VKH O
+syndrome O
+that O
+depends O
+on O
+the O
+recurrent O
+status O
+and O
+the O
+complicated O
+cataract O
+status O
+but O
+not O
+on O
+the O
+steroid B
+- O
+sensitive O
+status O
+. O
+
+
+Two O
+novel O
+mutations O
+in O
+the O
+MEN1 O
+gene O
+in O
+subjects O
+with O
+multiple O
+endocrine O
+neoplasia O
+- O
+1 O
+. O
+
+Multiple O
+endocrine O
+neoplasia O
+type O
+1 O
+( O
+MEN1 O
+) O
+is O
+characterized O
+by O
+parathyroid O
+, O
+enteropancreatic O
+endocrine O
+and O
+pituitary O
+adenomas O
+as O
+well O
+as O
+germline O
+mutation O
+of O
+the O
+MEN1 O
+gene O
+. O
+
+We O
+describe O
+2 O
+families O
+with O
+MEN1 O
+with O
+novel O
+mutations O
+in O
+the O
+MEN1 O
+gene O
+. O
+
+One O
+family O
+was O
+of O
+Turkish O
+origin O
+, O
+and O
+the O
+index O
+patient O
+had O
+primary O
+hyperparathyroidism O
+( O
+PHPT O
+) O
+plus O
+a O
+prolactinoma O
+; O
+three O
+relatives O
+had O
+PHPT O
+only O
+. O
+
+The O
+index O
+patient O
+in O
+the O
+second O
+family O
+was O
+a O
+46 O
+- O
+yr O
+- O
+old O
+woman O
+of O
+Chinese O
+origin O
+living O
+in O
+Taiwan O
+. O
+
+This O
+patient O
+presented O
+with O
+a O
+complaint O
+of O
+epigastric O
+pain O
+and O
+watery O
+diarrhea O
+over O
+the O
+past O
+3 O
+months O
+, O
+and O
+had O
+undergone O
+subtotal O
+parathyroidectomy O
+and O
+enucleation O
+of O
+pancreatic O
+islet O
+cell O
+tumor O
+about O
+10 O
+yr O
+before O
+. O
+
+There O
+was O
+also O
+a O
+prolactinoma O
+. O
+
+Sequence O
+analysis O
+of O
+the O
+MEN1 O
+gene O
+from O
+leukocyte O
+genomic O
+DNA O
+revealed O
+heterozygous O
+mutations O
+in O
+both O
+probands O
+. O
+
+The O
+Turkish O
+patient O
+and O
+her O
+affected O
+relatives O
+all O
+had O
+a O
+heterozygous O
+A O
+to O
+G O
+transition O
+at O
+codon O
+557 O
+( O
+AAG O
+--> O
+GAG O
+) O
+of O
+exon O
+10 O
+of O
+MEN1 O
+that O
+results O
+in O
+a O
+replacement O
+of O
+lysine O
+by O
+glutamic O
+acid O
+. O
+
+The O
+Chinese O
+index O
+patient O
+and O
+one O
+of O
+her O
+siblings O
+had O
+a O
+heterozygous O
+mutation O
+at O
+codon O
+418 O
+of O
+exon O
+9 O
+( O
+GAC O
+--> O
+TAT O
+) O
+that O
+results O
+in O
+a O
+substitution O
+of O
+aspartic O
+acid O
+by O
+tyrosine O
+. O
+
+In O
+conclusion O
+, O
+we O
+have O
+identified O
+2 O
+novel O
+missense O
+mutations O
+in O
+the O
+MEN1 O
+gene O
+. O
+
+
+Common O
+BRCA2 O
+variants O
+and O
+modification O
+of O
+breast O
+and O
+ovarian O
+cancer O
+risk O
+in O
+BRCA1 O
+mutation O
+carriers O
+. O
+
+The O
+HH O
+genotype O
+of O
+the O
+nonconservative O
+amino O
+acid O
+substitution O
+polymorphism O
+N372H O
+in O
+the O
+BRCA2 O
+gene O
+was O
+reported O
+to O
+be O
+associated O
+with O
+a O
+1 O
+. O
+3 O
+- O
+to O
+1 O
+. O
+5 O
+- O
+fold O
+increase O
+in O
+risk O
+of O
+both O
+breast O
+and O
+ovarian O
+cancer O
+. O
+
+As O
+these O
+studies O
+concerned O
+sporadic O
+cancer O
+cases O
+, O
+we O
+investigated O
+whether O
+N372H O
+and O
+another O
+common O
+variant O
+located O
+in O
+the O
+5 O
+'- O
+untranslated O
+region O
+( O
+203G O
+> O
+A O
+) O
+of O
+the O
+BRCA2 O
+gene O
+modify O
+breast O
+or O
+ovarian O
+cancer O
+risk O
+in O
+BRCA1 O
+mutation O
+carriers O
+. O
+
+The O
+study O
+includes O
+778 O
+women O
+carrying O
+a O
+BRCA1 O
+germ O
+- O
+line O
+mutation O
+belonging O
+to O
+403 O
+families O
+. O
+
+The O
+two O
+BRCA2 O
+variants O
+were O
+analyzed O
+by O
+the O
+TaqMan O
+allelic O
+discrimination O
+technique O
+. O
+
+Genotypes O
+were O
+analyzed O
+by O
+disease O
+- O
+free O
+survival O
+analysis O
+using O
+a O
+Cox O
+proportional O
+hazards O
+model O
+. O
+
+We O
+found O
+no O
+evidence O
+of O
+a O
+significant O
+modification O
+of O
+breast O
+cancer O
+penetrance O
+in O
+BRCA1 O
+mutation O
+carriers O
+by O
+either O
+polymorphism O
+. O
+
+In O
+respect O
+of O
+ovarian O
+cancer O
+risk O
+, O
+we O
+also O
+saw O
+no O
+effect O
+with O
+the O
+N372H O
+variant O
+but O
+we O
+did O
+observe O
+a O
+borderline O
+association O
+with O
+the O
+5 O
+'- O
+untranslated O
+region O
+203A O
+allele O
+( O
+hazard O
+ratio O
+, O
+1 O
+. O
+43 O
+; O
+CI O
+, O
+1 O
+. O
+1 O
+- O
+2 O
+. O
+0 O
+). O
+
+In O
+contrast O
+to O
+the O
+result O
+of O
+Healey O
+et O
+al O
+. O
+
+on O
+newborn O
+females O
+and O
+adult O
+female O
+controls O
+, O
+we O
+found O
+no O
+departure O
+from O
+Hardy O
+- O
+Weinberg O
+equilibrium O
+in O
+the O
+distribution O
+of O
+N372H O
+alleles O
+for O
+our O
+female O
+BRCA1 O
+carriers O
+. O
+
+We O
+conclude O
+that O
+if O
+these O
+single O
+- O
+nucleotide O
+polymorphisms O
+do O
+modify O
+the O
+risk O
+of O
+cancer O
+in O
+BRCA1 O
+mutation O
+carriers O
+, O
+their O
+effects O
+are O
+not O
+significantly O
+larger O
+than O
+that O
+of O
+N372H O
+previously O
+observed O
+in O
+the O
+general O
+population O
+. O
+
+
+Transgelin O
+increases O
+metastatic O
+potential O
+of O
+colorectal O
+cancer O
+cells O
+in O
+vivo O
+and O
+alters O
+expression O
+of O
+genes O
+involved O
+in O
+cell O
+motility O
+. O
+
+BACKGROUND O
+: O
+Transgelin O
+is O
+an O
+actin O
+- O
+binding O
+protein O
+that O
+promotes O
+motility O
+in O
+normal O
+cells O
+. O
+
+Although O
+the O
+role O
+of O
+transgelin O
+in O
+cancer O
+is O
+controversial O
+, O
+a O
+number O
+of O
+studies O
+have O
+shown O
+that O
+elevated O
+levels O
+correlate O
+with O
+aggressive O
+tumor O
+behavior O
+, O
+advanced O
+stage O
+, O
+and O
+poor O
+prognosis O
+. O
+
+Here O
+we O
+sought O
+to O
+determine O
+the O
+role O
+of O
+transgelin O
+more O
+directly O
+by O
+determining O
+whether O
+experimental O
+manipulation O
+of O
+transgelin O
+levels O
+in O
+colorectal O
+cancer O
+( O
+CRC O
+) O
+cells O
+led O
+to O
+changes O
+in O
+metastatic O
+potential O
+in O
+vivo O
+. O
+
+METHODS O
+: O
+Isogenic O
+CRC O
+cell O
+lines O
+that O
+differ O
+in O
+transgelin O
+expression O
+were O
+characterized O
+using O
+in O
+vitro O
+assays O
+of O
+growth O
+and O
+invasiveness O
+and O
+a O
+mouse O
+tail O
+vein O
+assay O
+of O
+experimental O
+metastasis O
+. O
+
+Downstream O
+effects O
+of O
+transgelin O
+overexpression O
+were O
+investigated O
+by O
+gene O
+expression O
+profiling O
+and O
+quantitative O
+PCR O
+. O
+
+RESULTS O
+: O
+Stable O
+overexpression O
+of O
+transgelin O
+in O
+RKO O
+cells O
+, O
+which O
+have O
+low O
+endogenous O
+levels O
+, O
+led O
+to O
+increased O
+invasiveness O
+, O
+growth O
+at O
+low O
+density O
+, O
+and O
+growth O
+in O
+soft O
+agar B
+. O
+
+Overexpression O
+also O
+led O
+to O
+an O
+increase O
+in O
+the O
+number O
+and O
+size O
+of O
+lung O
+metastases O
+in O
+the O
+mouse O
+tail O
+vein O
+injection O
+model O
+. O
+
+Similarly O
+, O
+attenuation O
+of O
+transgelin O
+expression O
+in O
+HCT116 O
+cells O
+, O
+which O
+have O
+high O
+endogenous O
+levels O
+, O
+decreased O
+metastases O
+in O
+the O
+same O
+model O
+. O
+
+Investigation O
+of O
+mRNA O
+expression O
+patterns O
+showed O
+that O
+transgelin O
+overexpression O
+altered O
+the O
+levels O
+of O
+approximately O
+250 O
+other O
+transcripts O
+, O
+with O
+over O
+- O
+representation O
+of O
+genes O
+that O
+affect O
+function O
+of O
+actin O
+or O
+other O
+cytoskeletal O
+proteins O
+. O
+
+Changes O
+included O
+increases O
+in O
+HOOK1 O
+, O
+SDCCAG8 O
+, O
+ENAH O
+/ O
+Mena O
+, O
+and O
+TNS1 O
+and O
+decreases O
+in O
+EMB O
+, O
+BCL11B O
+, O
+and O
+PTPRD O
+. O
+
+CONCLUSIONS O
+: O
+Increases O
+or O
+decreases O
+in O
+transgelin O
+levels O
+have O
+reciprocal O
+effects O
+on O
+tumor O
+cell O
+behavior O
+, O
+with O
+higher O
+expression O
+promoting O
+metastasis O
+. O
+
+Chronic O
+overexpression O
+influences O
+steady O
+- O
+state O
+levels O
+of O
+mRNAs O
+for O
+metastasis O
+- O
+related O
+genes O
+. O
+
+
+Association O
+of O
+sporadic O
+chondrocalcinosis O
+with O
+a O
+- O
+4 O
+- O
+basepair O
+G O
+- O
+to O
+- O
+A O
+transition O
+in O
+the O
+5 O
+'- O
+untranslated O
+region O
+of O
+ANKH O
+that O
+promotes O
+enhanced O
+expression O
+of O
+ANKH O
+protein O
+and O
+excess O
+generation O
+of O
+extracellular O
+inorganic B
+pyrophosphate I
+. O
+
+OBJECTIVE O
+: O
+Certain O
+mutations O
+in O
+ANKH O
+, O
+which O
+encodes O
+a O
+multiple O
+- O
+pass O
+transmembrane O
+protein O
+that O
+regulates O
+inorganic B
+pyrophosphate I
+( O
+PPi B
+) O
+transport O
+, O
+are O
+linked O
+to O
+autosomal O
+- O
+dominant O
+familial O
+chondrocalcinosis O
+. O
+
+This O
+study O
+investigated O
+the O
+potential O
+for O
+ANKH O
+sequence O
+variants O
+to O
+promote O
+sporadic O
+chondrocalcinosis O
+. O
+
+METHODS O
+: O
+ANKH O
+variants O
+identified O
+by O
+genomic O
+sequencing O
+were O
+screened O
+for O
+association O
+with O
+chondrocalcinosis O
+in O
+128 O
+patients O
+with O
+severe O
+sporadic O
+chondrocalcinosis O
+or O
+pseudogout O
+and O
+in O
+ethnically O
+matched O
+healthy O
+controls O
+. O
+
+The O
+effects O
+of O
+specific O
+variants O
+on O
+expression O
+of O
+common O
+markers O
+were O
+evaluated O
+by O
+in O
+vitro O
+transcription O
+/ O
+translation O
+. O
+
+The O
+function O
+of O
+these O
+variants O
+was O
+studied O
+in O
+transfected O
+human O
+immortalized O
+CH O
+- O
+8 O
+articular O
+chondrocytes O
+. O
+
+RESULTS O
+: O
+Sporadic O
+chondrocalcinosis O
+was O
+associated O
+with O
+a O
+G O
+- O
+to O
+- O
+A O
+transition O
+in O
+the O
+ANKH O
+5 O
+'- O
+untranslated O
+region O
+( O
+5 O
+'- O
+UTR O
+) O
+at O
+4 O
+bp O
+upstream O
+of O
+the O
+start O
+codon O
+( O
+in O
+homozygotes O
+of O
+the O
+minor O
+allele O
+, O
+genotype O
+relative O
+risk O
+6 O
+. O
+0 O
+, O
+P O
+= O
+0 O
+. O
+6 O
+; O
+overall O
+genotype O
+association O
+P O
+= O
+0 O
+. O
+2 O
+). O
+
+This O
+- O
+4 O
+- O
+bp O
+transition O
+, O
+as O
+well O
+as O
+2 O
+mutations O
+previously O
+linked O
+with O
+familial O
+and O
+sporadic O
+chondrocalcinosis O
+(+ O
+14 O
+bp O
+C O
+- O
+to O
+- O
+T O
+and O
+C O
+- O
+terminal O
+GAG O
+deletion O
+, O
+respectively O
+), O
+but O
+not O
+the O
+French O
+familial O
+chondrocalcinosis O
+kindred O
+143 O
+- O
+bp O
+T O
+- O
+to O
+- O
+C O
+mutation O
+, O
+increased O
+reticulocyte O
+ANKH O
+transcription O
+/ O
+ANKH O
+translation O
+in O
+vitro O
+. O
+
+Transfection O
+of O
+complementary O
+DNA O
+for O
+both O
+the O
+wild O
+- O
+type O
+ANKH O
+and O
+the O
+- O
+4 O
+- O
+bp O
+ANKH O
+protein O
+variant O
+promoted O
+increased O
+extracellular O
+PPi B
+in O
+CH O
+- O
+8 O
+cells O
+, O
+but O
+unexpectedly O
+, O
+these O
+ANKH O
+mutants O
+had O
+divergent O
+effects O
+on O
+the O
+expression O
+of O
+extracellular O
+PPi B
+and O
+the O
+chondrocyte O
+hypertrophy O
+marker O
+, O
+type O
+X O
+collagen O
+. O
+
+CONCLUSION O
+: O
+A O
+subset O
+of O
+sporadic O
+chondrocalcinosis O
+appears O
+to O
+be O
+heritable O
+via O
+a O
+- O
+4 O
+- O
+bp O
+G O
+- O
+to O
+- O
+A O
+ANKH O
+5 O
+'- O
+UTR O
+transition O
+that O
+up O
+- O
+regulates O
+expression O
+of O
+ANKH O
+and O
+extracellular O
+PPi O
+in O
+chondrocyte O
+cells O
+. O
+
+Distinct O
+ANKH O
+mutations O
+associated O
+with O
+heritable O
+chondrocalcinosis O
+may O
+promote O
+disease O
+by O
+divergent O
+effects O
+on O
+extracellular O
+PPi B
+and O
+chondrocyte O
+hypertrophy O
+, O
+which O
+is O
+likely O
+to O
+mediate O
+differences O
+in O
+the O
+clinical O
+phenotypes O
+and O
+severity O
+of O
+the O
+disease O
+. O
+
+
+Contribution O
+of O
+STAT4 O
+gene O
+single O
+- O
+nucleotide O
+polymorphism O
+to O
+systemic O
+lupus O
+erythematosus O
+in O
+the O
+Polish O
+population O
+. O
+
+The O
+STAT4 O
+has O
+been O
+found O
+to O
+be O
+a O
+susceptible O
+gene O
+in O
+the O
+development O
+of O
+systemic O
+lupus O
+erythematosus O
+( O
+SLE O
+) O
+in O
+various O
+populations O
+. O
+
+There O
+are O
+evident O
+population O
+differences O
+in O
+the O
+context O
+of O
+clinical O
+manifestations O
+of O
+SLE O
+, O
+therefore O
+we O
+investigated O
+the O
+prevalence O
+of O
+the O
+STAT4 O
+G O
+> O
+C O
+( O
+rs7582694 O
+) O
+polymorphism O
+in O
+patients O
+with O
+SLE O
+( O
+n O
+= O
+253 O
+) O
+and O
+controls O
+( O
+n O
+= O
+521 O
+) O
+in O
+a O
+sample O
+of O
+the O
+Polish O
+population O
+. O
+
+We O
+found O
+that O
+patients O
+with O
+the O
+STAT4 O
+C O
+/ O
+G O
+and O
+CC O
+genotypes O
+exhibited O
+a O
+1 O
+. O
+583 O
+- O
+fold O
+increased O
+risk O
+of O
+SLE O
+incidence O
+( O
+95 O
+% O
+CI O
+= O
+1 O
+. O
+168 O
+- O
+2 O
+. O
+145 O
+, O
+p O
+= O
+0 O
+. O
+3 O
+), O
+with O
+OR O
+for O
+the O
+C O
+/ O
+C O
+versus O
+C O
+/ O
+G O
+and O
+G O
+/ O
+G O
+genotypes O
+was O
+1 O
+. O
+967 O
+( O
+95 O
+% O
+CI O
+= O
+1 O
+. O
+152 O
+- O
+3 O
+. O
+358 O
+, O
+p O
+= O
+0 O
+. O
+119 O
+). O
+
+The O
+OR O
+for O
+the O
+STAT4 O
+C O
+allele O
+frequency O
+showed O
+a O
+1 O
+. O
+539 O
+- O
+fold O
+increased O
+risk O
+of O
+SLE O
+( O
+95 O
+% O
+CI O
+= O
+1 O
+. O
+209 O
+- O
+1 O
+. O
+959 O
+, O
+p O
+= O
+0 O
+. O
+4 O
+). O
+
+We O
+also O
+observed O
+an O
+increased O
+frequency O
+of O
+STAT4 O
+C O
+/ O
+C O
+and O
+C O
+/ O
+G O
+genotypes O
+in O
+SLE O
+patients O
+with O
+renal O
+symptoms O
+OR O
+= O
+2 O
+. O
+259 O
+( O
+1 O
+. O
+365 O
+- O
+3 O
+. O
+738 O
+, O
+p O
+= O
+0 O
+. O
+14 O
+), O
+( O
+p O
+( O
+corr O
+) O
+= O
+0 O
+. O
+238 O
+) O
+and O
+in O
+SLE O
+patients O
+with O
+neurologic O
+manifestations O
+OR O
+= O
+2 O
+. O
+867 O
+( O
+1 O
+. O
+467 O
+- O
+5 O
+. O
+604 O
+, O
+p O
+= O
+0 O
+. O
+16 O
+), O
+( O
+p O
+( O
+corr O
+) O
+= O
+0 O
+. O
+272 O
+). O
+
+Moreover O
+, O
+we O
+found O
+a O
+contribution O
+of O
+STAT4 O
+C O
+/ O
+C O
+and O
+C O
+/ O
+G O
+genotypes O
+to O
+the O
+presence O
+of O
+the O
+anti O
+- O
+snRNP O
+Ab O
+OR O
+= O
+3 O
+. O
+237 O
+( O
+1 O
+. O
+667 O
+- O
+6 O
+. O
+288 O
+, O
+p O
+= O
+0 O
+. O
+3 O
+), O
+( O
+p O
+( O
+corr O
+) O
+= O
+0 O
+. O
+51 O
+) O
+and O
+the O
+presence O
+of O
+the O
+anti O
+- O
+Scl O
+- O
+70 O
+Ab O
+OR O
+= O
+2 O
+. O
+665 O
+( O
+1 O
+. O
+380 O
+- O
+5 O
+. O
+147 O
+, O
+p O
+= O
+0 O
+. O
+28 O
+), O
+( O
+p O
+( O
+corr O
+) O
+= O
+0 O
+. O
+476 O
+). O
+
+Our O
+studies O
+confirmed O
+an O
+association O
+of O
+the O
+STAT4 O
+C O
+( O
+rs7582694 O
+) O
+variant O
+with O
+the O
+development O
+of O
+SLE O
+and O
+occurrence O
+of O
+some O
+clinical O
+manifestations O
+of O
+the O
+disease O
+. O
+
+
+Leukemia O
+inhibitory O
+factor O
+protects O
+the O
+lung O
+during O
+respiratory O
+syncytial O
+viral O
+infection O
+. O
+
+BACKGROUND O
+: O
+Respiratory O
+syncytial O
+virus O
+( O
+RSV O
+) O
+infects O
+the O
+lung O
+epithelium O
+where O
+it O
+stimulates O
+the O
+production O
+of O
+numerous O
+host O
+cytokines O
+that O
+are O
+associated O
+with O
+disease O
+burden O
+and O
+acute O
+lung O
+injury O
+. O
+
+Characterizing O
+the O
+host O
+cytokine O
+response O
+to O
+RSV O
+infection O
+, O
+the O
+regulation O
+of O
+host O
+cytokines O
+and O
+the O
+impact O
+of O
+neutralizing O
+an O
+RSV O
+- O
+inducible O
+cytokine O
+during O
+infection O
+were O
+undertaken O
+in O
+this O
+study O
+. O
+
+METHODS O
+: O
+A549 O
+, O
+primary O
+human O
+small O
+airway O
+epithelial O
+( O
+SAE O
+) O
+cells O
+and O
+wild O
+- O
+type O
+, O
+TIR O
+- O
+domain O
+- O
+containing O
+adapter O
+- O
+inducing O
+interferon O
+- O
+b O
+( O
+Trif O
+) O
+and O
+mitochondrial O
+antiviral O
+- O
+signaling O
+protein O
+( O
+Mavs O
+) O
+knockout O
+( O
+KO O
+) O
+mice O
+were O
+infected O
+with O
+RSV O
+and O
+cytokine O
+responses O
+were O
+investigated O
+by O
+ELISA O
+, O
+multiplex O
+analysis O
+and O
+qPCR O
+. O
+
+Neutralizing O
+anti O
+- O
+leukemia O
+inhibitory O
+factor O
+( O
+LIF O
+) O
+IgG O
+or O
+control O
+IgG O
+was O
+administered O
+to O
+a O
+group O
+of O
+wild O
+- O
+type O
+animals O
+prior O
+to O
+RSV O
+infection O
+. O
+
+RESULTS O
+AND O
+DISCUSSION O
+: O
+RSV O
+- O
+infected O
+A549 O
+and O
+SAE O
+cells O
+release O
+a O
+network O
+of O
+cytokines O
+, O
+including O
+newly O
+identified O
+RSV O
+- O
+inducible O
+cytokines O
+LIF O
+, O
+migration O
+inhibitory O
+factor O
+( O
+MIF O
+), O
+stem O
+cell O
+factor O
+( O
+SCF O
+), O
+CCL27 O
+, O
+CXCL12 O
+and O
+stem O
+cell O
+growth O
+factor O
+beta O
+( O
+SCGF O
+- O
+b O
+). O
+
+These O
+RSV O
+- O
+inducible O
+cytokines O
+were O
+also O
+observed O
+in O
+the O
+airways O
+of O
+mice O
+during O
+an O
+infection O
+. O
+
+To O
+identify O
+the O
+regulation O
+of O
+RSV O
+inducible O
+cytokines O
+, O
+Mavs O
+and O
+Trif O
+deficient O
+animals O
+were O
+infected O
+with O
+RSV O
+. O
+
+In O
+vivo O
+induction O
+of O
+airway O
+IL O
+- O
+1b O
+, O
+IL O
+- O
+4 O
+, O
+IL O
+- O
+5 O
+, O
+IL O
+- O
+6 O
+, O
+IL O
+- O
+12 O
+( O
+p40 O
+), O
+IFN O
+- O
+g O
+, O
+CCL2 O
+, O
+CCL5 O
+, O
+CCL3 O
+, O
+CXCL1 O
+, O
+IP O
+- O
+10 O
+/ O
+CXCL10 O
+, O
+IL O
+- O
+22 O
+, O
+MIG O
+/ O
+CXCL9 O
+and O
+MIF O
+were O
+dependent O
+on O
+Mavs O
+expression O
+in O
+mice O
+. O
+
+Loss O
+of O
+Trif O
+expression O
+in O
+mice O
+altered O
+the O
+RSV O
+induction O
+of O
+IL O
+- O
+1b O
+, O
+IL O
+- O
+5 O
+, O
+CXCL12 O
+, O
+MIF O
+, O
+LIF O
+, O
+CXCL12 O
+and O
+IFN O
+- O
+g O
+. O
+
+Silencing O
+of O
+retinoic O
+acid O
+- O
+inducible O
+gene O
+- O
+1 O
+( O
+RIG O
+- O
+I O
+) O
+expression O
+in O
+A549 O
+cells O
+had O
+a O
+greater O
+impact O
+on O
+RSV O
+- O
+inducible O
+cytokines O
+than O
+melanoma O
+differentiation O
+- O
+associated O
+protein O
+5 O
+( O
+MDA5 O
+) O
+and O
+laboratory O
+of O
+genetics O
+and O
+physiology O
+2 O
+( O
+LGP2 O
+), O
+and O
+Trif O
+expression O
+. O
+
+To O
+evaluate O
+the O
+role O
+of O
+LIF O
+in O
+the O
+airways O
+during O
+RSV O
+infection O
+, O
+animals O
+were O
+treated O
+with O
+neutralizing O
+anti O
+- O
+LIF O
+IgG O
+, O
+which O
+enhanced O
+RSV O
+pathology O
+observed O
+with O
+increased O
+airspace O
+protein O
+content O
+, O
+apoptosis O
+and O
+airway O
+hyperresponsiveness O
+compared O
+to O
+control O
+IgG O
+treatment O
+. O
+
+CONCLUSIONS O
+: O
+RSV O
+infection O
+in O
+the O
+epithelium O
+induces O
+a O
+network O
+of O
+immune O
+factors O
+to O
+counter O
+infection O
+, O
+primarily O
+in O
+a O
+RIG O
+- O
+I O
+dependent O
+manner O
+. O
+
+Expression O
+of O
+LIF O
+protects O
+the O
+lung O
+from O
+lung O
+injury O
+and O
+enhanced O
+pathology O
+during O
+RSV O
+infection O
+. O
+
+
+Urinary O
+bladder O
+cancer O
+in O
+Wegener O
+' O
+s O
+granulomatosis O
+: O
+risks O
+and O
+relation O
+to O
+cyclophosphamide B
+. O
+
+OBJECTIVE O
+: O
+To O
+assess O
+and O
+characterise O
+the O
+risk O
+of O
+bladder O
+cancer O
+, O
+and O
+its O
+relation O
+to O
+cyclophosphamide B
+, O
+in O
+patients O
+with O
+Wegener O
+' O
+s O
+granulomatosis O
+. O
+
+METHODS O
+: O
+In O
+the O
+population O
+based O
+, O
+nationwide O
+Swedish O
+Inpatient O
+Register O
+a O
+cohort O
+of O
+1065 O
+patients O
+with O
+Wegener O
+' O
+s O
+granulomatosis O
+, O
+1969 O
+- O
+95 O
+, O
+was O
+identified O
+. O
+
+Through O
+linkage O
+with O
+the O
+Swedish O
+Cancer O
+Register O
+, O
+all O
+subjects O
+in O
+this O
+cohort O
+diagnosed O
+with O
+bladder O
+cancer O
+were O
+identified O
+. O
+
+Nested O
+within O
+the O
+cohort O
+, O
+a O
+matched O
+case O
+- O
+control O
+study O
+was O
+performed O
+to O
+estimate O
+the O
+association O
+between O
+cyclophosphamide B
+and O
+bladder O
+cancer O
+using O
+odds O
+ratios O
+( O
+ORs O
+) O
+as O
+relative O
+risk O
+. O
+
+In O
+the O
+cohort O
+the O
+cumulative O
+risk O
+of O
+bladder O
+cancer O
+after O
+Wegener O
+' O
+s O
+granulomatosis O
+, O
+and O
+the O
+relative O
+prevalence O
+of O
+a O
+history O
+of O
+bladder O
+cancer O
+at O
+the O
+time O
+of O
+diagnosis O
+of O
+Wegener O
+' O
+s O
+granulomatosis O
+, O
+were O
+also O
+estimated O
+. O
+
+RESULTS O
+: O
+The O
+median O
+cumulative O
+doses O
+of O
+cyclophosphamide B
+among O
+cases O
+( O
+n O
+= O
+11 O
+) O
+and O
+controls O
+( O
+n O
+= O
+25 O
+) O
+were O
+113 O
+g O
+and O
+25 O
+g O
+, O
+respectively O
+. O
+
+The O
+risk O
+of O
+bladder O
+cancer O
+doubled O
+for O
+every O
+10 O
+g O
+increment O
+in O
+cyclophosphamide B
+( O
+OR O
+= O
+2 O
+. O
+0 O
+, O
+95 O
+% O
+confidence O
+interval O
+( O
+CI O
+) O
+0 O
+. O
+8 O
+to O
+4 O
+. O
+9 O
+). O
+
+Treatment O
+duration O
+longer O
+than O
+1 O
+year O
+was O
+associated O
+with O
+an O
+eightfold O
+increased O
+risk O
+( O
+OR O
+= O
+7 O
+. O
+7 O
+, O
+95 O
+% O
+CI O
+0 O
+. O
+9 O
+to O
+69 O
+). O
+
+The O
+absolute O
+risk O
+for O
+bladder O
+cancer O
+in O
+the O
+cohort O
+reached O
+10 O
+% O
+16 O
+years O
+after O
+diagnosis O
+of O
+Wegener O
+' O
+s O
+granulomatosis O
+, O
+and O
+a O
+history O
+of O
+bladder O
+cancer O
+was O
+( O
+non O
+- O
+significantly O
+) O
+twice O
+as O
+common O
+as O
+expected O
+at O
+the O
+time O
+of O
+diagnosis O
+of O
+Wegener O
+' O
+s O
+granulomatosis O
+. O
+
+CONCLUSION O
+: O
+The O
+results O
+indicate O
+a O
+dose O
+- O
+response O
+relationship O
+between O
+cyclophosphamide B
+and O
+the O
+risk O
+of O
+bladder O
+cancer O
+, O
+high O
+cumulative O
+risks O
+in O
+the O
+entire O
+cohort O
+, O
+and O
+also O
+the O
+possibility O
+of O
+risk O
+factors O
+operating O
+even O
+before O
+Wegener O
+' O
+s O
+granulomatosis O
+. O
+
+
+Co O
+- O
+inheritance O
+of O
+a O
+PKD1 O
+mutation O
+and O
+homozygous O
+PKD2 O
+variant O
+: O
+a O
+potential O
+modifier O
+in O
+autosomal O
+dominant O
+polycystic O
+kidney O
+disease O
+. O
+
+BACKGROUND O
+: O
+Autosomal O
+dominant O
+polycystic O
+kidney O
+disease O
+( O
+ADPKD O
+), O
+which O
+is O
+caused O
+by O
+mutations O
+in O
+polycystins O
+1 O
+( O
+PC1 O
+) O
+and O
+2 O
+( O
+PC2 O
+), O
+is O
+one O
+of O
+the O
+most O
+commonly O
+inherited O
+renal O
+diseases O
+, O
+affecting O
+~ O
+1 O
+: O
+1000 O
+Caucasians O
+. O
+
+MATERIALS O
+AND O
+METHODS O
+: O
+We O
+screened O
+Greek O
+ADPKD O
+patients O
+with O
+the O
+denaturing O
+gradient O
+gel O
+electrophoresis O
+( O
+DGGE O
+) O
+assay O
+and O
+direct O
+sequencing O
+. O
+
+RESULTS O
+: O
+We O
+identified O
+a O
+patient O
+homozygous O
+for O
+a O
+nucleotide O
+change O
+c O
+. O
+1445T O
+> O
+G O
+, O
+resulting O
+in O
+a O
+novel O
+homozygous O
+substitution O
+of O
+the O
+non O
+- O
+polar O
+hydrophobic O
+phenylalanine O
+to O
+the O
+polar O
+hydrophilic O
+cysteine O
+in O
+exon O
+6 O
+at O
+codon O
+482 O
+( O
+p O
+. O
+F482C O
+) O
+of O
+the O
+PKD2 O
+gene O
+and O
+a O
+de O
+- O
+novo O
+PKD1 O
+splice O
+- O
+site O
+variant O
+IVS21 O
+- O
+2delAG O
+. O
+
+We O
+did O
+not O
+find O
+this O
+PKD2 O
+variant O
+in O
+a O
+screen O
+of O
+280 O
+chromosomes O
+of O
+healthy O
+subjects O
+, O
+supporting O
+its O
+pathogenicity O
+. O
+
+The O
+proband O
+' O
+s O
+parents O
+did O
+not O
+have O
+the O
+PKD1 O
+mutation O
+. O
+
+Real O
+- O
+time O
+PCR O
+of O
+the O
+PKD2 O
+transcript O
+from O
+a O
+skin O
+biopsy O
+revealed O
+20 O
+- O
+fold O
+higher O
+expression O
+in O
+the O
+patient O
+than O
+in O
+a O
+healthy O
+subject O
+and O
+was O
+higher O
+in O
+the O
+patient O
+' O
+s O
+peripheral O
+blood O
+mononuclear O
+cells O
+( O
+PBMCs O
+) O
+than O
+in O
+those O
+of O
+her O
+heterozygote O
+daughter O
+and O
+a O
+healthy O
+subject O
+. O
+
+The O
+greater O
+gene O
+expression O
+was O
+also O
+supported O
+by O
+Western O
+blotting O
+. O
+
+Inner O
+medullar O
+collecting O
+duct O
+( O
+IMCD O
+) O
+cells O
+transfected O
+with O
+the O
+mutant O
+PKD2 O
+mouse O
+gene O
+presented O
+a O
+perinuclear O
+and O
+diffuse O
+cytoplasmic O
+localization O
+compared O
+with O
+the O
+wild O
+type O
+ER O
+localization O
+. O
+
+Patch O
+- O
+clamping O
+of O
+PBMCs O
+from O
+the O
+p O
+. O
+F482C O
+homozygous O
+and O
+heterozygous O
+subjects O
+revealed O
+lower O
+polycystin O
+- O
+2 O
+channel O
+function O
+than O
+in O
+controls O
+. O
+
+CONCLUSIONS O
+: O
+We O
+report O
+for O
+the O
+first O
+time O
+a O
+patient O
+with O
+ADPKD O
+who O
+is O
+heterozygous O
+for O
+a O
+de O
+novo O
+PKD1 O
+variant O
+and O
+homozygous O
+for O
+a O
+novel O
+PKD2 O
+mutation O
+. O
+
+
+Two O
+novel O
+mutations O
+of O
+the O
+TSH O
+- O
+beta O
+subunit O
+gene O
+underlying O
+congenital O
+central O
+hypothyroidism O
+undetectable O
+in O
+neonatal O
+TSH O
+screening O
+. O
+
+CONTEXT O
+: O
+Patients O
+with O
+TSH O
+- O
+beta O
+subunit O
+defects O
+and O
+congenital O
+hypothyroidism O
+are O
+missed O
+by O
+TSH O
+- O
+based O
+neonatal O
+screening O
+. O
+
+OBJECTIVE O
+: O
+Our O
+objective O
+was O
+to O
+report O
+the O
+molecular O
+consequences O
+of O
+a O
+novel O
+splice O
+- O
+junction O
+mutation O
+and O
+a O
+novel O
+missense O
+mutation O
+in O
+the O
+TSH O
+- O
+beta O
+subunit O
+gene O
+found O
+in O
+two O
+patients O
+with O
+congenital O
+central O
+hypothyroidism O
+and O
+conventional O
+treatment O
+- O
+resistant O
+anemia O
+. O
+
+RESULTS O
+: O
+Patient O
+1 O
+had O
+a O
+homozygous O
+G O
+to O
+A O
+nucleotide O
+change O
+at O
+the O
+5 O
+' O
+donor O
+splice O
+site O
+of O
+exon O
+/ O
+intron O
+2 O
+. O
+
+This O
+resulted O
+in O
+a O
+silent O
+change O
+at O
+codon O
+34 O
+of O
+the O
+mature O
+protein O
+. O
+
+In O
+vitro O
+splicing O
+assays O
+showed O
+that O
+the O
+mutant O
+minigene O
+dramatically O
+affected O
+pre O
+- O
+mRNA O
+processing O
+, O
+causing O
+exon O
+2 O
+to O
+be O
+completely O
+skipped O
+. O
+
+The O
+putative O
+product O
+from O
+a O
+new O
+out O
+- O
+of O
+- O
+frame O
+translational O
+start O
+point O
+in O
+exon O
+3 O
+is O
+expected O
+to O
+yield O
+a O
+nonsense O
+25 O
+- O
+amino O
+- O
+acid O
+peptide O
+. O
+
+In O
+patient O
+2 O
+, O
+sequence O
+analysis O
+revealed O
+a O
+compound O
+heterozygosis O
+for O
+the O
+already O
+reported O
+313delT O
+( O
+C105Vfs114X O
+) O
+mutation O
+and O
+for O
+a O
+second O
+novel O
+mutation O
+in O
+exon O
+3 O
+, O
+substituting O
+G O
+for O
+A O
+at O
+cDNA O
+nucleotide O
+position O
+323 O
+, O
+resulting O
+in O
+a O
+C88Y O
+change O
+. O
+
+This O
+cysteine O
+residue O
+is O
+conserved O
+among O
+all O
+dimeric O
+pituitary O
+and O
+placental O
+glycoprotein O
+hormone O
+- O
+beta O
+subunits O
+. O
+
+Data O
+from O
+in O
+silico O
+analysis O
+confirmed O
+that O
+the O
+C88Y O
+mutation O
+would O
+affect O
+subunit O
+conformation O
+. O
+
+Indeed O
+, O
+two O
+different O
+bioinformatics O
+approaches O
+, O
+PolyPhen O
+and O
+SIFT O
+analysis O
+, O
+predicted O
+C88Y O
+to O
+be O
+a O
+damaging O
+substitution O
+. O
+
+CONCLUSIONS O
+: O
+In O
+isolated O
+TSH O
+deficiency O
+, O
+the O
+exact O
+molecular O
+diagnosis O
+is O
+mandatory O
+for O
+diagnosis O
+of O
+isolated O
+pituitary O
+deficiency O
+, O
+delineation O
+of O
+prognosis O
+, O
+and O
+genetic O
+counseling O
+. O
+
+Moreover O
+, O
+diagnosis O
+of O
+central O
+hypothyroidism O
+should O
+be O
+considered O
+in O
+the O
+face O
+of O
+severe O
+infant O
+anemia O
+of O
+uncertain O
+etiology O
+. O
+
+
+Mutations O
+in O
+the O
+NDP O
+gene O
+: O
+contribution O
+to O
+Norrie O
+disease O
+, O
+familial O
+exudative O
+vitreoretinopathy O
+and O
+retinopathy O
+of O
+prematurity O
+. O
+
+BACKGROUND O
+: O
+To O
+examine O
+the O
+contribution O
+of O
+mutations O
+within O
+the O
+Norrie O
+disease O
+( O
+NDP O
+) O
+gene O
+to O
+the O
+clinically O
+similar O
+retinal O
+diseases O
+Norrie O
+disease O
+, O
+X O
+- O
+linked O
+familial O
+exudative O
+vitreoretinopathy O
+( O
+FEVR O
+), O
+Coat O
+' O
+s O
+disease O
+and O
+retinopathy O
+of O
+prematurity O
+( O
+ROP O
+). O
+
+METHODS O
+: O
+A O
+dataset O
+comprising O
+13 O
+Norrie O
+- O
+FEVR O
+, O
+one O
+Coat O
+' O
+s O
+disease O
+, O
+31 O
+ROP O
+patients O
+and O
+90 O
+ex O
+- O
+premature O
+babies O
+of O
+< O
+32 O
+weeks O
+' O
+gestation O
+underwent O
+an O
+ophthalmologic O
+examination O
+and O
+were O
+screened O
+for O
+mutations O
+within O
+the O
+NDP O
+gene O
+by O
+direct O
+DNA O
+sequencing O
+, O
+denaturing O
+high O
+- O
+performance O
+liquid O
+chromatography O
+or O
+gel O
+electrophoresis O
+. O
+
+Controls O
+were O
+only O
+screened O
+using O
+denaturing O
+high O
+- O
+performance O
+liquid O
+chromatography O
+and O
+gel O
+electrophoresis O
+. O
+
+Confirmation O
+of O
+mutations O
+identified O
+was O
+obtained O
+by O
+DNA O
+sequencing O
+. O
+
+RESULTS O
+: O
+Evidence O
+for O
+two O
+novel O
+mutations O
+in O
+the O
+NDP O
+gene O
+was O
+presented O
+: O
+Leu103Val O
+in O
+one O
+FEVR O
+patient O
+and O
+His43Arg O
+in O
+monozygotic O
+twin O
+Norrie O
+disease O
+patients O
+. O
+
+Furthermore O
+, O
+a O
+previously O
+described O
+14 O
+- O
+bp O
+deletion O
+located O
+in O
+the O
+5 O
+' O
+unstranslated O
+region O
+of O
+the O
+NDP O
+gene O
+was O
+detected O
+in O
+three O
+cases O
+of O
+regressed O
+ROP O
+. O
+
+A O
+second O
+heterozygotic O
+14 O
+- O
+bp O
+deletion O
+was O
+detected O
+in O
+an O
+unaffected O
+ex O
+- O
+premature O
+girl O
+. O
+
+Only O
+two O
+of O
+the O
+13 O
+Norrie O
+- O
+FEVR O
+index O
+cases O
+had O
+the O
+full O
+features O
+of O
+Norrie O
+disease O
+with O
+deafness O
+and O
+mental O
+retardation O
+. O
+
+CONCLUSION O
+: O
+Two O
+novel O
+mutations O
+within O
+the O
+coding O
+region O
+of O
+the O
+NDP O
+gene O
+were O
+found O
+, O
+one O
+associated O
+with O
+a O
+severe O
+disease O
+phenotypes O
+of O
+Norrie O
+disease O
+and O
+the O
+other O
+with O
+FEVR O
+. O
+
+A O
+deletion O
+within O
+the O
+non O
+- O
+coding O
+region O
+was O
+associated O
+with O
+only O
+mild O
+- O
+regressed O
+ROP O
+, O
+despite O
+the O
+presence O
+of O
+low O
+birthweight O
+, O
+prematurity O
+and O
+exposure O
+to O
+oxygen B
+. O
+
+In O
+full O
+- O
+term O
+children O
+with O
+retinal O
+detachment O
+only O
+15 O
+% O
+appear O
+to O
+have O
+the O
+full O
+features O
+of O
+Norrie O
+disease O
+and O
+this O
+is O
+important O
+for O
+counselling O
+parents O
+on O
+the O
+possible O
+long O
+- O
+term O
+outcome O
+. O
+
+
+Growth O
+hormone O
+dose O
+in O
+growth O
+hormone O
+- O
+deficient O
+adults O
+is O
+not O
+associated O
+with O
+IGF O
+- O
+1 O
+gene O
+polymorphisms O
+. O
+
+AIMS O
+: O
+Several O
+SNPs O
+and O
+a O
+microsatellite O
+cytosine O
+- O
+adenine O
+repeat O
+promoter O
+polymorphism O
+of O
+the O
+IGF O
+- O
+1 O
+gene O
+have O
+been O
+reported O
+to O
+be O
+associated O
+with O
+circulating O
+IGF O
+- O
+1 O
+serum O
+concentrations O
+. O
+
+Variance O
+in O
+IGF O
+- O
+1 O
+concentrations O
+due O
+to O
+genetic O
+variations O
+may O
+affect O
+different O
+response O
+to O
+growth O
+hormone O
+( O
+GH O
+) O
+treatment O
+, O
+resulting O
+in O
+different O
+individually O
+required O
+GH O
+- O
+doses O
+in O
+GH O
+- O
+deficient O
+patients O
+. O
+
+The O
+aim O
+of O
+this O
+study O
+was O
+to O
+test O
+if O
+the O
+IGF O
+- O
+1 O
+gene O
+polymorphisms O
+are O
+associated O
+with O
+the O
+GH O
+- O
+dose O
+of O
+GH O
+- O
+deficient O
+adults O
+. O
+
+MATERIALS O
+& O
+METHODS O
+: O
+A O
+total O
+of O
+nine O
+tagging O
+SNPs O
+, O
+five O
+additionally O
+selected O
+SNPs O
+and O
+a O
+cytosine O
+- O
+adenine O
+repeat O
+polymorphism O
+were O
+determined O
+in O
+133 O
+German O
+adult O
+patients O
+( O
+66 O
+men O
+, O
+67 O
+women O
+; O
+mean O
+age O
+45 O
+. O
+4 O
+years O
++/- O
+13 O
+. O
+1 O
+standard O
+deviation O
+; O
+majority O
+Caucasian O
+) O
+with O
+GH O
+- O
+deficiency O
+( O
+GHD O
+) O
+of O
+different O
+origin O
+, O
+derived O
+from O
+the O
+prospective O
+Pfizer O
+International O
+Metabolic O
+Study O
+( O
+KIMS O
+) O
+Pharmacogenetics O
+Study O
+. O
+
+Patients O
+received O
+GH O
+- O
+treatment O
+for O
+12 O
+months O
+with O
+finished O
+dose O
+- O
+titration O
+of O
+GH O
+and O
+centralized O
+IGF O
+- O
+1 O
+measurements O
+. O
+
+GH O
+- O
+dose O
+after O
+1 O
+year O
+of O
+treatment O
+, O
+IGF O
+- O
+1 O
+concentrations O
+, O
+IGF O
+- O
+1 O
+- O
+standard O
+deviation O
+score O
+( O
+SDS O
+), O
+the O
+IGF O
+- O
+1 O
+: O
+GH O
+ratio O
+and O
+anthropometric O
+data O
+were O
+analyzed O
+by O
+genotype O
+. O
+
+RESULTS O
+: O
+Except O
+for O
+rs1019731 O
+, O
+which O
+showed O
+a O
+significant O
+difference O
+of O
+IGF O
+- O
+1 O
+- O
+SDS O
+by O
+genotypes O
+( O
+p O
+= O
+0 O
+. O
+2 O
+), O
+all O
+polymorphisms O
+showed O
+no O
+associations O
+with O
+the O
+GH O
+- O
+doses O
+, O
+IGF O
+- O
+1 O
+concentrations O
+, O
+IGF O
+- O
+1 O
+- O
+SDS O
+and O
+IGF O
+- O
+1 O
+: O
+GH O
+ratio O
+after O
+adjusting O
+for O
+the O
+confounding O
+variables O
+gender O
+, O
+age O
+and O
+BMI O
+. O
+
+CONCLUSION O
+: O
+IGF O
+- O
+1 O
+gene O
+polymorphisms O
+were O
+not O
+associated O
+with O
+the O
+responsiveness O
+to O
+exogenous O
+GH O
+in O
+GHD O
+. O
+
+Therefore O
+, O
+genetic O
+variations O
+of O
+the O
+IGF O
+- O
+1 O
+gene O
+seem O
+not O
+to O
+be O
+major O
+influencing O
+factors O
+of O
+the O
+GH O
+- O
+IGF O
+- O
+axis O
+causing O
+variable O
+response O
+to O
+exogenous O
+GH O
+- O
+treatment O
+. O
+
+
+Mutation O
+analysis O
+of O
+FOXF2 O
+in O
+patients O
+with O
+disorders O
+of O
+sex O
+development O
+( O
+DSD O
+) O
+in O
+combination O
+with O
+cleft O
+palate O
+. O
+
+In O
+contrast O
+to O
+disorders O
+of O
+sexual O
+differentiation O
+caused O
+by O
+lack O
+of O
+androgen B
+production O
+or O
+inhibited O
+androgen B
+action O
+, O
+defects O
+affecting O
+development O
+of O
+the O
+bipotent O
+genital O
+anlagen O
+have O
+rarely O
+been O
+investigated O
+in O
+humans O
+. O
+
+We O
+have O
+previously O
+documented O
+that O
+the O
+transcription O
+factor O
+FOXF2 O
+is O
+highly O
+expressed O
+in O
+human O
+foreskin O
+. O
+
+Moreover O
+, O
+Foxf2 O
+knockout O
+mice O
+present O
+with O
+cleft O
+palate O
+in O
+combination O
+with O
+hypoplasia O
+of O
+the O
+genital O
+tubercle O
+. O
+
+We O
+hypothesized O
+that O
+humans O
+with O
+disorders O
+of O
+sex O
+development O
+( O
+DSD O
+) O
+in O
+combination O
+with O
+cleft O
+palate O
+could O
+have O
+mutations O
+in O
+the O
+FOXF2 O
+gene O
+. O
+
+Eighteen O
+children O
+with O
+DSD O
+and O
+cleft O
+palate O
+were O
+identified O
+in O
+the O
+L O
+beck O
+DSD O
+database O
+( O
+about O
+1 O
+, O
+500 O
+entries O
+). O
+
+Genomic O
+DNA O
+sequence O
+analysis O
+of O
+the O
+FOXF2 O
+gene O
+was O
+performed O
+and O
+compared O
+with O
+10 O
+normal O
+female O
+and O
+10 O
+normal O
+male O
+controls O
+, O
+respectively O
+. O
+
+Two O
+heterozygous O
+DNA O
+sequence O
+variations O
+were O
+solely O
+present O
+in O
+one O
+single O
+patient O
+each O
+but O
+in O
+none O
+of O
+the O
+20 O
+normal O
+controls O
+: O
+a O
+duplication O
+of O
+GCC O
+( O
+c O
+. O
+97GCC O
+[ O
+9 O
+]+[ O
+10 O
+]) O
+resulting O
+in O
+an O
+extra O
+alanine O
+within O
+exon O
+1 O
+and O
+a O
+25 O
+* O
+G O
+> O
+A O
+substitution O
+in O
+the O
+3 O
+'- O
+untranslated O
+region O
+. O
+
+Two O
+patients O
+carried O
+a O
+c O
+. O
+262G O
+> O
+A O
+sequence O
+variation O
+predicting O
+for O
+an O
+Ala88Thr O
+exchange O
+which O
+was O
+also O
+detected O
+in O
+2 O
+normal O
+controls O
+. O
+
+Two O
+silent O
+mutations O
+, O
+c O
+. O
+1272C O
+> O
+T O
+( O
+Ser424Ser O
+) O
+and O
+c O
+. O
+1284T O
+> O
+C O
+( O
+Tyr428Tyr O
+), O
+respectively O
+, O
+occurred O
+in O
+the O
+coding O
+region O
+of O
+exon O
+2 O
+, O
+again O
+in O
+both O
+patients O
+and O
+normal O
+controls O
+. O
+
+In O
+conclusion O
+, O
+the O
+majority O
+of O
+the O
+detected O
+sequence O
+alterations O
+were O
+polymorphisms O
+without O
+obvious O
+functional O
+relevance O
+. O
+
+However O
+, O
+it O
+cannot O
+be O
+excluded O
+that O
+the O
+2 O
+unique O
+DNA O
+sequence O
+alterations O
+could O
+have O
+affected O
+FOXF2 O
+on O
+the O
+mRNA O
+or O
+protein O
+level O
+thus O
+contributing O
+to O
+the O
+observed O
+disturbances O
+in O
+genital O
+and O
+palate O
+development O
+. O
+
+
+A O
+novel O
+mutation O
+screening O
+system O
+for O
+Ehlers O
+- O
+Danlos O
+Syndrome O
+, O
+vascular O
+type O
+by O
+high O
+- O
+resolution O
+melting O
+curve O
+analysis O
+in O
+combination O
+with O
+small O
+amplicon O
+genotyping O
+using O
+genomic O
+DNA O
+. O
+
+Ehlers O
+- O
+Danlos O
+syndrome O
+, O
+vascular O
+type O
+( O
+vEDS O
+) O
+( O
+MIM O
+# O
+130050 O
+) O
+is O
+an O
+autosomal O
+dominant O
+disorder O
+caused O
+by O
+type O
+III O
+procollagen O
+gene O
+( O
+COL3A1 O
+) O
+mutations O
+. O
+
+Most O
+COL3A1 O
+mutations O
+are O
+detected O
+by O
+using O
+total O
+RNA O
+from O
+patient O
+- O
+derived O
+fibroblasts O
+, O
+which O
+requires O
+an O
+invasive O
+skin O
+biopsy O
+. O
+
+High O
+- O
+resolution O
+melting O
+curve O
+analysis O
+( O
+hrMCA O
+) O
+has O
+recently O
+been O
+developed O
+as O
+a O
+post O
+- O
+PCR O
+mutation O
+scanning O
+method O
+which O
+enables O
+simple O
+, O
+rapid O
+, O
+cost O
+- O
+effective O
+, O
+and O
+highly O
+sensitive O
+mutation O
+screening O
+of O
+large O
+genes O
+. O
+
+We O
+established O
+a O
+hrMCA O
+method O
+to O
+screen O
+for O
+COL3A1 O
+mutations O
+using O
+genomic O
+DNA O
+. O
+
+PCR O
+primers O
+pairs O
+for O
+COL3A1 O
+( O
+52 O
+amplicons O
+) O
+were O
+designed O
+to O
+cover O
+all O
+coding O
+regions O
+of O
+the O
+52 O
+exons O
+, O
+including O
+the O
+splicing O
+sites O
+. O
+
+We O
+used O
+15 O
+DNA O
+samples O
+( O
+8 O
+validation O
+samples O
+and O
+7 O
+samples O
+of O
+clinically O
+suspected O
+vEDS O
+patients O
+) O
+in O
+this O
+study O
+. O
+
+The O
+eight O
+known O
+COL3A1 O
+mutations O
+in O
+validation O
+samples O
+were O
+all O
+successfully O
+detected O
+by O
+the O
+hrMCA O
+. O
+
+In O
+addition O
+, O
+we O
+identified O
+five O
+novel O
+COL3A1 O
+mutations O
+, O
+including O
+one O
+deletion O
+( O
+c O
+. O
+2187delA O
+) O
+and O
+one O
+nonsense O
+mutation O
+( O
+c O
+. O
+2992C O
+> O
+T O
+) O
+that O
+could O
+not O
+be O
+determined O
+by O
+the O
+conventional O
+total O
+RNA O
+method O
+. O
+
+Furthermore O
+, O
+we O
+established O
+a O
+small O
+amplicon O
+genotyping O
+( O
+SAG O
+) O
+method O
+for O
+detecting O
+three O
+high O
+frequency O
+coding O
+- O
+region O
+SNPs O
+( O
+rs1800255 O
+: O
+G O
+> O
+A O
+, O
+rs1801184 O
+: O
+T O
+> O
+C O
+, O
+and O
+rs2271683 O
+: O
+A O
+> O
+G O
+) O
+in O
+COL3A1 O
+to O
+differentiate O
+mutations O
+before O
+sequencing O
+. O
+
+The O
+use O
+of O
+hrMCA O
+in O
+combination O
+with O
+SAG O
+from O
+genomic O
+DNA O
+enables O
+rapid O
+detection O
+of O
+COL3A1 O
+mutations O
+with O
+high O
+efficiency O
+and O
+specificity O
+. O
+
+A O
+better O
+understanding O
+of O
+the O
+genotype O
+- O
+phenotype O
+correlation O
+in O
+COL3A1 O
+using O
+this O
+method O
+will O
+lead O
+to O
+improve O
+in O
+diagnosis O
+and O
+treatment O
+. O
+
+
+Critical O
+role O
+of O
+neuronal O
+pentraxin O
+1 O
+in O
+mitochondria O
+- O
+mediated O
+hypoxic O
+- O
+ischemic O
+neuronal O
+injury O
+. O
+
+Developing O
+brain O
+is O
+highly O
+susceptible O
+to O
+hypoxic O
+- O
+ischemic O
+( O
+HI O
+) O
+injury O
+leading O
+to O
+severe O
+neurological O
+disabilities O
+in O
+surviving O
+infants O
+and O
+children O
+. O
+
+Previously O
+, O
+we O
+have O
+reported O
+induction O
+of O
+neuronal O
+pentraxin O
+1 O
+( O
+NP1 O
+), O
+a O
+novel O
+neuronal O
+protein O
+of O
+long O
+- O
+pentraxin O
+family O
+, O
+following O
+HI O
+neuronal O
+injury O
+. O
+
+Here O
+, O
+we O
+investigated O
+how O
+this O
+specific O
+signal O
+is O
+propagated O
+to O
+cause O
+the O
+HI O
+neuronal O
+death O
+. O
+
+We O
+used O
+wild O
+- O
+type O
+( O
+WT O
+) O
+and O
+NP1 O
+knockout O
+( O
+NP1 O
+- O
+KO O
+) O
+mouse O
+hippocampal O
+cultures O
+, O
+modeled O
+in O
+vitro O
+following O
+exposure O
+to O
+oxygen B
+glucose I
+deprivation O
+( O
+OGD O
+), O
+and O
+in O
+vivo O
+neonatal O
+( O
+P9 O
+- O
+10 O
+) O
+mouse O
+model O
+of O
+HI O
+brain O
+injury O
+. O
+
+Our O
+results O
+show O
+induction O
+of O
+NP1 O
+in O
+primary O
+hippocampal O
+neurons O
+following O
+OGD O
+exposure O
+( O
+4 O
+- O
+8 O
+h O
+) O
+and O
+in O
+the O
+ipsilateral O
+hippocampal O
+CA1 O
+and O
+CA3 O
+regions O
+at O
+24 O
+- O
+48 O
+h O
+post O
+- O
+HI O
+compared O
+to O
+the O
+contralateral O
+side O
+. O
+
+We O
+also O
+found O
+increased O
+PTEN O
+activity O
+concurrent O
+with O
+OGD O
+time O
+- O
+dependent O
+( O
+4 O
+- O
+8 O
+h O
+) O
+dephosphorylation O
+of O
+Akt O
+( O
+Ser473 O
+) O
+and O
+GSK O
+- O
+3b O
+( O
+Ser9 O
+). O
+
+OGD O
+also O
+caused O
+a O
+time O
+- O
+dependent O
+decrease O
+in O
+the O
+phosphorylation O
+of O
+Bad O
+( O
+Ser136 O
+), O
+and O
+Bax O
+protein O
+levels O
+. O
+
+Immunofluorescence O
+staining O
+and O
+subcellular O
+fractionation O
+analyses O
+revealed O
+increased O
+mitochondrial O
+translocation O
+of O
+Bad O
+and O
+Bax O
+proteins O
+from O
+cytoplasm O
+following O
+OGD O
+( O
+4 O
+h O
+) O
+and O
+simultaneously O
+increased O
+release O
+of O
+Cyt O
+C O
+from O
+mitochondria O
+followed O
+by O
+activation O
+of O
+caspase O
+- O
+3 O
+. O
+
+NP1 O
+protein O
+was O
+immunoprecipitated O
+with O
+Bad O
+and O
+Bax O
+proteins O
+; O
+OGD O
+caused O
+increased O
+interactions O
+of O
+NP1 O
+with O
+Bad O
+and O
+Bax O
+, O
+thereby O
+, O
+facilitating O
+their O
+mitochondrial O
+translocation O
+and O
+dissipation O
+of O
+mitochondrial O
+membrane O
+potential O
+( O
+D O
+( O
+m O
+)). O
+
+This O
+NP1 O
+induction O
+preceded O
+the O
+increased O
+mitochondrial O
+release O
+of O
+cytochrome B
+C I
+( O
+Cyt B
+C I
+) O
+into O
+the O
+cytosol O
+, O
+activation O
+of O
+caspase O
+- O
+3 O
+and O
+OGD O
+time O
+- O
+dependent O
+cell O
+death O
+in O
+WT O
+primary O
+hippocampal O
+neurons O
+. O
+
+In O
+contrast O
+, O
+in O
+NP1 O
+- O
+KO O
+neurons O
+there O
+was O
+no O
+translocation O
+of O
+Bad O
+and O
+Bax O
+from O
+cytosol O
+to O
+the O
+mitochondria O
+, O
+and O
+no O
+evidence O
+of O
+D O
+( O
+m O
+) O
+loss O
+, O
+increased O
+Cyt O
+C O
+release O
+and O
+caspase O
+- O
+3 O
+activation O
+following O
+OGD O
+; O
+which O
+resulted O
+in O
+significantly O
+reduced O
+neuronal O
+death O
+. O
+
+Our O
+results O
+indicate O
+a O
+regulatory O
+role O
+of O
+NP1 O
+in O
+Bad O
+/ O
+Bax O
+- O
+dependent O
+mitochondrial O
+release O
+of O
+Cyt O
+C O
+and O
+caspase O
+- O
+3 O
+activation O
+. O
+
+Together O
+our O
+findings O
+demonstrate O
+a O
+novel O
+mechanism O
+by O
+which O
+NP1 O
+regulates O
+mitochondria O
+- O
+driven O
+hippocampal O
+cell O
+death O
+; O
+suggesting O
+NP1 O
+as O
+a O
+potential O
+therapeutic O
+target O
+against O
+HI O
+brain O
+injury O
+in O
+neonates O
+. O
+
+
+Neuroprotective O
+effect O
+of O
+neuroserpin O
+in O
+oxygen B
+- O
+glucose O
+deprivation O
+- O
+and O
+reoxygenation O
+- O
+treated O
+rat O
+astrocytes O
+in O
+vitro O
+. O
+
+Neuroserpin O
+( O
+NSP O
+) O
+reportedly O
+exerts O
+neuroprotective O
+effects O
+in O
+cerebral O
+ischemic O
+animal O
+models O
+and O
+patients O
+; O
+however O
+, O
+the O
+mechanism O
+of O
+protection O
+is O
+poorly O
+understood O
+. O
+
+We O
+thus O
+attempted O
+to O
+confirm O
+neuroprotective O
+effects O
+of O
+NSP B
+on O
+astrocytes O
+in O
+the O
+ischemic O
+state O
+and O
+then O
+explored O
+the O
+relative O
+mechanisms O
+. O
+
+Astrocytes O
+from O
+neonatal O
+rats O
+were O
+treated O
+with O
+oxygen B
+- O
+glucose O
+deprivation O
+( O
+OGD O
+) O
+followed O
+by O
+reoxygenation O
+( O
+OGD O
+/ O
+R O
+). O
+
+To O
+confirm O
+the O
+neuroprotective O
+effects O
+of O
+NSP O
+, O
+we O
+measured O
+the O
+cell O
+survival O
+rate O
+, O
+relative O
+lactate O
+dehydrogenase O
+( O
+LDH O
+) O
+release O
+; O
+we O
+also O
+performed O
+morphological O
+methods O
+, O
+namely O
+Hoechst O
+33342 O
+staining O
+and O
+Annexin O
+V O
+assay O
+. O
+
+To O
+explore O
+the O
+potential O
+mechanisms O
+of O
+NSP O
+, O
+the O
+release O
+of O
+nitric B
+oxide I
+( O
+NO B
+) O
+and O
+TNF O
+- O
+alpha O
+related O
+to O
+NSP O
+administration O
+were O
+measured O
+by O
+enzyme O
+- O
+linked O
+immunosorbent O
+assay O
+. O
+
+The O
+proteins O
+related O
+to O
+the O
+NF O
+- O
+kappaB O
+, O
+ERK1 O
+/ O
+2 O
+, O
+and O
+PI3K O
+/ O
+Akt O
+pathways O
+were O
+investigated O
+by O
+Western O
+blotting O
+. O
+
+To O
+verify O
+the O
+cause O
+- O
+and O
+- O
+effect O
+relationship O
+between O
+neuroprotection O
+and O
+the O
+NF O
+- O
+kappaB O
+pathway O
+, O
+a O
+NF O
+- O
+kappaB O
+pathway O
+inhibitor O
+sc3060 B
+was O
+employed O
+to O
+observe O
+the O
+effects O
+of O
+NSP O
+- O
+induced O
+neuroprotection O
+. O
+
+We O
+found O
+that O
+NSP O
+significantly O
+increased O
+the O
+cell O
+survival O
+rate O
+and O
+reduced O
+LDH B
+release O
+in O
+OGD O
+/ O
+R O
+- O
+treated O
+astrocytes O
+. O
+
+It O
+also O
+reduced O
+NO B
+/ O
+TNF O
+- O
+alpha O
+release O
+. O
+
+Western O
+blotting O
+showed O
+that O
+the O
+protein O
+levels O
+of O
+p O
+- O
+IKKBalpha O
+/ O
+beta O
+and O
+P65 O
+were O
+upregulated O
+by O
+the O
+OGD O
+/ O
+R O
+treatment O
+and O
+such O
+effects O
+were O
+significantly O
+inhibited O
+by O
+NSP O
+administration O
+. O
+
+The O
+NSP O
+- O
+induced O
+inhibition O
+could O
+be O
+significantly O
+reversed O
+by O
+administration O
+of O
+the O
+NF O
+- O
+kappaB O
+pathway O
+inhibitor O
+sc3060 B
+, O
+whereas O
+, O
+expressions O
+of O
+p O
+- O
+ERK1 O
+, O
+p O
+- O
+ERK2 O
+, O
+and O
+p O
+- O
+AKT O
+were O
+upregulated O
+by O
+the O
+OGD O
+/ O
+R O
+treatment O
+; O
+however O
+, O
+their O
+levels O
+were O
+unchanged O
+by O
+NSP O
+administration O
+. O
+
+Our O
+results O
+thus O
+verified O
+the O
+neuroprotective O
+effects O
+of O
+NSP O
+in O
+ischemic O
+astrocytes O
+. O
+
+The O
+potential O
+mechanisms O
+include O
+inhibition O
+of O
+the O
+release O
+of O
+NO B
+/ O
+TNF O
+- O
+alpha O
+and O
+repression O
+of O
+the O
+NF O
+- O
+kappaB O
+signaling O
+pathways O
+. O
+
+Our O
+data O
+also O
+indicated O
+that O
+NSP O
+has O
+little O
+influence O
+on O
+the O
+MAPK O
+and O
+PI3K O
+/ O
+Akt O
+pathways O
+. O
+
+
+Interleukin O
+6 O
+( O
+IL O
+- O
+6 O
+) O
+and O
+Tumor O
+Necrosis O
+Factor O
+alpha O
+( O
+TNF O
+- O
+alpha O
+) O
+Single O
+Nucleotide O
+Polymorphisms O
+( O
+SNPs O
+), O
+Inflammation O
+and O
+Metabolism O
+in O
+Gestational O
+Diabetes O
+Mellitus O
+in O
+Inner O
+Mongolia O
+. O
+
+BACKGROUND O
+Gestational O
+diabetes O
+mellitus O
+( O
+GDM O
+) O
+is O
+common O
+all O
+over O
+the O
+world O
+. O
+
+GDM O
+women O
+are O
+with O
+inflammatory O
+and O
+metabolisms O
+abnormalities O
+. O
+
+However O
+, O
+few O
+studies O
+have O
+focused O
+on O
+the O
+association O
+of O
+IL O
+- O
+65 O
+- O
+72C O
+/ O
+G O
+and O
+TNF O
+- O
+alpha O
+- O
+857C O
+/ O
+T O
+single O
+nucleotide O
+polymorphisms O
+( O
+SNPs O
+), O
+inflammatory O
+biomarkers O
+, O
+and O
+metabolic O
+indexes O
+in O
+women O
+with O
+GDM O
+, O
+especially O
+in O
+the O
+Inner O
+Mongolia O
+population O
+. O
+
+The O
+aim O
+of O
+this O
+study O
+was O
+to O
+investigate O
+the O
+associations O
+of O
+IL O
+- O
+65 O
+- O
+72C O
+/ O
+G O
+and O
+TNF O
+- O
+alpha O
+- O
+857C O
+/ O
+T O
+SNPs O
+, O
+and O
+inflammation O
+and O
+metabolic O
+biomarkers O
+in O
+women O
+with O
+GDM O
+pregnancies O
+. O
+
+MATERIAL O
+AND O
+METHODS O
+Blood O
+samples O
+and O
+placentas O
+from O
+140 O
+women O
+with O
+GDM O
+and O
+140 O
+women O
+with O
+healthy O
+pregnancies O
+were O
+collected O
+. O
+
+Matrix O
+- O
+assisted O
+laser O
+desorption O
+ionization O
+time O
+of O
+flight O
+mass O
+spectrometry O
+( O
+MALDI O
+- O
+TOF O
+- O
+MS O
+) O
+and O
+MassARRAY O
+- O
+IPLEX O
+were O
+performed O
+to O
+analyze O
+IL O
+- O
+65 O
+- O
+72C O
+/ O
+G O
+and O
+TNF O
+- O
+alpha O
+- O
+857C O
+/ O
+T O
+SNPs O
+. O
+
+Enzyme O
+linked O
+immunosorbent O
+assay O
+( O
+ELISA O
+) O
+was O
+performed O
+to O
+analyze O
+inflammatory O
+biomarkers O
+and O
+adipokines O
+. O
+
+RESULTS O
+Distribution O
+frequency O
+of O
+TNF O
+- O
+alpha O
+- O
+857CT O
+( O
+OR O
+= O
+3 O
+. O
+316 O
+, O
+95 O
+% O
+CI O
+= O
+1 O
+. O
+92 O
+- O
+8 O
+. O
+304 O
+, O
+p O
+= O
+0 O
+. O
+25 O
+) O
+in O
+women O
+with O
+GDM O
+pregnancies O
+were O
+obviously O
+higher O
+than O
+that O
+in O
+women O
+with O
+healthy O
+pregnancies O
+. O
+
+Women O
+with O
+GDM O
+were O
+of O
+older O
+maternal O
+age O
+, O
+had O
+higher O
+BMI O
+, O
+were O
+more O
+nulliparous O
+, O
+and O
+had O
+T2DM O
+and O
+GDM O
+history O
+, O
+compared O
+to O
+women O
+with O
+healthy O
+pregnancies O
+( O
+p O
+< O
+0 O
+. O
+5 O
+). O
+
+Inflammatory O
+biomarkers O
+in O
+serum O
+( O
+hs O
+- O
+CRP O
+, O
+IL O
+- O
+6 O
+, O
+IL O
+- O
+8 O
+, O
+IL O
+- O
+6 O
+/ O
+IL O
+- O
+10 O
+ratio O
+) O
+and O
+placental O
+( O
+NF O
+- O
+kappaB O
+, O
+IL O
+- O
+6 O
+, O
+IL O
+- O
+8 O
+, O
+IL O
+- O
+6 O
+/ O
+IL O
+- O
+10 O
+ratio O
+, O
+IL O
+- O
+1b O
+, O
+TNF O
+- O
+alpha O
+) O
+were O
+significantly O
+different O
+( O
+p O
+< O
+0 O
+. O
+5 O
+) O
+between O
+women O
+with O
+GDM O
+and O
+women O
+with O
+healthy O
+pregnancies O
+. O
+
+Differences O
+were O
+found O
+for O
+serum O
+FBG O
+, O
+FINS O
+, O
+HOMA O
+- O
+IR O
+, O
+and O
+HOMA O
+- O
+beta O
+, O
+and O
+placental O
+IRS O
+- O
+1 O
+, O
+IRS O
+- O
+2 O
+, O
+leptin O
+, O
+adiponectin O
+, O
+visfatin O
+, O
+RBP O
+- O
+4 O
+, O
+chemerin O
+, O
+nesfatin O
+- O
+1 O
+, O
+FATP O
+- O
+4 O
+, O
+EL O
+, O
+LPL O
+, O
+FABP O
+- O
+1 O
+, O
+FABP O
+- O
+3 O
+, O
+FABP O
+- O
+4 O
+, O
+and O
+FABP O
+- O
+5 O
+. O
+
+CONCLUSIONS O
+TNF O
+- O
+alpha O
+- O
+857C O
+/ O
+T O
+SNP O
+, O
+hs O
+- O
+CRP O
+, O
+IL O
+- O
+6 O
+, O
+IL O
+- O
+8 O
+, O
+and O
+IL O
+- O
+6 O
+/ O
+IL O
+- O
+10 O
+were O
+associated O
+with O
+GDM O
+in O
+women O
+from O
+Inner O
+Mongolia O
+, O
+as O
+was O
+serious O
+inflammation O
+and O
+disordered O
+lipid B
+and O
+glucose B
+metabolisms O
+. O
+
+
+Fine O
+mapping O
+and O
+identification O
+of O
+a O
+candidate O
+gene O
+SSH1 O
+in O
+disseminated O
+superficial O
+actinic O
+porokeratosis O
+. O
+
+Disseminated O
+superficial O
+actinic O
+porokeratosis O
+( O
+DSAP O
+) O
+is O
+an O
+uncommon O
+autosomal O
+dominant O
+chronic O
+keratinization O
+disorder O
+, O
+characterized O
+by O
+multiple O
+superficial O
+keratotic O
+lesions O
+surrounded O
+by O
+a O
+slightly O
+raised O
+keratotic O
+border O
+. O
+
+Thus O
+far O
+, O
+although O
+two O
+loci O
+for O
+DSAP O
+have O
+been O
+identified O
+, O
+the O
+genetic O
+basis O
+and O
+pathogenesis O
+of O
+this O
+disorder O
+have O
+not O
+been O
+elucidated O
+yet O
+. O
+
+In O
+this O
+study O
+, O
+we O
+performed O
+a O
+genome O
+- O
+wide O
+linkage O
+analysis O
+in O
+three O
+Chinese O
+affected O
+families O
+and O
+localized O
+the O
+gene O
+in O
+an O
+8 O
+. O
+0 O
+cM O
+interval O
+defined O
+by O
+D12S330 O
+and O
+D12S354 O
+on O
+chromosome O
+12 O
+. O
+
+Upon O
+screening O
+30 O
+candidate O
+genes O
+, O
+we O
+identified O
+a O
+missense O
+mutation O
+, O
+p O
+. O
+Ser63Asn O
+in O
+SSH1 O
+in O
+one O
+family O
+, O
+a O
+frameshift O
+mutation O
+, O
+p O
+. O
+Ser19CysfsX24 O
+in O
+an O
+alternative O
+variant O
+( O
+isoform O
+f O
+) O
+of O
+SSH1 O
+in O
+another O
+family O
+, O
+and O
+a O
+frameshift O
+mutation O
+, O
+p O
+. O
+Pro27ProfsX54 O
+in O
+the O
+same O
+alternative O
+variant O
+in O
+one O
+non O
+- O
+familial O
+case O
+with O
+DSAP O
+. O
+
+SSH1 O
+encodes O
+a O
+phosphatase O
+that O
+plays O
+a O
+pivotal O
+role O
+in O
+actin O
+dynamics O
+. O
+
+Our O
+data O
+suggested O
+that O
+cytoskeleton O
+disorganization O
+in O
+epidermal O
+cells O
+is O
+likely O
+associated O
+with O
+the O
+pathogenesis O
+of O
+DSAP O
+. O
+
+
+Array O
+- O
+based O
+comparative O
+genomic O
+hybridization O
+analysis O
+reveals O
+recurrent O
+chromosomal O
+alterations O
+and O
+prognostic O
+parameters O
+in O
+primary O
+cutaneous O
+large O
+B O
+- O
+cell O
+lymphoma O
+. O
+
+PURPOSE O
+: O
+To O
+evaluate O
+the O
+clinical O
+relevance O
+of O
+genomic O
+aberrations O
+in O
+primary O
+cutaneous O
+large O
+B O
+- O
+cell O
+lymphoma O
+( O
+PCLBCL O
+). O
+
+PATIENTS O
+AND O
+METHODS O
+: O
+Skin O
+biopsy O
+samples O
+of O
+31 O
+patients O
+with O
+a O
+PCLBCL O
+classified O
+as O
+either O
+primary O
+cutaneous O
+follicle O
+center O
+lymphoma O
+( O
+PCFCL O
+; O
+n O
+= O
+19 O
+) O
+or O
+PCLBCL O
+, O
+leg O
+type O
+( O
+n O
+= O
+12 O
+), O
+according O
+to O
+the O
+WHO O
+- O
+European O
+Organisation O
+for O
+Research O
+and O
+Treatment O
+of O
+Cancer O
+( O
+EORTC O
+) O
+classification O
+, O
+were O
+investigated O
+using O
+array O
+- O
+based O
+comparative O
+genomic O
+hybridization O
+, O
+fluorescence O
+in O
+situ O
+hybridization O
+( O
+FISH O
+), O
+and O
+examination O
+of O
+promoter O
+hypermethylation O
+. O
+
+RESULTS O
+: O
+The O
+most O
+recurrent O
+alterations O
+in O
+PCFCL O
+were O
+high O
+- O
+level O
+DNA O
+amplifications O
+at O
+2p16 O
+. O
+1 O
+( O
+63 O
+%) O
+and O
+deletion O
+of O
+chromosome O
+14q32 O
+. O
+33 O
+( O
+68 O
+%). O
+
+FISH O
+analysis O
+confirmed O
+c O
+- O
+REL O
+amplification O
+in O
+patients O
+with O
+gains O
+at O
+2p16 O
+. O
+1 O
+. O
+
+In O
+PCLBCL O
+, O
+leg O
+type O
+, O
+most O
+prominent O
+aberrations O
+were O
+a O
+high O
+- O
+level O
+DNA O
+amplification O
+of O
+18q21 O
+. O
+31 O
+- O
+q21 O
+. O
+33 O
+( O
+67 O
+%), O
+including O
+the O
+BCL O
+- O
+2 O
+and O
+MALT1 O
+genes O
+as O
+confirmed O
+by O
+FISH O
+, O
+and O
+deletions O
+of O
+a O
+small O
+region O
+within O
+9p21 O
+. O
+3 O
+containing O
+the O
+CDKN2A O
+, O
+CDKN2B O
+, O
+and O
+NSG O
+- O
+x O
+genes O
+. O
+
+Homozygous O
+deletion O
+of O
+9p21 O
+. O
+3 O
+was O
+detected O
+in O
+five O
+of O
+12 O
+patients O
+with O
+PCLBCL O
+, O
+leg O
+type O
+, O
+but O
+in O
+zero O
+of O
+19 O
+patients O
+with O
+PCFCL O
+. O
+
+Complete O
+methylation O
+of O
+the O
+promoter O
+region O
+of O
+the O
+CDKN2A O
+gene O
+was O
+demonstrated O
+in O
+one O
+PCLBCL O
+, O
+leg O
+type O
+, O
+patient O
+with O
+hemizygous O
+deletion O
+, O
+in O
+one O
+patient O
+without O
+deletion O
+, O
+but O
+in O
+zero O
+of O
+19 O
+patients O
+with O
+PCFCL O
+. O
+
+Seven O
+of O
+seven O
+PCLBCL O
+, O
+leg O
+type O
+, O
+patients O
+with O
+deletion O
+of O
+9p21 O
+. O
+3 O
+and O
+/ O
+or O
+complete O
+methylation O
+of O
+CDKN2A O
+died O
+as O
+a O
+result O
+of O
+their O
+lymphoma O
+. O
+
+CONCLUSION O
+: O
+Our O
+results O
+demonstrate O
+prominent O
+differences O
+in O
+chromosomal O
+alterations O
+between O
+PCFCL O
+and O
+PCLBCL O
+, O
+leg O
+type O
+, O
+that O
+support O
+their O
+classification O
+as O
+separate O
+entities O
+within O
+the O
+WHO O
+- O
+EORTC O
+scheme O
+. O
+
+Inactivation O
+of O
+CDKN2A O
+by O
+either O
+deletion O
+or O
+methylation O
+of O
+its O
+promoter O
+could O
+be O
+an O
+important O
+prognostic O
+parameter O
+for O
+the O
+group O
+of O
+PCLBCL O
+, O
+leg O
+type O
+. O
+
+
+Osteogenesis O
+imperfecta O
+type O
+III O
+with O
+intracranial O
+hemorrhage O
+and O
+brachydactyly O
+associated O
+with O
+mutations O
+in O
+exon O
+49 O
+of O
+COL1A2 O
+. O
+
+Osteogenesis O
+imperfecta O
+( O
+OI O
+) O
+is O
+a O
+heritable O
+bone O
+disorder O
+characterized O
+by O
+fractures O
+with O
+minimal O
+trauma O
+. O
+
+Intracranial O
+hemorrhage O
+has O
+been O
+reported O
+in O
+a O
+small O
+number O
+of O
+OI O
+patients O
+. O
+
+Here O
+we O
+describe O
+three O
+patients O
+, O
+a O
+boy O
+( O
+aged O
+15 O
+years O
+) O
+and O
+two O
+girls O
+( O
+aged O
+17 O
+and O
+7 O
+years O
+) O
+with O
+OI O
+type O
+III O
+who O
+suffered O
+intracranial O
+hemorrhage O
+and O
+in O
+addition O
+had O
+brachydactyly O
+and O
+nail O
+hypoplasia O
+. O
+
+In O
+all O
+of O
+these O
+patients O
+, O
+OI O
+was O
+caused O
+by O
+glycine O
+mutations O
+affecting O
+exon O
+49 O
+of O
+the O
+COL1A2 O
+gene O
+, O
+which O
+codes O
+for O
+the O
+most O
+carboxy O
+- O
+terminal O
+part O
+of O
+the O
+triple O
+- O
+helical O
+domain O
+of O
+the O
+collagen O
+type O
+I O
+alpha O
+2 O
+chain O
+. O
+
+These O
+observations O
+suggest O
+that O
+mutations O
+in O
+this O
+region O
+of O
+the O
+collagen O
+type O
+I O
+alpha O
+2 O
+chain O
+carry O
+a O
+high O
+risk O
+of O
+abnormal O
+limb O
+development O
+and O
+intracranial O
+bleeding O
+. O
+
+
+Bilateral O
+haemorrhagic O
+infarction O
+of O
+the O
+globus O
+pallidus O
+after O
+cocaine B
+and O
+alcohol B
+intoxication O
+. O
+
+Cocaine B
+is O
+a O
+risk O
+factor O
+for O
+both O
+ischemic O
+and O
+haemorrhagic O
+stroke O
+. O
+
+We O
+present O
+the O
+case O
+of O
+a O
+31 O
+- O
+year O
+- O
+old O
+man O
+with O
+bilateral O
+ischemia O
+of O
+the O
+globus O
+pallidus O
+after O
+excessive O
+alcohol B
+and O
+intranasal O
+cocaine B
+use O
+. O
+
+Drug O
+- O
+related O
+globus O
+pallidus O
+infarctions O
+are O
+most O
+often O
+associated O
+with O
+heroin O
+. O
+
+Bilateral O
+basal O
+ganglia O
+infarcts O
+after O
+the O
+use O
+of O
+cocaine B
+, O
+without O
+concurrent O
+heroin O
+use O
+, O
+have O
+never O
+been O
+reported O
+. O
+
+In O
+our O
+patient O
+, O
+transient O
+cardiac O
+arrhythmia O
+or O
+respiratory O
+dysfunction O
+related O
+to O
+cocaine B
+and O
+/ O
+or O
+ethanol B
+use O
+were O
+the O
+most O
+likely O
+causes O
+of O
+cerebral O
+hypoperfusion O
+. O
+
+
+The O
+fibrinogen O
+gamma O
+10034C O
+> O
+T O
+polymorphism O
+is O
+not O
+associated O
+with O
+Peripheral O
+Arterial O
+Disease O
+. O
+
+Conversion O
+of O
+fibrinogen O
+to O
+fibrin O
+plays O
+an O
+essential O
+role O
+in O
+hemostasis O
+and O
+results O
+in O
+stabilization O
+of O
+the O
+fibrin O
+clot O
+. O
+
+Fibrinogen O
+consists O
+of O
+three O
+pairs O
+of O
+non O
+- O
+identical O
+polypeptide O
+chains O
+, O
+encoded O
+by O
+different O
+genes O
+( O
+fibrinogen O
+alpha O
+[ O
+FGA O
+], O
+fibrinogen O
+beta O
+[ O
+FGB O
+] O
+and O
+fibrinogen O
+gamma O
+[ O
+FGG O
+]). O
+
+A O
+functional O
+single O
+nucleotide O
+polymorphism O
+( O
+SNP O
+) O
+in O
+the O
+3 O
+' O
+untranslated O
+region O
+of O
+the O
+FGG O
+gene O
+( O
+FGG O
+10034C O
+> O
+T O
+, O
+rs2066865 O
+) O
+has O
+been O
+associated O
+with O
+deep O
+venous O
+thrombosis O
+and O
+myocardial O
+infarction O
+. O
+
+Aim O
+of O
+the O
+present O
+study O
+was O
+to O
+analyze O
+the O
+role O
+of O
+this O
+polymorphism O
+in O
+peripheral O
+arterial O
+disease O
+( O
+PAD O
+). O
+
+The O
+study O
+was O
+designed O
+as O
+case O
+- O
+control O
+study O
+including O
+891 O
+patients O
+with O
+documented O
+PAD O
+and O
+777 O
+control O
+subjects O
+. O
+
+FGG O
+genotypes O
+were O
+determined O
+by O
+exonuclease O
+( O
+TaqMan O
+) O
+assays O
+. O
+
+FGG O
+genotype O
+frequencies O
+were O
+not O
+significantly O
+different O
+between O
+PAD O
+patients O
+( O
+CC O
+: O
+57 O
+. O
+3 O
+%, O
+CT O
+: O
+36 O
+. O
+7 O
+%, O
+TT O
+: O
+5 O
+. O
+8 O
+%) O
+and O
+control O
+subjects O
+( O
+CC O
+: O
+60 O
+. O
+9 O
+%, O
+CT O
+: O
+33 O
+. O
+5 O
+%, O
+TT O
+5 O
+. O
+6 O
+%; O
+p O
+= O
+0 O
+. O
+35 O
+). O
+
+In O
+a O
+multivariate O
+logistic O
+regression O
+analysis O
+including O
+age O
+, O
+sex O
+, O
+smoking O
+, O
+diabetes O
+, O
+arterial O
+hypertension O
+and O
+hypercholesterolemia O
+, O
+the O
+FGG O
+10034 O
+T O
+variant O
+was O
+not O
+significantly O
+associated O
+with O
+the O
+presence O
+of O
+PAD O
+( O
+Odds O
+ratio O
+1 O
+. O
+7 O
+, O
+95 O
+% O
+confidence O
+interval O
+0 O
+. O
+84 O
+- O
+1 O
+. O
+37 O
+; O
+p O
+= O
+0 O
+. O
+60 O
+). O
+
+The O
+FGG O
+10034C O
+> O
+T O
+polymorphism O
+was O
+furthermore O
+not O
+associated O
+with O
+age O
+at O
+onset O
+of O
+PAD O
+. O
+
+We O
+conclude O
+that O
+the O
+thrombophilic O
+FGG O
+10034 O
+T O
+gene O
+variant O
+does O
+not O
+contribute O
+to O
+the O
+genetic O
+susceptibility O
+to O
+PAD O
+. O
+
+
+Genotype O
+rs8099917 O
+near O
+the O
+IL28B O
+gene O
+and O
+amino O
+acid O
+substitution O
+at O
+position O
+70 O
+in O
+the O
+core O
+region O
+of O
+the O
+hepatitis O
+C O
+virus O
+are O
+determinants O
+of O
+serum O
+apolipoprotein O
+B O
+- O
+100 O
+concentration O
+in O
+chronic O
+hepatitis O
+C O
+. O
+
+The O
+life O
+cycle O
+of O
+the O
+hepatitis O
+C O
+virus O
+( O
+HCV O
+) O
+is O
+closely O
+related O
+to O
+host O
+lipoprotein O
+metabolism O
+. O
+
+Serum O
+levels O
+of O
+lipid B
+are O
+associated O
+with O
+the O
+response O
+to O
+pegylated B
+interferon I
+plus O
+ribavirin B
+( O
+PEG O
+- O
+IFN O
+/ O
+RBV O
+) O
+therapy O
+, O
+while O
+single O
+nucleotide O
+polymorphisms O
+( O
+SNPs O
+) O
+around O
+the O
+human O
+interleukin O
+28B O
+( O
+IL28B O
+) O
+gene O
+locus O
+and O
+amino O
+acid O
+substitutions O
+in O
+the O
+core O
+region O
+of O
+the O
+HCV O
+have O
+been O
+reported O
+to O
+affect O
+the O
+efficacy O
+of O
+PEG O
+- O
+IFN O
+/ O
+RBV O
+therapy O
+in O
+chronic O
+hepatitis O
+with O
+HCV O
+genotype O
+1b O
+infection O
+. O
+
+The O
+aim O
+of O
+this O
+study O
+was O
+to O
+elucidate O
+the O
+relationship O
+between O
+serum O
+lipid B
+and O
+factors O
+that O
+are O
+able O
+to O
+predict O
+the O
+efficacy O
+of O
+PEG O
+- O
+IFN O
+/ O
+RB O
+therapy O
+, O
+with O
+specific O
+focus O
+on O
+apolipoprotein O
+B O
+- O
+100 O
+( O
+apoB O
+- O
+100 O
+) O
+in O
+148 O
+subjects O
+with O
+chronic O
+HCV O
+G1b O
+infection O
+. O
+
+Our O
+results O
+demonstrated O
+that O
+both O
+the O
+aa O
+70 O
+substitution O
+in O
+the O
+core O
+region O
+of O
+the O
+HCV O
+and O
+the O
+rs8099917 O
+SNP O
+located O
+proximal O
+to O
+the O
+IL28B O
+were O
+independent O
+factors O
+in O
+determining O
+serum O
+apoB O
+- O
+100 O
+and O
+low B
+- I
+density I
+lipoprotein I
+( I
+LDL I
+) I
+cholesterol I
+levels O
+. O
+
+A O
+significant O
+association O
+was O
+noted O
+between O
+higher O
+levels O
+of O
+apoB O
+- O
+100 O
+( O
+P O
+= O
+1 O
+. O
+1 O
+10 O
+(- O
+3 O
+)) O
+and O
+LDL B
+cholesterol I
+( O
+P O
+= O
+0 O
+. O
+2 O
+) O
+and O
+the O
+subjects O
+having O
+Arg70 O
+. O
+
+A O
+significant O
+association O
+was O
+also O
+observed O
+between O
+subjects O
+carrying O
+the O
+rs8099917 O
+TT O
+responder O
+genotype O
+and O
+higher O
+levels O
+of O
+apoB O
+- O
+100 O
+( O
+P O
+= O
+6 O
+. O
+4 O
+10 O
+(- O
+3 O
+)) O
+and O
+LDL B
+cholesterol I
+( O
+P O
+= O
+4 O
+. O
+2 O
+10 O
+(- O
+3 O
+)). O
+
+Our O
+results O
+suggest O
+that O
+apoB O
+- O
+100 O
+and O
+LDL B
+cholesterol I
+are O
+markers O
+of O
+impaired O
+cellular O
+lipoprotein O
+pathways O
+and O
+/ O
+or O
+host O
+endogenous O
+interferon O
+response O
+to O
+HCV O
+in O
+chronic O
+HCV O
+infection O
+. O
+
+In O
+particular O
+, O
+serum O
+apoB O
+- O
+100 O
+concentration O
+might O
+be O
+an O
+informative O
+marker O
+for O
+judging O
+changes O
+in O
+HCV O
+- O
+associated O
+intracellular O
+lipoprotein O
+metabolism O
+in O
+patients O
+carrying O
+the O
+rs8099917 O
+responder O
+genotype O
+. O
+
+
+Phosphatidylinositol O
+4 O
+- O
+kinase O
+IIb O
+negatively O
+regulates O
+invadopodia O
+formation O
+and O
+suppresses O
+an O
+invasive O
+cellular O
+phenotype O
+. O
+
+The O
+type O
+II O
+phosphatidylinositol O
+4 O
+- O
+kinase O
+( O
+PI4KII O
+) O
+enzymes O
+synthesize O
+the O
+lipid B
+phosphatidylinositol I
+4 I
+- I
+phosphate I
+( O
+PI B
+( I
+4 I
+) I
+P I
+), O
+which O
+has O
+been O
+detected O
+at O
+the O
+Golgi O
+complex O
+and O
+endosomal O
+compartments O
+and O
+recruits O
+clathrin O
+adaptors O
+. O
+
+Despite O
+common O
+mechanistic O
+similarities O
+between O
+the O
+isoforms O
+, O
+the O
+extent O
+of O
+their O
+redundancy O
+is O
+unclear O
+. O
+
+We O
+found O
+that O
+depletion O
+of O
+PI4KIIa O
+and O
+PI4KIIb O
+using O
+small O
+interfering O
+RNA O
+led O
+to O
+actin O
+remodeling O
+. O
+
+Depletion O
+of O
+PI4KIIb O
+also O
+induced O
+the O
+formation O
+of O
+invadopodia O
+containing O
+membrane O
+type O
+I O
+matrix O
+metalloproteinase O
+( O
+MT1 O
+- O
+MMP O
+). O
+
+Depletion O
+of O
+PI4KII O
+isoforms O
+also O
+differentially O
+affected O
+trans O
+- O
+Golgi O
+network O
+( O
+TGN O
+) O
+pools O
+of O
+PI B
+( I
+4 I
+) I
+P I
+and O
+post O
+- O
+TGN O
+traffic O
+. O
+
+PI4KIIb O
+depletion O
+caused O
+increased O
+MT1 O
+- O
+MMP O
+trafficking O
+to O
+invasive O
+structures O
+at O
+the O
+plasma O
+membrane O
+and O
+was O
+accompanied O
+by O
+reduced O
+colocalization O
+of O
+MT1 O
+- O
+MMP O
+with O
+membranes O
+containing O
+the O
+endosomal O
+markers O
+Rab5 O
+and O
+Rab7 O
+but O
+increased O
+localization O
+with O
+the O
+exocytic O
+Rab8 O
+. O
+
+Depletion O
+of O
+PI4KIIb O
+was O
+sufficient O
+to O
+confer O
+an O
+aggressive O
+invasive O
+phenotype O
+on O
+minimally O
+invasive O
+HeLa O
+and O
+MCF O
+- O
+7 O
+cell O
+lines O
+. O
+
+Mining O
+oncogenomic O
+databases O
+revealed O
+that O
+loss O
+of O
+the O
+PI4K2B O
+allele O
+and O
+underexpression O
+of O
+PI4KIIb O
+mRNA O
+are O
+associated O
+with O
+human O
+cancers O
+. O
+
+This O
+finding O
+supports O
+the O
+cell O
+data O
+and O
+suggests O
+that O
+PI4KIIb O
+may O
+be O
+a O
+clinically O
+significant O
+suppressor O
+of O
+invasion O
+. O
+
+We O
+propose O
+that O
+PI4KIIb O
+synthesizes O
+a O
+pool O
+of O
+PI B
+( I
+4 I
+) I
+P I
+that O
+maintains O
+MT1 O
+- O
+MMP O
+traffic O
+in O
+the O
+degradative O
+pathway O
+and O
+suppresses O
+the O
+formation O
+of O
+invadopodia O
+. O
+
+
+CenpH O
+regulates O
+meiotic O
+G2 O
+/ O
+M O
+transition O
+by O
+modulating O
+the O
+APC O
+/ O
+CCdh1 O
+- O
+cyclin O
+B1 O
+pathway O
+in O
+oocytes O
+. O
+
+Meiotic O
+resumption O
+( O
+G2 O
+/ O
+M O
+transition O
+) O
+and O
+progression O
+through O
+meiosis O
+I O
+( O
+MI O
+) O
+are O
+two O
+key O
+stages O
+for O
+producing O
+fertilization O
+- O
+competent O
+eggs O
+. O
+
+Here O
+, O
+we O
+report O
+that O
+CenpH O
+, O
+a O
+component O
+of O
+the O
+kinetochore O
+inner O
+plate O
+, O
+is O
+responsible O
+for O
+G2 O
+/ O
+M O
+transition O
+in O
+meiotic O
+mouse O
+oocytes O
+. O
+
+Depletion O
+of O
+CenpH O
+by O
+morpholino B
+injection O
+decreased O
+cyclin O
+B1 O
+levels O
+, O
+resulting O
+in O
+attenuation O
+of O
+maturation O
+- O
+promoting O
+factor O
+( O
+MPF O
+) O
+activation O
+, O
+and O
+severely O
+compromised O
+meiotic O
+resumption O
+. O
+
+CenpH O
+protects O
+cyclin O
+B1 O
+from O
+destruction O
+by O
+competing O
+with O
+the O
+action O
+of O
+APC O
+/ O
+C O
+( O
+Cdh1 O
+) O
+Impaired O
+G2 O
+/ O
+M O
+transition O
+after O
+CenpH O
+depletion O
+could O
+be O
+rescued O
+by O
+expression O
+of O
+exogenous O
+cyclin O
+B1 O
+. O
+
+Unexpectedly O
+, O
+blocking O
+CenpH O
+did O
+not O
+affect O
+spindle O
+organization O
+and O
+meiotic O
+cell O
+cycle O
+progression O
+after O
+germinal O
+vesicle O
+breakdown O
+. O
+
+Our O
+findings O
+reveal O
+a O
+novel O
+role O
+of O
+CenpH O
+in O
+regulating O
+meiotic O
+G2 O
+/ O
+M O
+transition O
+by O
+acting O
+via O
+the O
+APC O
+/ O
+C O
+( O
+Cdh1 O
+)- O
+cyclin O
+B1 O
+pathway O
+. O
+
+
+CRYBA3 O
+/ O
+A1 O
+gene O
+mutation O
+associated O
+with O
+suture O
+- O
+sparing O
+autosomal O
+dominant O
+congenital O
+nuclear O
+cataract O
+: O
+a O
+novel O
+phenotype O
+. O
+
+PURPOSE O
+: O
+To O
+identify O
+the O
+genetic O
+defect O
+leading O
+to O
+the O
+congenital O
+nuclear O
+cataract O
+affecting O
+a O
+large O
+five O
+- O
+generation O
+Swiss O
+family O
+. O
+
+METHODS O
+: O
+Family O
+history O
+and O
+clinical O
+data O
+were O
+recorded O
+. O
+
+The O
+phenotype O
+was O
+documented O
+by O
+both O
+slit O
+lamp O
+and O
+Scheimpflug O
+photography O
+. O
+
+One O
+cortical O
+lens O
+was O
+evaluated O
+by O
+electron O
+microscopy O
+after O
+cataract O
+extraction O
+. O
+
+Lenticular O
+phenotyping O
+and O
+genotyping O
+were O
+performed O
+independently O
+with O
+short O
+tandem O
+repeat O
+polymorphism O
+. O
+
+Linkage O
+analysis O
+was O
+performed O
+, O
+and O
+candidate O
+genes O
+were O
+PCR O
+amplified O
+and O
+screened O
+for O
+mutations O
+on O
+both O
+strands O
+using O
+direct O
+sequencing O
+. O
+
+RESULTS O
+: O
+Affected O
+individuals O
+had O
+a O
+congenital O
+nuclear O
+lactescent O
+cataract O
+in O
+both O
+eyes O
+. O
+
+Linkage O
+was O
+observed O
+on O
+chromosome O
+17 O
+for O
+DNA O
+marker O
+D17S1857 O
+( O
+lod O
+score O
+: O
+3 O
+. O
+44 O
+at O
+theta O
+= O
+0 O
+). O
+
+Direct O
+sequencing O
+of O
+CRYBA3 O
+/ O
+A1 O
+, O
+which O
+maps O
+to O
+the O
+vicinity O
+, O
+revealed O
+an O
+in O
+- O
+frame O
+3 O
+- O
+bp O
+deletion O
+in O
+exon O
+4 O
+( O
+279delGAG O
+). O
+
+This O
+mutation O
+involved O
+a O
+deletion O
+of O
+glycine O
+- O
+91 O
+, O
+cosegregated O
+in O
+all O
+affected O
+individuals O
+, O
+and O
+was O
+not O
+observed O
+in O
+unaffected O
+individuals O
+or O
+in O
+250 O
+normal O
+control O
+subjects O
+from O
+the O
+same O
+ethnic O
+background O
+. O
+
+Electron O
+microscopy O
+showed O
+that O
+cortical O
+lens O
+fiber O
+morphology O
+was O
+normal O
+. O
+
+CONCLUSIONS O
+: O
+The O
+DeltaG91 O
+mutation O
+in O
+CRYBA3 O
+/ O
+A1 O
+is O
+associated O
+with O
+an O
+autosomal O
+dominant O
+congenital O
+nuclear O
+lactescent O
+cataract O
+. O
+
+A O
+splice O
+mutation O
+( O
+IVS3 O
++ O
+1G O
+/ O
+A O
+) O
+in O
+this O
+gene O
+has O
+been O
+reported O
+in O
+a O
+zonular O
+cataract O
+with O
+sutural O
+opacities O
+. O
+
+These O
+results O
+indicate O
+phenotypic O
+heterogeneity O
+related O
+to O
+mutations O
+in O
+this O
+gene O
+. O
+
+
+Vitamin O
+D O
+- O
+binding O
+protein O
+gene O
+polymorphism O
+association O
+with O
+IA O
+- O
+2 O
+autoantibodies O
+in O
+type O
+1 O
+diabetes O
+. O
+
+BACKGROUND O
+: O
+Vitamin O
+D O
+- O
+binding O
+protein O
+( O
+DBP O
+) O
+is O
+the O
+main O
+systemic O
+transporter O
+of O
+1 B
+. I
+25 I
+( I
+OH I
+) I
+2D3 I
+and O
+is O
+essential O
+for O
+its O
+cellular O
+endocytosis O
+. O
+
+There O
+are O
+two O
+known O
+polymorphisms O
+in O
+exon O
+11 O
+of O
+the O
+DBP O
+gene O
+resulting O
+in O
+amino O
+acid O
+variants O
+: O
+GAT O
+--> O
+GAG O
+substitution O
+replaces O
+aspartic O
+acid O
+by O
+glutamic O
+acid O
+in O
+codon O
+416 O
+; O
+and O
+ACG O
+--> O
+AAG O
+substitution O
+in O
+codon O
+420 O
+leads O
+to O
+an O
+exchange O
+of O
+threonine O
+for O
+lysine O
+. O
+
+These O
+DBP O
+variants O
+lead O
+to O
+differences O
+in O
+the O
+affinity O
+for O
+1 B
+. I
+25 I
+( I
+OH I
+) I
+2D3 I
+. O
+
+Correlations O
+between O
+DBP O
+alleles O
+and O
+type O
+1 O
+diabetes O
+have O
+been O
+described O
+in O
+different O
+populations O
+. O
+
+Therefore O
+, O
+we O
+investigated O
+the O
+polymorphism O
+in O
+codon O
+416 O
+of O
+the O
+DBP O
+gene O
+for O
+an O
+association O
+with O
+autoimmune O
+markers O
+of O
+type O
+1 O
+diabetes O
+. O
+
+DESIGN O
+AND O
+METHODS O
+: O
+The O
+present O
+analysis O
+was O
+a O
+case O
+control O
+study O
+. O
+
+110 O
+patients O
+, O
+68 O
+controls O
+, O
+and O
+115 O
+first O
+- O
+degree O
+relatives O
+were O
+genotyped O
+for O
+the O
+DBP O
+polymorphism O
+in O
+codon O
+416 O
+. O
+
+DNA O
+typing O
+of O
+DBP O
+locus O
+was O
+performed O
+by O
+the O
+PCR O
+- O
+restriction O
+fragment O
+length O
+polymorphism O
+method O
+( O
+RFLP O
+). O
+
+RESULTS O
+: O
+The O
+frequencies O
+of O
+the O
+Asp O
+/ O
+Glu O
+and O
+Glu O
+/ O
+Glu O
+were O
+significantly O
+increased O
+in O
+diabetic O
+subjects O
+with O
+detectable O
+IA O
+- O
+2 O
+antibodies O
+( O
+P O
+< O
+0 O
+. O
+1 O
+). O
+
+On O
+the O
+contrary O
+, O
+the O
+DBP O
+Glu O
+- O
+containing O
+genotype O
+was O
+not O
+accompanied O
+by O
+differences O
+in O
+the O
+prevalence O
+of O
+GAD65 O
+antibodies O
+. O
+
+These O
+finding O
+supports O
+a O
+role O
+of O
+the O
+vitamin B
+D I
+endocrine O
+system O
+in O
+the O
+autoimmune O
+process O
+of O
+type O
+1 O
+diabetes O
+. O
+
+
+Characterization O
+of O
+Bietti O
+crystalline O
+dystrophy O
+patients O
+with O
+CYP4V2 O
+mutations O
+. O
+
+PURPOSE O
+: O
+Mutations O
+of O
+the O
+CYP4V2 O
+gene O
+, O
+a O
+novel O
+family O
+member O
+of O
+the O
+cytochrome O
+P450 O
+genes O
+on O
+chromosome O
+4q35 O
+, O
+have O
+recently O
+been O
+identified O
+in O
+patients O
+with O
+Bietti O
+crystalline O
+dystrophy O
+( O
+BCD O
+). O
+
+The O
+aim O
+of O
+this O
+study O
+was O
+to O
+investigate O
+the O
+spectrum O
+of O
+mutations O
+in O
+this O
+gene O
+in O
+BCD O
+patients O
+from O
+Singapore O
+, O
+and O
+to O
+characterize O
+their O
+phenotype O
+. O
+
+METHODS O
+: O
+Nine O
+patients O
+with O
+BCD O
+from O
+six O
+families O
+were O
+recruited O
+into O
+the O
+study O
+. O
+
+The O
+11 O
+exons O
+of O
+the O
+CYP4V2 O
+gene O
+were O
+amplified O
+from O
+genomic O
+DNA O
+of O
+patients O
+by O
+polymerase O
+chain O
+reaction O
+and O
+then O
+sequenced O
+. O
+
+Detailed O
+characterization O
+of O
+the O
+patients O
+' O
+phenotype O
+was O
+performed O
+with O
+fundal O
+photography O
+, O
+visual O
+field O
+testing O
+, O
+fundal O
+fluorescein O
+angiography O
+, O
+and O
+electroretinography O
+( O
+ERG O
+). O
+
+RESULTS O
+: O
+Three O
+pathogenic O
+mutations O
+were O
+identified O
+; O
+two O
+mutations O
+, O
+S482X O
+and O
+K386T O
+, O
+were O
+novel O
+and O
+found O
+in O
+three O
+patients O
+. O
+
+The O
+third O
+mutation O
+, O
+a O
+previously O
+identified O
+15 O
+- O
+bp O
+deletion O
+that O
+included O
+the O
+3 O
+' O
+splice O
+site O
+for O
+exon O
+7 O
+, O
+was O
+found O
+in O
+all O
+nine O
+patients O
+, O
+with O
+six O
+patients O
+carrying O
+the O
+deletion O
+in O
+the O
+homozygous O
+state O
+. O
+
+Haplotype O
+analysis O
+in O
+patients O
+and O
+controls O
+indicated O
+a O
+founder O
+effect O
+for O
+this O
+deletion O
+mutation O
+in O
+exon O
+7 O
+. O
+
+Clinical O
+heterogeneity O
+was O
+present O
+in O
+the O
+patients O
+. O
+
+Compound O
+heterozygotes O
+for O
+the O
+deletion O
+in O
+exon O
+7 O
+seemed O
+to O
+have O
+more O
+severe O
+disease O
+compared O
+to O
+patients O
+homozygous O
+for O
+the O
+deletion O
+. O
+
+There O
+was O
+good O
+correlation O
+between O
+clinical O
+stage O
+of O
+disease O
+and O
+ERG O
+changes O
+, O
+but O
+age O
+did O
+not O
+correlate O
+with O
+disease O
+severity O
+. O
+
+CONCLUSIONS O
+: O
+This O
+study O
+identified O
+novel O
+mutations O
+in O
+the O
+CYP4V2 O
+gene O
+as O
+a O
+cause O
+of O
+BCD O
+. O
+
+A O
+high O
+carrier O
+frequency O
+for O
+the O
+15 O
+- O
+bp O
+deletion O
+in O
+exon O
+7 O
+may O
+exist O
+in O
+the O
+Singapore O
+population O
+. O
+
+Phenotype O
+characterization O
+showed O
+clinical O
+heterogeneity O
+, O
+and O
+age O
+did O
+not O
+correlate O
+with O
+disease O
+severity O
+. O
+
+
+An O
+extremely O
+rare O
+case O
+of O
+delusional O
+parasitosis O
+in O
+a O
+chronic O
+hepatitis O
+C O
+patient O
+during O
+pegylated B
+interferon I
+alpha I
+- I
+2b I
+and O
+ribavirin B
+treatment O
+. O
+
+During O
+treatment O
+of O
+chronic O
+hepatitis O
+C O
+patients O
+with O
+interferon B
+and O
+ribavirin B
+, O
+a O
+lot O
+of O
+side O
+effects O
+are O
+described O
+. O
+
+Twenty O
+- O
+three O
+percent O
+to O
+44 O
+% O
+of O
+patients O
+develop O
+depression O
+. O
+
+A O
+minority O
+of O
+patients O
+evolve O
+to O
+psychosis O
+. O
+
+To O
+the O
+best O
+of O
+our O
+knowledge O
+, O
+no O
+cases O
+of O
+psychogenic O
+parasitosis O
+occurring O
+during O
+interferon B
+therapy O
+have O
+been O
+described O
+in O
+the O
+literature O
+. O
+
+We O
+present O
+a O
+49 O
+- O
+year O
+- O
+old O
+woman O
+who O
+developed O
+a O
+delusional O
+parasitosis O
+during O
+treatment O
+with O
+pegylated B
+interferon I
+alpha I
+- I
+2b I
+weekly O
+and O
+ribavirin B
+. O
+
+She O
+complained O
+of O
+seeing O
+parasites O
+and O
+the O
+larvae O
+of O
+fleas O
+in O
+her O
+stools O
+. O
+
+This O
+could O
+not O
+be O
+confirmed O
+by O
+any O
+technical O
+examination O
+. O
+
+All O
+the O
+complaints O
+disappeared O
+after O
+stopping O
+pegylated B
+interferon I
+alpha I
+- I
+2b I
+and O
+reappeared O
+after O
+restarting O
+it O
+. O
+
+She O
+had O
+a O
+complete O
+sustained O
+viral O
+response O
+. O
+
+
+Protein O
+- O
+Trap O
+Insertional O
+Mutagenesis O
+Uncovers O
+New O
+Genes O
+Involved O
+in O
+Zebrafish O
+Skin O
+Development O
+, O
+Including O
+a O
+Neuregulin O
+2a O
+- O
+Based O
+ErbB O
+Signaling O
+Pathway O
+Required O
+during O
+Median O
+Fin O
+Fold O
+Morphogenesis O
+. O
+
+Skin O
+disorders O
+are O
+widespread O
+, O
+but O
+available O
+treatments O
+are O
+limited O
+. O
+
+A O
+more O
+comprehensive O
+understanding O
+of O
+skin O
+development O
+mechanisms O
+will O
+drive O
+identification O
+of O
+new O
+treatment O
+targets O
+and O
+modalities O
+. O
+
+Here O
+we O
+report O
+the O
+Zebrafish O
+Integument O
+Project O
+( O
+ZIP O
+), O
+an O
+expression O
+- O
+driven O
+platform O
+for O
+identifying O
+new O
+skin O
+genes O
+and O
+phenotypes O
+in O
+the O
+vertebrate O
+model O
+Danio O
+rerio O
+( O
+zebrafish O
+). O
+
+In O
+vivo O
+selection O
+for O
+skin O
+- O
+specific O
+expression O
+of O
+gene O
+- O
+break O
+transposon O
+( O
+GBT O
+) O
+mutant O
+lines O
+identified O
+eleven O
+new O
+, O
+revertible O
+GBT O
+alleles O
+of O
+genes O
+involved O
+in O
+skin O
+development O
+. O
+
+Eight O
+genes O
+-- O
+fras1 O
+, O
+grip1 O
+, O
+hmcn1 O
+, O
+msxc O
+, O
+col4a4 O
+, O
+ahnak O
+, O
+capn12 O
+, O
+and O
+nrg2a O
+-- O
+had O
+been O
+described O
+in O
+an O
+integumentary O
+context O
+to O
+varying O
+degrees O
+, O
+while O
+arhgef25b O
+, O
+fkbp10b O
+, O
+and O
+megf6a O
+emerged O
+as O
+novel O
+skin O
+genes O
+. O
+
+Embryos O
+homozygous O
+for O
+a O
+GBT O
+insertion O
+within O
+neuregulin O
+2a O
+( O
+nrg2a O
+) O
+revealed O
+a O
+novel O
+requirement O
+for O
+a O
+Neuregulin O
+2a O
+( O
+Nrg2a O
+)- O
+ErbB2 O
+/ O
+3 O
+- O
+AKT O
+signaling O
+pathway O
+governing O
+the O
+apicobasal O
+organization O
+of O
+a O
+subset O
+of O
+epidermal O
+cells O
+during O
+median O
+fin O
+fold O
+( O
+MFF O
+) O
+morphogenesis O
+. O
+
+In O
+nrg2a O
+mutant O
+larvae O
+, O
+the O
+basal O
+keratinocytes O
+within O
+the O
+apical O
+MFF O
+, O
+known O
+as O
+ridge O
+cells O
+, O
+displayed O
+reduced O
+pAKT O
+levels O
+as O
+well O
+as O
+reduced O
+apical O
+domains O
+and O
+exaggerated O
+basolateral O
+domains O
+. O
+
+Those O
+defects O
+compromised O
+proper O
+ridge O
+cell O
+elongation O
+into O
+a O
+flattened O
+epithelial O
+morphology O
+, O
+resulting O
+in O
+thickened O
+MFF O
+edges O
+. O
+
+Pharmacological O
+inhibition O
+verified O
+that O
+Nrg2a O
+signals O
+through O
+the O
+ErbB O
+receptor O
+tyrosine O
+kinase O
+network O
+. O
+
+Moreover O
+, O
+knockdown O
+of O
+the O
+epithelial O
+polarity O
+regulator O
+and O
+tumor O
+suppressor O
+lgl2 O
+ameliorated O
+the O
+nrg2a O
+mutant O
+phenotype O
+. O
+
+Identifying O
+Lgl2 O
+as O
+an O
+antagonist O
+of O
+Nrg2a O
+- O
+ErbB O
+signaling O
+revealed O
+a O
+significantly O
+earlier O
+role O
+for O
+Lgl2 O
+during O
+epidermal O
+morphogenesis O
+than O
+has O
+been O
+described O
+to O
+date O
+. O
+
+Furthermore O
+, O
+our O
+findings O
+demonstrated O
+that O
+successive O
+, O
+coordinated O
+ridge O
+cell O
+shape O
+changes O
+drive O
+apical O
+MFF O
+development O
+, O
+making O
+MFF O
+ridge O
+cells O
+a O
+valuable O
+model O
+for O
+investigating O
+how O
+the O
+coordinated O
+regulation O
+of O
+cell O
+polarity O
+and O
+cell O
+shape O
+changes O
+serves O
+as O
+a O
+crucial O
+mechanism O
+of O
+epithelial O
+morphogenesis O
+. O
+
+
+Mutation O
+analysis O
+of O
+CHRNA1 O
+, O
+CHRNB1 O
+, O
+CHRND O
+, O
+and O
+RAPSN O
+genes O
+in O
+multiple O
+pterygium O
+syndrome O
+/ O
+fetal O
+akinesia O
+patients O
+. O
+
+Multiple O
+pterygium O
+syndromes O
+( O
+MPS O
+) O
+comprise O
+a O
+group O
+of O
+multiple O
+congenital O
+anomaly O
+disorders O
+characterized O
+by O
+webbing O
+( O
+pterygia O
+) O
+of O
+the O
+neck O
+, O
+elbows O
+, O
+and O
+/ O
+or O
+knees O
+and O
+joint O
+contractures O
+( O
+arthrogryposis O
+). O
+
+MPS O
+are O
+phenotypically O
+and O
+genetically O
+heterogeneous O
+but O
+are O
+traditionally O
+divided O
+into O
+prenatally O
+lethal O
+and O
+nonlethal O
+( O
+Escobar O
+) O
+types O
+. O
+
+Previously O
+, O
+we O
+and O
+others O
+reported O
+that O
+recessive O
+mutations O
+in O
+the O
+embryonal O
+acetylcholine O
+receptor O
+g O
+subunit O
+( O
+CHRNG O
+) O
+can O
+cause O
+both O
+lethal O
+and O
+nonlethal O
+MPS O
+, O
+thus O
+demonstrating O
+that O
+pterygia O
+resulted O
+from O
+fetal O
+akinesia O
+. O
+
+We O
+hypothesized O
+that O
+mutations O
+in O
+acetylcholine O
+receptor O
+- O
+related O
+genes O
+might O
+also O
+result O
+in O
+a O
+MPS O
+/ O
+fetal O
+akinesia O
+phenotype O
+and O
+so O
+we O
+analyzed O
+15 O
+cases O
+of O
+lethal O
+MPS O
+/ O
+fetal O
+akinesia O
+without O
+CHRNG O
+mutations O
+for O
+mutations O
+in O
+the O
+CHRNA1 O
+, O
+CHRNB1 O
+, O
+CHRND O
+, O
+and O
+rapsyn O
+( O
+RAPSN O
+) O
+genes O
+. O
+
+No O
+CHRNA1 O
+, O
+CHRNB1 O
+, O
+or O
+CHRND O
+mutations O
+were O
+detected O
+, O
+but O
+a O
+homozygous O
+RAPSN O
+frameshift O
+mutation O
+, O
+c O
+. O
+1177 O
+- O
+1178delAA O
+, O
+was O
+identified O
+in O
+a O
+family O
+with O
+three O
+children O
+affected O
+with O
+lethal O
+fetal O
+akinesia O
+sequence O
+. O
+
+Previously O
+, O
+RAPSN O
+mutations O
+have O
+been O
+reported O
+in O
+congenital O
+myasthenia O
+. O
+
+Functional O
+studies O
+were O
+consistent O
+with O
+the O
+hypothesis O
+that O
+whereas O
+incomplete O
+loss O
+of O
+rapsyn O
+function O
+may O
+cause O
+congenital O
+myasthenia O
+, O
+more O
+severe O
+loss O
+of O
+function O
+can O
+result O
+in O
+a O
+lethal O
+fetal O
+akinesia O
+phenotype O
+. O
+
+
+Pure O
+monosomy O
+and O
+pure O
+trisomy O
+of O
+13q21 O
+. O
+2 O
+- O
+31 O
+. O
+1 O
+consequent O
+to O
+a O
+familial O
+insertional O
+translocation O
+: O
+exclusion O
+of O
+PCDH9 O
+as O
+the O
+responsible O
+gene O
+for O
+autosomal O
+dominant O
+auditory O
+neuropathy O
+( O
+AUNA1 O
+). O
+
+Insertional O
+translocations O
+( O
+IT O
+) O
+are O
+rare O
+structural O
+rearrangements O
+. O
+
+Offspring O
+of O
+IT O
+balanced O
+carriers O
+are O
+at O
+high O
+risk O
+to O
+have O
+either O
+pure O
+partial O
+trisomy O
+or O
+monosomy O
+for O
+the O
+inserted O
+segment O
+as O
+manifested O
+by O
+pure O
+phenotypes O
+. O
+
+We O
+describe O
+an O
+IT O
+between O
+chromosomes O
+3 O
+and O
+13 O
+segregating O
+in O
+a O
+three O
+- O
+generation O
+pedigree O
+. O
+
+Short O
+tandem O
+repeat O
+( O
+STR O
+) O
+segregation O
+analysis O
+and O
+array O
+- O
+comparative O
+genomic O
+hybridization O
+were O
+used O
+to O
+define O
+the O
+IT O
+as O
+a O
+25 O
+. O
+1 O
+Mb O
+segment O
+spanning O
+13q21 O
+. O
+2 O
+- O
+q31 O
+. O
+1 O
+. O
+
+The O
+phenotype O
+of O
+pure O
+monosomy O
+included O
+deafness O
+, O
+duodenal O
+stenosis O
+, O
+developmental O
+and O
+growth O
+delay O
+, O
+vertebral O
+anomalies O
+, O
+and O
+facial O
+dysmorphisms O
+; O
+the O
+trisomy O
+was O
+manifested O
+by O
+only O
+minor O
+dysmorphisms O
+. O
+
+As O
+the O
+AUNA1 O
+deafness O
+locus O
+on O
+13q14 O
+- O
+21 O
+overlaps O
+the O
+IT O
+in O
+the O
+PCDH9 O
+( O
+protocadherin O
+- O
+9 O
+) O
+gene O
+region O
+, O
+PCDH9 O
+was O
+investigated O
+as O
+a O
+candidate O
+gene O
+for O
+deafness O
+in O
+both O
+families O
+. O
+
+Genotyping O
+of O
+STRs O
+and O
+single O
+nucleotide O
+polymorphisms O
+defined O
+the O
+AUNA1 O
+breakpoint O
+as O
+35 O
+kb O
+5 O
+' O
+to O
+PCDH9 O
+, O
+with O
+a O
+2 O
+. O
+4 O
+Mb O
+area O
+of O
+overlap O
+with O
+the O
+IT O
+. O
+
+DNA O
+sequencing O
+of O
+coding O
+regions O
+in O
+the O
+AUNA1 O
+family O
+and O
+in O
+the O
+retained O
+homologue O
+chromosome O
+in O
+the O
+monosomic O
+patient O
+revealed O
+no O
+mutations O
+. O
+
+We O
+conclude O
+that O
+AUNA1 O
+deafness O
+does O
+not O
+share O
+a O
+common O
+etiology O
+with O
+deafness O
+associated O
+with O
+monosomy O
+13q21 O
+. O
+2 O
+- O
+q31 O
+. O
+3 O
+; O
+deafness O
+may O
+result O
+from O
+monosomy O
+of O
+PCHD9 O
+or O
+another O
+gene O
+in O
+the O
+IT O
+, O
+as O
+has O
+been O
+demonstrated O
+in O
+contiguous O
+gene O
+deletion O
+syndromes O
+. O
+
+Precise O
+characterization O
+of O
+the O
+breakpoints O
+of O
+the O
+translocated O
+region O
+is O
+useful O
+to O
+identify O
+which O
+genes O
+may O
+be O
+contributing O
+to O
+the O
+phenotype O
+, O
+either O
+through O
+haploinsufficiency O
+or O
+extra O
+dosage O
+effects O
+, O
+in O
+order O
+to O
+define O
+genotype O
+- O
+phenotype O
+correlations O
+. O
+
+
+A O
+Taiwanese O
+boy O
+with O
+congenital O
+generalized O
+lipodystrophy O
+caused O
+by O
+homozygous O
+Ile262fs O
+mutation O
+in O
+the O
+BSCL2 O
+gene O
+. O
+
+Congenital O
+generalized O
+lipodystrophy O
+( O
+CGL O
+) O
+is O
+a O
+rare O
+autosomal O
+recessive O
+disease O
+that O
+is O
+characterized O
+by O
+a O
+near O
+- O
+complete O
+absence O
+of O
+adipose O
+tissue O
+from O
+birth O
+or O
+early O
+infancy O
+. O
+
+Mutations O
+in O
+the O
+BSCL2 O
+gene O
+are O
+known O
+to O
+result O
+in O
+CGL2 O
+, O
+a O
+more O
+severe O
+phenotype O
+than O
+CGL1 O
+, O
+with O
+earlier O
+onset O
+, O
+more O
+extensive O
+fat O
+loss O
+and O
+biochemical O
+changes O
+, O
+more O
+severe O
+intellectual O
+impairment O
+, O
+and O
+more O
+severe O
+cardiomyopathy O
+. O
+
+We O
+report O
+a O
+3 O
+- O
+month O
+- O
+old O
+Taiwanese O
+boy O
+with O
+initial O
+presentation O
+of O
+a O
+lack O
+of O
+subcutaneous O
+fat O
+, O
+prominent O
+musculature O
+, O
+generalized O
+eruptive O
+xanthomas O
+, O
+and O
+extreme O
+hypertriglyceridemia O
+. O
+
+Absence O
+of O
+mechanical O
+adipose O
+tissue O
+in O
+the O
+orbits O
+and O
+scalp O
+was O
+revealed O
+by O
+head O
+magnetic O
+resonance O
+imaging O
+. O
+
+Hepatomegaly O
+was O
+noticed O
+, O
+and O
+histological O
+examination O
+of O
+a O
+liver O
+biopsy O
+specimen O
+suggested O
+severe O
+hepatic O
+steatosis O
+and O
+periportal O
+necrosis O
+. O
+
+However O
+, O
+echocardiography O
+indicated O
+no O
+sign O
+of O
+cardiomyopathy O
+and O
+he O
+showed O
+no O
+distinct O
+intellectual O
+impairment O
+that O
+interfered O
+with O
+daily O
+life O
+. O
+
+About O
+1 O
+year O
+later O
+, O
+abdominal O
+computed O
+tomography O
+revealed O
+enlargement O
+of O
+kidneys O
+. O
+
+He O
+had O
+a O
+homozygous O
+insertion O
+of O
+a O
+nucleotide O
+, O
+783insG O
+( O
+Ile262fs O
+mutation O
+), O
+in O
+exon O
+7 O
+of O
+the O
+BSCL2 O
+gene O
+. O
+
+We O
+reviewed O
+the O
+genotype O
+of O
+CGL O
+cases O
+from O
+Japan O
+, O
+India O
+, O
+China O
+and O
+Taiwan O
+, O
+and O
+found O
+that O
+BSCL2 O
+is O
+a O
+major O
+causative O
+gene O
+for O
+CGL O
+in O
+Asian O
+. O
+
+
+Concordance O
+between O
+PIK3CA O
+mutations O
+in O
+endoscopic O
+biopsy O
+and O
+surgically O
+resected O
+specimens O
+of O
+esophageal O
+squamous O
+cell O
+carcinoma O
+. O
+
+BACKGROUND O
+: O
+PIK3CA O
+mutations O
+are O
+expected O
+to O
+be O
+potential O
+therapeutic O
+targets O
+for O
+esophageal O
+squamous O
+cell O
+carcinoma O
+( O
+ESCC O
+). O
+
+We O
+aimed O
+to O
+clarify O
+the O
+concordance O
+between O
+PIK3CA O
+mutations O
+detected O
+in O
+endoscopic O
+biopsy O
+specimens O
+and O
+corresponding O
+surgically O
+resected O
+specimens O
+. O
+
+METHODS O
+: O
+We O
+examined O
+five O
+hotspot O
+mutations O
+in O
+the O
+PIK3CA O
+gene O
+( O
+E542K O
+, O
+E545K O
+, O
+E546K O
+, O
+H1047R O
+, O
+and O
+H1047L O
+) O
+in O
+formalin B
+- O
+fixed O
+and O
+paraffin B
+- O
+embedded O
+tissue O
+sections O
+of O
+paired O
+endoscopic O
+biopsy O
+and O
+surgically O
+resected O
+specimens O
+from O
+181 O
+patients O
+undergoing O
+curative O
+resection O
+for O
+ESCC O
+between O
+2000 O
+and O
+2011 O
+using O
+a O
+Luminex O
+technology O
+- O
+based O
+multiplex O
+gene O
+mutation O
+detection O
+kit O
+. O
+
+RESULTS O
+: O
+Mutation O
+analyses O
+were O
+successfully O
+performed O
+for O
+both O
+endoscopic O
+biopsy O
+and O
+surgically O
+resected O
+specimens O
+in O
+all O
+the O
+cases O
+. O
+
+A O
+PIK3CA O
+mutation O
+was O
+detected O
+in O
+either O
+type O
+of O
+specimen O
+in O
+13 O
+cases O
+( O
+7 O
+. O
+2 O
+%, O
+95 O
+% O
+confidence O
+interval O
+: O
+3 O
+. O
+9 O
+- O
+12 O
+. O
+0 O
+). O
+
+The O
+overall O
+concordance O
+rate O
+, O
+positive O
+predictive O
+value O
+, O
+and O
+negative O
+predictive O
+value O
+were O
+98 O
+. O
+3 O
+% O
+( O
+178 O
+/ O
+181 O
+), O
+90 O
+. O
+9 O
+% O
+( O
+10 O
+/ O
+11 O
+), O
+and O
+98 O
+. O
+8 O
+% O
+( O
+168 O
+/ O
+170 O
+), O
+respectively O
+. O
+
+Among O
+patients O
+with O
+a O
+PIK3CA O
+mutation O
+detected O
+in O
+both O
+types O
+of O
+specimens O
+, O
+the O
+concordance O
+between O
+PIK3CA O
+mutation O
+genotypes O
+was O
+100 O
+%. O
+
+There O
+were O
+three O
+cases O
+with O
+a O
+discordant O
+mutation O
+status O
+between O
+the O
+types O
+of O
+specimens O
+( O
+PIK3CA O
+mutation O
+in O
+surgically O
+resected O
+specimen O
+and O
+wild O
+- O
+type O
+in O
+biopsy O
+specimen O
+in O
+two O
+cases O
+, O
+and O
+the O
+opposite O
+pattern O
+in O
+one O
+case O
+), O
+suggesting O
+possible O
+intratumoral O
+heterogeneity O
+in O
+the O
+PIK3CA O
+mutation O
+status O
+. O
+
+CONCLUSIONS O
+: O
+The O
+PIK3CA O
+mutation O
+status O
+was O
+highly O
+concordant O
+between O
+endoscopic O
+biopsy O
+and O
+surgically O
+resected O
+specimens O
+from O
+the O
+same O
+patient O
+, O
+suggesting O
+that O
+endoscopic O
+biopsy O
+specimens O
+can O
+be O
+clinically O
+used O
+to O
+detect O
+PIK3CA O
+mutations O
+in O
+patients O
+with O
+ESCC O
+. O
+
+
+Polymorphisms O
+of O
+the O
+DNA O
+mismatch O
+repair O
+gene O
+HMSH2 O
+in O
+breast O
+cancer O
+occurence O
+and O
+progression O
+. O
+
+The O
+response O
+of O
+the O
+cell O
+to O
+DNA O
+damage O
+and O
+its O
+ability O
+to O
+maintain O
+genomic O
+stability O
+by O
+DNA O
+repair O
+are O
+crucial O
+in O
+preventing O
+cancer O
+initiation O
+and O
+progression O
+. O
+
+Therefore O
+, O
+polymorphism O
+of O
+DNA O
+repair O
+genes O
+may O
+affect O
+the O
+process O
+of O
+carcinogenesis O
+. O
+
+The O
+importance O
+of O
+genetic O
+variability O
+of O
+the O
+components O
+of O
+mismatch O
+repair O
+( O
+MMR O
+) O
+genes O
+is O
+well O
+documented O
+in O
+colorectal O
+cancer O
+, O
+but O
+little O
+is O
+known O
+about O
+its O
+role O
+in O
+breast O
+cancer O
+. O
+
+hMSH2 O
+is O
+one O
+of O
+the O
+crucial O
+proteins O
+of O
+MMR O
+. O
+
+We O
+performed O
+a O
+case O
+- O
+control O
+study O
+to O
+test O
+the O
+association O
+between O
+two O
+polymorphisms O
+in O
+the O
+hMSH2 O
+gene O
+: O
+an O
+A O
+--> O
+G O
+transition O
+at O
+127 O
+position O
+producing O
+an O
+Asn O
+--> O
+Ser O
+substitution O
+at O
+codon O
+127 O
+( O
+the O
+Asn127Ser O
+polymorphism O
+) O
+and O
+a O
+G O
+--> O
+A O
+transition O
+at O
+1032 O
+position O
+resulting O
+in O
+a O
+Gly O
+--> O
+Asp O
+change O
+at O
+codon O
+322 O
+( O
+the O
+Gly322Asp O
+polymorphism O
+) O
+and O
+breast O
+cancer O
+risk O
+and O
+cancer O
+progression O
+. O
+
+Genotypes O
+were O
+determined O
+in O
+DNA O
+from O
+peripheral O
+blood O
+lymphocytes O
+of O
+150 O
+breast O
+cancer O
+patients O
+and O
+150 O
+age O
+- O
+matched O
+women O
+( O
+controls O
+) O
+by O
+restriction O
+fragment O
+length O
+polymorphism O
+and O
+allele O
+- O
+specific O
+PCR O
+. O
+
+We O
+did O
+not O
+observe O
+any O
+correlation O
+between O
+studied O
+polymorphisms O
+and O
+breast O
+cancer O
+progression O
+evaluated O
+by O
+node O
+- O
+metastasis O
+, O
+tumor O
+size O
+and O
+Bloom O
+- O
+Richardson O
+grading O
+. O
+
+A O
+strong O
+association O
+between O
+breast O
+cancer O
+occurrence O
+and O
+the O
+Gly O
+/ O
+Gly O
+phenotype O
+of O
+the O
+Gly322Asp O
+polymorphism O
+( O
+odds O
+ratio O
+8 O
+. O
+39 O
+; O
+95 O
+% O
+confidence O
+interval O
+1 O
+. O
+44 O
+- O
+48 O
+. O
+8 O
+) O
+was O
+found O
+. O
+
+Therefore O
+, O
+MMR O
+may O
+play O
+a O
+role O
+in O
+the O
+breast O
+carcinogenesis O
+and O
+the O
+Gly322Asp O
+polymorphism O
+of O
+the O
+hMSH2 O
+gene O
+may O
+be O
+considered O
+as O
+a O
+potential O
+marker O
+in O
+breast O
+cancer O
+. O
+
+
+Atorvastatin B
+prevented O
+and O
+reversed O
+dexamethasone B
+- O
+induced O
+hypertension O
+in O
+the O
+rat O
+. O
+
+To O
+assess O
+the O
+antioxidant O
+effects O
+of O
+atorvastatin B
+( O
+atorva B
+) O
+on O
+dexamethasone B
+( O
+dex B
+)- O
+induced O
+hypertension O
+, O
+60 O
+male O
+Sprague O
+- O
+Dawley O
+rats O
+were O
+treated O
+with O
+atorva B
+30 O
+mg O
+/ O
+kg O
+/ O
+day O
+or O
+tap O
+water O
+for O
+15 O
+days O
+. O
+
+Dex B
+increased O
+systolic O
+blood O
+pressure O
+( O
+SBP O
+) O
+from O
+109 O
++/- O
+1 O
+. O
+8 O
+to O
+135 O
++/- O
+0 O
+. O
+6 O
+mmHg O
+and O
+plasma O
+superoxide B
+( O
+5711 O
++/- O
+284 O
+. O
+9 O
+saline O
+, O
+7931 O
++/- O
+392 O
+. O
+8 O
+U O
+/ O
+ml O
+dex B
+, O
+P O
+< O
+0 O
+. O
+1 O
+). O
+
+In O
+this O
+prevention O
+study O
+, O
+SBP O
+in O
+the O
+atorva B
++ O
+dex B
+group O
+was O
+increased O
+from O
+115 O
++/- O
+0 O
+. O
+4 O
+to O
+124 O
++/- O
+1 O
+. O
+5 O
+mmHg O
+, O
+but O
+this O
+was O
+significantly O
+lower O
+than O
+in O
+the O
+dex B
+- O
+only O
+group O
+( O
+P O
+' O
+< O
+0 O
+. O
+5 O
+). O
+
+Atorva O
+reversed O
+dex B
+- O
+induced O
+hypertension O
+( O
+129 O
++/- O
+0 O
+. O
+6 O
+mmHg O
+, O
+vs O
+. O
+
+135 O
++/- O
+0 O
+. O
+6 O
+mmHg O
+P O
+' O
+< O
+0 O
+. O
+5 O
+) O
+and O
+decreased O
+plasma O
+superoxide B
+( O
+7931 O
++/- O
+392 O
+. O
+8 O
+dex O
+, O
+1187 O
++/- O
+441 O
+. O
+2 O
+atorva O
++ O
+dex B
+, O
+P O
+< O
+0 O
+. O
+1 O
+). O
+
+Plasma O
+nitrate B
+/ O
+nitrite B
+( O
+NOx B
+) O
+was O
+decreased O
+in O
+dex B
+- O
+treated O
+rats O
+compared O
+to O
+saline O
+- O
+treated O
+rats O
+( O
+11 O
+. O
+2 O
++/- O
+1 O
+. O
+8 O
+microm O
+, O
+15 O
+. O
+3 O
++/- O
+1 O
+. O
+17 O
+microm O
+, O
+respectively O
+, O
+P O
+< O
+0 O
+. O
+5 O
+). O
+
+Atorva O
+affected O
+neither O
+plasma O
+NOx B
+nor O
+thymus O
+weight O
+. O
+
+Thus O
+, O
+atorvastatin B
+prevented O
+and O
+reversed O
+dexamethasone B
+- O
+induced O
+hypertension O
+in O
+the O
+rat O
+. O
+
+
+Gene O
+polymorphisms O
+implicated O
+in O
+influencing O
+susceptibility O
+to O
+venous O
+and O
+arterial O
+thromboembolism O
+: O
+frequency O
+distribution O
+in O
+a O
+healthy O
+German O
+population O
+. O
+
+Evolvement O
+and O
+progression O
+of O
+cardiovascular O
+diseases O
+affecting O
+the O
+venous O
+and O
+arterial O
+system O
+are O
+influenced O
+by O
+a O
+multitude O
+of O
+environmental O
+and O
+hereditary O
+factors O
+. O
+
+Many O
+of O
+these O
+hereditary O
+factors O
+consist O
+of O
+defined O
+gene O
+polymorphisms O
+, O
+such O
+as O
+single O
+nucleotide O
+polymorphisms O
+( O
+SNPs O
+) O
+or O
+insertion O
+- O
+deletion O
+polymorphisms O
+, O
+which O
+directly O
+or O
+indirectly O
+affect O
+the O
+hemostatic O
+system O
+. O
+
+The O
+frequencies O
+of O
+individual O
+hemostatic O
+gene O
+polymorphisms O
+in O
+different O
+normal O
+populations O
+are O
+well O
+defined O
+. O
+
+However O
+, O
+descriptions O
+of O
+patterns O
+of O
+genetic O
+variability O
+of O
+a O
+larger O
+extent O
+of O
+different O
+factors O
+of O
+hereditary O
+hypercoagulability O
+in O
+single O
+populations O
+are O
+scarce O
+. O
+
+The O
+aim O
+of O
+this O
+study O
+was O
+i O
+) O
+to O
+give O
+a O
+detailed O
+description O
+of O
+the O
+frequencies O
+of O
+factors O
+of O
+hereditary O
+thrombophilia O
+and O
+their O
+combinations O
+in O
+a O
+German O
+population O
+( O
+n O
+= O
+282 O
+) O
+and O
+ii O
+) O
+to O
+compare O
+their O
+distributions O
+with O
+those O
+reported O
+for O
+other O
+regions O
+. O
+
+Variants O
+of O
+coagulation O
+factors O
+[ O
+factor O
+V O
+1691G O
+> O
+A O
+( O
+factor O
+V O
+Leiden O
+), O
+factor O
+V O
+4070A O
+> O
+G O
+( O
+factor O
+V O
+HR2 O
+haplotype O
+), O
+factor O
+VII O
+Arg353Gln O
+, O
+factor O
+XIII O
+Val34Leu O
+, O
+beta O
+- O
+fibrinogen O
+- O
+455G O
+> O
+A O
+, O
+prothrombin O
+20210G O
+> O
+A O
+], O
+coagulation O
+inhibitors O
+[ O
+tissue O
+factor O
+pathway O
+inhibitor O
+536C O
+> O
+T O
+, O
+thrombomodulin O
+127G O
+> O
+A O
+], O
+fibrinolytic O
+factors O
+[ O
+angiotensin O
+converting O
+enzyme O
+intron O
+16 O
+insertion O
+
+/ O
+deletion O
+, O
+factor O
+VII O
+- O
+activating O
+protease O
+1601G O
+> O
+A O
+( O
+FSAP O
+Marburg O
+I O
+), O
+plasminogen O
+activator O
+inhibitor O
+1 O
+- O
+675 O
+insertion O
+/ O
+deletion O
+( O
+5G O
+/ O
+4G O
+), O
+tissue O
+plasminogen O
+activator O
+intron O
+h O
+deletion O
+/ O
+insertion O
+], O
+and O
+other O
+factors O
+implicated O
+in O
+influencing O
+susceptibility O
+to O
+thromboembolic O
+diseases O
+[ O
+apolipoprotein O
+E2 O
+/ O
+E3 O
+/ O
+E4 O
+, O
+glycoprotein O
+Ia O
+807C O
+> O
+T O
+, O
+
+methylenetetrahydrofolate O
+reductase O
+677C O
+> O
+T O
+] O
+were O
+included O
+. O
+
+The O
+distribution O
+of O
+glycoprotein O
+Ia O
+807C O
+> O
+T O
+deviated O
+significantly O
+from O
+the O
+Hardy O
+- O
+Weinberg O
+equilibrium O
+, O
+and O
+a O
+comparison O
+with O
+previously O
+published O
+data O
+indicates O
+marked O
+region O
+and O
+ethnicity O
+dependent O
+differences O
+in O
+the O
+genotype O
+distributions O
+of O
+some O
+other O
+factors O
+. O
+
+
+Necrotising O
+fasciitis O
+after O
+bortezomib B
+and O
+dexamethasone B
+- O
+containing O
+regimen O
+in O
+an O
+elderly O
+patient O
+of O
+Waldenstrom O
+macroglobulinaemia O
+. O
+
+Bortezomib B
+and O
+high O
+- O
+dose O
+dexamethasone B
+- O
+containing O
+regimens O
+are O
+considered O
+to O
+be O
+generally O
+tolerable O
+with O
+few O
+severe O
+bacterial O
+infections O
+in O
+patients O
+with O
+B O
+- O
+cell O
+malignancies O
+. O
+
+However O
+, O
+information O
+is O
+limited O
+concerning O
+the O
+safety O
+of O
+the O
+regimen O
+in O
+elderly O
+patients O
+. O
+
+We O
+report O
+a O
+case O
+of O
+a O
+76 O
+- O
+year O
+- O
+old O
+man O
+with O
+Waldenstrom O
+macroglobulinaemia O
+who O
+suffered O
+necrotising O
+fasciitis O
+without O
+neutropenia O
+after O
+the O
+combination O
+treatment O
+with O
+bortezomib B
+, O
+high O
+- O
+dose O
+dexamethasone B
+and O
+rituximab B
+. O
+
+Despite O
+immediate O
+intravenous O
+antimicrobial O
+therapy O
+, O
+he O
+succumbed O
+23 O
+h O
+after O
+the O
+onset O
+. O
+
+Physicians O
+should O
+recognise O
+the O
+possibility O
+of O
+fatal O
+bacterial O
+infections O
+related O
+to O
+bortezomib B
+plus O
+high O
+- O
+dose O
+dexamethasone B
+in O
+elderly O
+patients O
+, O
+and O
+we O
+believe O
+this O
+case O
+warrants O
+further O
+investigation O
+. O
+
+
+rTMS O
+of O
+supplementary O
+motor O
+area O
+modulates O
+therapy O
+- O
+induced O
+dyskinesias O
+in O
+Parkinson O
+disease O
+. O
+
+The O
+neural O
+mechanisms O
+and O
+circuitry O
+involved O
+in O
+levodopa B
+- O
+induced O
+dyskinesia O
+are O
+unclear O
+. O
+
+Using O
+repetitive O
+transcranial O
+magnetic O
+stimulation O
+( O
+rTMS O
+) O
+over O
+the O
+supplementary O
+motor O
+area O
+( O
+SMA O
+) O
+in O
+a O
+group O
+of O
+patients O
+with O
+advanced O
+Parkinson O
+disease O
+, O
+the O
+authors O
+investigated O
+whether O
+modulation O
+of O
+SMA O
+excitability O
+may O
+result O
+in O
+a O
+modification O
+of O
+a O
+dyskinetic O
+state O
+induced O
+by O
+continuous O
+apomorphine B
+infusion O
+. O
+
+rTMS O
+at O
+1 O
+Hz O
+was O
+observed O
+to O
+markedly O
+reduce O
+drug O
+- O
+induced O
+dyskinesias O
+, O
+whereas O
+5 O
+- O
+Hz O
+rTMS O
+induced O
+a O
+slight O
+but O
+not O
+significant O
+increase O
+. O
+
+
+Angiotensin O
+converting O
+enzyme O
+gene O
+polymorphism O
+in O
+Turkish O
+asthmatic O
+patients O
+. O
+
+Asthma O
+is O
+a O
+chronic O
+inflammatory O
+disease O
+of O
+the O
+airways O
+. O
+
+Several O
+candidate O
+genes O
+have O
+been O
+identified O
+with O
+a O
+potential O
+role O
+in O
+the O
+pathogenesis O
+of O
+asthma O
+, O
+including O
+the O
+angiotensin O
+converting O
+enzyme O
+( O
+ACE O
+) O
+gene O
+. O
+
+We O
+aimed O
+to O
+investigate O
+the O
+frequency O
+of O
+an O
+ACE O
+gene O
+polymorphism O
+in O
+Turkish O
+asthmatic O
+patients O
+and O
+to O
+determine O
+its O
+impact O
+on O
+clinical O
+parameters O
+and O
+disease O
+severity O
+. O
+
+Ninety O
+- O
+seven O
+asthmatic O
+patients O
+( O
+M O
+/ O
+F O
+25 O
+/ O
+72 O
+, O
+mean O
+age O
+39 O
++/- O
+13 O
+years O
+) O
+and O
+96 O
+healthy O
+subjects O
+( O
+M O
+/ O
+F O
+26 O
+/ O
+70 O
+, O
+mean O
+age O
+38 O
++/- O
+12 O
+years O
+) O
+were O
+included O
+. O
+
+At O
+baseline O
+, O
+all O
+participants O
+completed O
+a O
+questionnaire O
+on O
+demographics O
+, O
+symptoms O
+, O
+triggering O
+factors O
+, O
+severity O
+of O
+asthma O
+, O
+and O
+the O
+presence O
+of O
+atopism O
+. O
+
+Blood O
+samples O
+were O
+obtained O
+from O
+all O
+patients O
+and O
+genomic O
+DNA O
+was O
+isolated O
+. O
+
+The O
+frequency O
+of O
+the O
+ACE O
+genotypes O
+( O
+I O
+= O
+insertion O
+and O
+D O
+= O
+deletion O
+) O
+among O
+asthmatics O
+and O
+controls O
+were O
+compared O
+: O
+asthmatics O
+showed O
+a O
+40 O
+. O
+2 O
+% O
+prevalence O
+of O
+the O
+DD O
+genotype O
+( O
+n O
+= O
+39 O
+), O
+ID O
+was O
+45 O
+. O
+4 O
+% O
+( O
+n O
+= O
+44 O
+), O
+and O
+II O
+was O
+14 O
+. O
+4 O
+% O
+( O
+n O
+= O
+14 O
+. O
+4 O
+). O
+
+In O
+the O
+control O
+subjects O
+, O
+the O
+frequency O
+of O
+DD O
+was O
+18 O
+. O
+8 O
+% O
+( O
+n O
+= O
+18 O
+), O
+ID O
+was O
+50 O
+% O
+( O
+n O
+= O
+48 O
+) O
+and O
+II O
+was O
+31 O
+. O
+3 O
+% O
+( O
+n O
+= O
+30 O
+). O
+
+The O
+DD O
+ACE O
+genotype O
+was O
+significantly O
+more O
+frequent O
+in O
+asthmatics O
+compared O
+with O
+controls O
+( O
+p O
+< O
+0 O
+. O
+1 O
+). O
+
+Asthmatics O
+with O
+the O
+ID O
+ACE O
+genotype O
+showed O
+a O
+higher O
+frequency O
+of O
+drug O
+allergies O
+, O
+although O
+this O
+was O
+not O
+statistically O
+significant O
+( O
+p O
+= O
+0 O
+. O
+8 O
+). O
+
+Asthmatics O
+with O
+the O
+DD O
+genotype O
+appeared O
+to O
+have O
+a O
+higher O
+incidence O
+of O
+asthmatic O
+episode O
+exacerbations O
+due O
+to O
+viral O
+infections O
+, O
+but O
+again O
+this O
+was O
+not O
+statistically O
+significant O
+( O
+p O
+= O
+0 O
+. O
+8 O
+). O
+
+Patients O
+with O
+mild O
+or O
+moderate O
+- O
+severe O
+asthma O
+had O
+similar O
+frequencies O
+of O
+these O
+mutations O
+. O
+
+We O
+found O
+a O
+higher O
+frequency O
+of O
+the O
+ACE O
+DD O
+gene O
+mutation O
+in O
+Turkish O
+asthmatic O
+patients O
+compared O
+with O
+non O
+- O
+asthmatics O
+, O
+suggesting O
+that O
+this O
+ACE O
+gene O
+polymorphism O
+may O
+be O
+a O
+risk O
+factor O
+for O
+asthma O
+but O
+does O
+not O
+increase O
+the O
+severity O
+of O
+the O
+disease O
+. O
+
+
+The O
+impact O
+of O
+PPARa O
+activation O
+on O
+whole O
+genome O
+gene O
+expression O
+in O
+human O
+precision O
+cut O
+liver O
+slices O
+. O
+
+BACKGROUND O
+: O
+Studies O
+in O
+mice O
+have O
+shown O
+that O
+PPARa O
+is O
+an O
+important O
+regulator O
+of O
+lipid B
+metabolism O
+in O
+liver O
+and O
+key O
+transcription O
+factor O
+involved O
+in O
+the O
+adaptive O
+response O
+to O
+fasting O
+. O
+
+However O
+, O
+much O
+less O
+is O
+known O
+about O
+the O
+role O
+of O
+PPARa O
+in O
+human O
+liver O
+. O
+
+METHODS O
+: O
+Here O
+we O
+set O
+out O
+to O
+study O
+the O
+function O
+of O
+PPARa O
+in O
+human O
+liver O
+via O
+analysis O
+of O
+whole O
+genome O
+gene O
+regulation O
+in O
+human O
+liver O
+slices O
+treated O
+with O
+the O
+PPARa O
+agonist O
+Wy14643 B
+. O
+
+RESULTS O
+: O
+Quantitative O
+PCR O
+indicated O
+that O
+PPARa O
+is O
+well O
+expressed O
+in O
+human O
+liver O
+and O
+human O
+liver O
+slices O
+and O
+that O
+the O
+classical O
+PPARa O
+targets O
+PLIN2 O
+, O
+VLDLR O
+, O
+ANGPTL4 O
+, O
+CPT1A O
+and O
+PDK4 O
+are O
+robustly O
+induced O
+by O
+PPARa O
+activation O
+. O
+
+Transcriptomics O
+analysis O
+indicated O
+that O
+617 O
+genes O
+were O
+upregulated O
+and O
+665 O
+genes O
+were O
+downregulated O
+by O
+PPARa O
+activation O
+( O
+q O
+value O
+< O
+0 O
+. O
+5 O
+). O
+
+Many O
+genes O
+induced O
+by O
+PPARa O
+activation O
+were O
+involved O
+in O
+lipid B
+metabolism O
+( O
+ACSL5 O
+, O
+AGPAT9 O
+, O
+FADS1 O
+, O
+SLC27A4 O
+), O
+xenobiotic B
+metabolism O
+( O
+POR O
+, O
+ABCC2 O
+, O
+CYP3A5 O
+) O
+or O
+the O
+unfolded O
+protein O
+response O
+, O
+whereas O
+most O
+of O
+the O
+downregulated O
+genes O
+were O
+involved O
+in O
+immune O
+- O
+related O
+pathways O
+. O
+
+Among O
+the O
+most O
+highly O
+repressed O
+genes O
+upon O
+PPARa O
+activation O
+were O
+several O
+chemokines O
+( O
+e O
+. O
+g O
+. O
+
+CXCL9 O
+- O
+11 O
+, O
+CCL8 O
+, O
+CX3CL1 O
+, O
+CXCL6 O
+), O
+interferon O
+g O
+- O
+induced O
+genes O
+( O
+e O
+. O
+g O
+. O
+
+IFITM1 O
+, O
+IFIT1 O
+, O
+IFIT2 O
+, O
+IFIT3 O
+) O
+and O
+numerous O
+other O
+immune O
+- O
+related O
+genes O
+( O
+e O
+. O
+g O
+. O
+
+TLR3 O
+, O
+NOS2 O
+, O
+and O
+LCN2 O
+). O
+
+Comparative O
+analysis O
+of O
+gene O
+regulation O
+by O
+Wy14643 B
+between O
+human O
+liver O
+slices O
+and O
+primary O
+human O
+hepatocytes O
+showed O
+that O
+down O
+- O
+regulation O
+of O
+gene O
+expression O
+by O
+PPARa O
+is O
+much O
+better O
+captured O
+by O
+liver O
+slices O
+as O
+compared O
+to O
+primary O
+hepatocytes O
+. O
+
+In O
+particular O
+, O
+PPARa O
+activation O
+markedly O
+suppressed O
+immunity O
+/ O
+inflammation O
+- O
+related O
+genes O
+in O
+human O
+liver O
+slices O
+but O
+not O
+in O
+primary O
+hepatocytes O
+. O
+
+Finally O
+, O
+several O
+putative O
+new O
+target O
+genes O
+of O
+PPARa O
+were O
+identified O
+that O
+were O
+commonly O
+induced O
+by O
+PPARa O
+activation O
+in O
+the O
+two O
+human O
+liver O
+model O
+systems O
+, O
+including O
+TSKU O
+, O
+RHOF O
+, O
+CA12 O
+and O
+VSIG10L O
+. O
+
+CONCLUSION O
+: O
+Our O
+paper O
+demonstrates O
+the O
+suitability O
+and O
+superiority O
+of O
+human O
+liver O
+slices O
+over O
+primary O
+hepatocytes O
+for O
+studying O
+the O
+functional O
+role O
+of O
+PPARa O
+in O
+human O
+liver O
+. O
+
+Our O
+data O
+underscore O
+the O
+major O
+role O
+of O
+PPARa O
+in O
+regulation O
+of O
+hepatic O
+lipid B
+and O
+xenobiotic B
+metabolism O
+in O
+human O
+liver O
+and O
+reveal O
+a O
+marked O
+immuno O
+- O
+suppressive O
+/ O
+anti O
+- O
+inflammatory O
+effect O
+of O
+PPARa O
+in O
+human O
+liver O
+slices O
+that O
+may O
+be O
+therapeutically O
+relevant O
+for O
+non O
+- O
+alcoholic O
+fatty O
+liver O
+disease O
+. O
+
+
+Oncogenic O
+activity O
+of O
+amplified O
+miniature O
+chromosome O
+maintenance O
+8 O
+in O
+human O
+malignancies O
+. O
+
+Miniature O
+chromosome O
+maintenance O
+( O
+MCM O
+) O
+proteins O
+play O
+critical O
+roles O
+in O
+DNA O
+replication O
+licensing O
+, O
+initiation O
+and O
+elongation O
+. O
+
+MCM8 O
+, O
+one O
+of O
+the O
+MCM O
+proteins O
+playing O
+a O
+critical O
+role O
+in O
+DNA O
+repairing O
+and O
+recombination O
+, O
+was O
+found O
+to O
+have O
+overexpression O
+and O
+increased O
+DNA O
+copy O
+number O
+in O
+a O
+variety O
+of O
+human O
+malignancies O
+. O
+
+The O
+gain O
+of O
+MCM8 O
+is O
+associated O
+with O
+aggressive O
+clinical O
+features O
+of O
+several O
+human O
+cancers O
+. O
+
+Increased O
+expression O
+of O
+MCM8 O
+in O
+prostate O
+cancer O
+is O
+associated O
+with O
+cancer O
+recurrence O
+. O
+
+Forced O
+expression O
+of O
+MCM8 O
+in O
+RWPE1 O
+cells O
+, O
+the O
+immortalized O
+but O
+non O
+- O
+transformed O
+prostate O
+epithelial O
+cell O
+line O
+, O
+exhibited O
+fast O
+cell O
+growth O
+and O
+transformation O
+, O
+while O
+knock O
+down O
+of O
+MCM8 O
+in O
+PC3 O
+, O
+DU145 O
+and O
+LNCaP O
+cells O
+induced O
+cell O
+growth O
+arrest O
+, O
+and O
+decreased O
+tumour O
+volumes O
+and O
+mortality O
+of O
+severe O
+combined O
+immunodeficiency O
+mice O
+xenografted O
+with O
+PC3 O
+and O
+DU145 O
+cells O
+. O
+
+MCM8 O
+bound O
+cyclin O
+D1 O
+and O
+activated O
+Rb O
+protein O
+phosphorylation O
+by O
+cyclin O
+- O
+dependent O
+kinase O
+4 O
+in O
+vitro O
+and O
+in O
+vivo O
+. O
+
+The O
+cyclin O
+D1 O
+/ O
+MCM8 O
+interaction O
+is O
+required O
+for O
+Rb O
+phosphorylation O
+and O
+S O
+- O
+phase O
+entry O
+in O
+cancer O
+cells O
+. O
+
+As O
+a O
+result O
+, O
+our O
+study O
+showed O
+that O
+copy O
+number O
+increase O
+and O
+overexpression O
+of O
+MCM8 O
+may O
+play O
+critical O
+roles O
+in O
+human O
+cancer O
+development O
+. O
+
+
+Enhanced O
+isoproterenol B
+- O
+induced O
+cardiac O
+hypertrophy O
+in O
+transgenic O
+rats O
+with O
+low O
+brain O
+angiotensinogen O
+. O
+
+We O
+have O
+previously O
+shown O
+that O
+a O
+permanent O
+deficiency O
+in O
+the O
+brain O
+renin O
+- O
+angiotensin O
+system O
+( O
+RAS O
+) O
+may O
+increase O
+the O
+sensitivity O
+of O
+the O
+baroreflex O
+control O
+of O
+heart O
+rate O
+. O
+
+In O
+this O
+study O
+we O
+aimed O
+at O
+studying O
+the O
+involvement O
+of O
+the O
+brain O
+RAS O
+in O
+the O
+cardiac O
+reactivity O
+to O
+the O
+beta O
+- O
+adrenoceptor O
+( O
+beta O
+- O
+AR O
+) O
+agonist O
+isoproterenol B
+( O
+Iso B
+). O
+
+Transgenic O
+rats O
+with O
+low O
+brain O
+angiotensinogen O
+( O
+TGR O
+) O
+were O
+used O
+. O
+
+In O
+isolated O
+hearts O
+, O
+Iso B
+induced O
+a O
+significantly O
+greater O
+increase O
+in O
+left O
+ventricular O
+( O
+LV O
+) O
+pressure O
+and O
+maximal O
+contraction O
+(+ O
+dP O
+/ O
+dt O
+( O
+max O
+)) O
+in O
+the O
+TGR O
+than O
+in O
+the O
+Sprague O
+- O
+Dawley O
+( O
+SD O
+) O
+rats O
+. O
+
+LV O
+hypertrophy O
+induced O
+by O
+Iso B
+treatment O
+was O
+significantly O
+higher O
+in O
+TGR O
+than O
+in O
+SD O
+rats O
+( O
+in O
+g O
+LV O
+wt O
+/ O
+100 O
+g O
+body O
+wt O
+, O
+0 O
+. O
+28 O
++/- O
+0 O
+. O
+4 O
+vs O
+. O
+
+0 O
+. O
+24 O
++/- O
+0 O
+. O
+4 O
+, O
+respectively O
+). O
+
+The O
+greater O
+LV O
+hypertrophy O
+in O
+TGR O
+rats O
+was O
+associated O
+with O
+more O
+pronounced O
+downregulation O
+of O
+beta O
+- O
+AR O
+and O
+upregulation O
+of O
+LV O
+beta O
+- O
+AR O
+kinase O
+- O
+1 O
+mRNA O
+levels O
+compared O
+with O
+those O
+in O
+SD O
+rats O
+. O
+
+The O
+decrease O
+in O
+the O
+heart O
+rate O
+( O
+HR O
+) O
+induced O
+by O
+the O
+beta O
+- O
+AR O
+antagonist O
+metoprolol B
+in O
+conscious O
+rats O
+was O
+significantly O
+attenuated O
+in O
+TGR O
+compared O
+with O
+SD O
+rats O
+(- O
+9 O
+. O
+9 O
++/- O
+1 O
+. O
+7 O
+% O
+vs O
+. O
+
+- O
+18 O
+. O
+1 O
++/- O
+1 O
+. O
+5 O
+%), O
+whereas O
+the O
+effect O
+of O
+parasympathetic O
+blockade O
+by O
+atropine B
+on O
+HR O
+was O
+similar O
+in O
+both O
+strains O
+. O
+
+These O
+results O
+indicate O
+that O
+TGR O
+are O
+more O
+sensitive O
+to O
+beta O
+- O
+AR O
+agonist O
+- O
+induced O
+cardiac O
+inotropic O
+response O
+and O
+hypertrophy O
+, O
+possibly O
+due O
+to O
+chronically O
+low O
+sympathetic O
+outflow O
+directed O
+to O
+the O
+heart O
+. O
+
+
+Intronic O
+deletions O
+in O
+the O
+SLC34A3 O
+gene O
+cause O
+hereditary O
+hypophosphatemic O
+rickets O
+with O
+hypercalciuria O
+. O
+
+CONTEXT O
+: O
+Hereditary O
+hypophosphatemic O
+rickets O
+with O
+hypercalciuria O
+( O
+HHRH O
+) O
+is O
+a O
+rare O
+metabolic O
+disorder O
+, O
+characterized O
+by O
+hypophosphatemia O
+and O
+rickets O
+/ O
+osteomalacia O
+with O
+increased O
+serum O
+1 B
+, I
+25 I
+- I
+dihydroxyvitamin I
+D I
+[ O
+1 B
+, I
+25 I
+-( I
+OH I
+)( I
+2 I
+) I
+D I
+] O
+resulting O
+in O
+hypercalciuria O
+. O
+
+OBJECTIVE O
+: O
+Our O
+objective O
+was O
+to O
+determine O
+whether O
+mutations O
+in O
+the O
+SLC34A3 O
+gene O
+, O
+which O
+encodes O
+sodium O
+- O
+phosphate O
+cotransporter O
+type O
+IIc O
+, O
+are O
+responsible O
+for O
+the O
+occurrence O
+of O
+HHRH O
+. O
+
+DESIGN O
+AND O
+SETTING O
+: O
+Mutation O
+analysis O
+of O
+exons O
+and O
+adjacent O
+introns O
+in O
+the O
+SLC34A3 O
+gene O
+was O
+conducted O
+at O
+an O
+academic O
+research O
+laboratory O
+and O
+medical O
+center O
+. O
+
+PATIENTS O
+OR O
+OTHER O
+PARTICIPANTS O
+: O
+Members O
+of O
+two O
+unrelated O
+families O
+with O
+HHRH O
+participated O
+in O
+the O
+study O
+. O
+
+RESULTS O
+: O
+Two O
+affected O
+siblings O
+in O
+one O
+family O
+were O
+homozygous O
+for O
+a O
+101 O
+- O
+bp O
+deletion O
+in O
+intron O
+9 O
+. O
+
+Haplotype O
+analysis O
+of O
+the O
+SLC34A3 O
+locus O
+in O
+the O
+family O
+showed O
+that O
+the O
+two O
+deletions O
+are O
+on O
+different O
+haplotypes O
+. O
+
+An O
+unrelated O
+individual O
+with O
+HHRH O
+was O
+a O
+compound O
+heterozygote O
+for O
+an O
+85 O
+- O
+bp O
+deletion O
+in O
+intron O
+10 O
+and O
+a O
+G O
+- O
+to O
+- O
+A O
+substitution O
+at O
+the O
+last O
+nucleotide O
+in O
+exon O
+7 O
+. O
+
+The O
+intron O
+9 O
+deletion O
+( O
+and O
+likely O
+the O
+other O
+two O
+mutations O
+) O
+identified O
+in O
+this O
+study O
+causes O
+aberrant O
+RNA O
+splicing O
+. O
+
+Sequence O
+analysis O
+of O
+the O
+deleted O
+regions O
+revealed O
+the O
+presence O
+of O
+direct O
+repeats O
+of O
+homologous O
+sequences O
+. O
+
+CONCLUSION O
+: O
+HHRH O
+is O
+caused O
+by O
+biallelic O
+mutations O
+in O
+the O
+SLC34A3 O
+gene O
+. O
+
+Haplotype O
+analysis O
+suggests O
+that O
+the O
+two O
+intron O
+9 O
+deletions O
+arose O
+independently O
+. O
+
+The O
+identification O
+of O
+three O
+independent O
+deletions O
+in O
+introns O
+9 O
+and O
+10 O
+suggests O
+that O
+the O
+SLC34A3 O
+gene O
+may O
+be O
+susceptible O
+to O
+unequal O
+crossing O
+over O
+because O
+of O
+sequence O
+misalignment O
+during O
+meiosis O
+. O
+
+
+Vitamin O
+D O
+receptor O
+expression O
+is O
+associated O
+with O
+PIK3CA O
+and O
+KRAS O
+mutations O
+in O
+colorectal O
+cancer O
+. O
+
+Vitamin B
+D I
+is O
+associated O
+with O
+decreased O
+risks O
+of O
+various O
+cancers O
+, O
+including O
+colon O
+cancer O
+. O
+
+The O
+vitamin O
+D O
+receptor O
+( O
+VDR O
+) O
+is O
+a O
+transcription O
+factor O
+, O
+which O
+plays O
+an O
+important O
+role O
+in O
+cellular O
+differentiation O
+and O
+inhibition O
+of O
+proliferation O
+. O
+
+A O
+link O
+between O
+VDR O
+and O
+the O
+RAS O
+- O
+mitogen O
+- O
+activated O
+protein O
+kinase O
+( O
+MAPK O
+) O
+or O
+phosphatidylinositol O
+3 O
+- O
+kinase O
+( O
+PI3K O
+)- O
+AKT O
+pathway O
+has O
+been O
+suggested O
+. O
+
+However O
+, O
+the O
+prognostic O
+role O
+of O
+VDR O
+expression O
+or O
+its O
+relationship O
+with O
+PIK3CA O
+or O
+KRAS O
+mutation O
+remains O
+uncertain O
+. O
+
+Among O
+619 O
+colorectal O
+cancers O
+in O
+two O
+prospective O
+cohort O
+studies O
+, O
+233 O
+( O
+38 O
+%) O
+tumors O
+showed O
+VDR O
+overexpression O
+by O
+immunohistochemistry O
+. O
+
+We O
+analyzed O
+for O
+PIK3CA O
+and O
+KRAS O
+mutations O
+and O
+LINE O
+- O
+1 O
+methylation O
+by O
+Pyrosequencing O
+, O
+microsatellite O
+instability O
+( O
+MSI O
+), O
+and O
+DNA O
+methylation O
+( O
+epigenetic O
+changes O
+) O
+in O
+eight O
+CpG O
+island O
+methylator O
+phenotype O
+( O
+CIMP O
+)- O
+specific O
+promoters O
+[ O
+CACNA1G O
+, O
+CDKN2A O
+( O
+p16 O
+), O
+CRABP1 O
+, O
+IGF2 O
+, O
+MLH1 O
+, O
+NEUROG1 O
+, O
+RUNX3 O
+, O
+and O
+SOCS1 O
+] O
+by O
+MethyLight O
+( O
+real O
+
+- O
+time O
+PCR O
+). O
+
+VDR O
+overexpression O
+was O
+significantly O
+associated O
+with O
+KRAS O
+mutation O
+( O
+odds O
+ratio O
+, O
+1 O
+. O
+55 O
+; O
+95 O
+% O
+confidence O
+interval O
+, O
+1 O
+. O
+11 O
+- O
+2 O
+. O
+16 O
+) O
+and O
+PIK3CA O
+mutation O
+( O
+odds O
+ratio O
+, O
+2 O
+. O
+17 O
+; O
+95 O
+% O
+confidence O
+interval O
+, O
+1 O
+. O
+36 O
+- O
+3 O
+. O
+47 O
+), O
+both O
+of O
+which O
+persisted O
+in O
+multivariate O
+logistic O
+regression O
+analysis O
+. O
+
+VDR O
+was O
+not O
+independently O
+associated O
+with O
+body O
+mass O
+index O
+, O
+family O
+history O
+of O
+colorectal O
+cancer O
+, O
+tumor O
+location O
+( O
+colon O
+versus O
+rectum O
+), O
+stage O
+, O
+tumor O
+grade O
+, O
+signet O
+ring O
+cells O
+, O
+CIMP O
+, O
+MSI O
+, O
+LINE O
+- O
+1 O
+hypomethylation O
+, O
+BRAF O
+, O
+p53 O
+, O
+p21 O
+, O
+beta O
+- O
+catenin O
+, O
+or O
+cyclooxygenase O
+- O
+2 O
+. O
+
+VDR O
+expression O
+was O
+not O
+significantly O
+related O
+with O
+patient O
+survival O
+, O
+prognosis O
+, O
+or O
+clinical O
+outcome O
+. O
+
+In O
+conclusion O
+, O
+VDR O
+overexpression O
+in O
+colorectal O
+cancer O
+is O
+independently O
+associated O
+with O
+PIK3CA O
+and O
+KRAS O
+mutations O
+. O
+
+Our O
+data O
+support O
+potential O
+interactions O
+between O
+the O
+VDR O
+, O
+RAS O
+- O
+MAPK O
+and O
+PI3K O
+- O
+AKT O
+pathways O
+, O
+and O
+possible O
+influence O
+by O
+KRAS O
+or O
+PIK3CA O
+mutation O
+on O
+therapy O
+or O
+chemoprevention O
+targeting O
+VDR O
+. O
+
+
+Cultured O
+mycelium O
+Cordyceps O
+sinensis O
+protects O
+liver O
+sinusoidal O
+endothelial O
+cells O
+in O
+acute O
+liver O
+injured O
+mice O
+. O
+
+Cultured O
+mycelium O
+Cordyceps O
+sinensis O
+( O
+CMCS O
+) O
+was O
+widely O
+used O
+for O
+a O
+variety O
+of O
+diseases O
+including O
+liver O
+injury O
+, O
+the O
+current O
+study O
+aims O
+to O
+investigate O
+the O
+protective O
+effects O
+of O
+CMCS O
+on O
+liver O
+sinusoidal O
+endothelial O
+cells O
+( O
+LSECs O
+) O
+in O
+acute O
+injury O
+liver O
+and O
+related O
+action O
+mechanisms O
+. O
+
+The O
+mice O
+were O
+injected O
+intraperitoneally O
+with O
+lipopolysaccharide B
+( O
+LPS B
+) O
+and O
+D B
+- I
+galactosamine I
+( O
+D B
+- I
+GalN I
+). O
+
+39 O
+male O
+BABL O
+/ O
+c O
+mice O
+were O
+randomly O
+divided O
+into O
+four O
+groups O
+: O
+normal O
+control O
+, O
+model O
+control O
+, O
+CMCS B
+treatment O
+and O
+1 B
+, I
+10 I
+- I
+phenanthroline I
+treatment O
+groups O
+. O
+
+The O
+Serum O
+liver O
+function O
+parameters O
+including O
+alanine B
+aminotransferase I
+( O
+ALT O
+) O
+and O
+aspartate B
+aminotransferase I
+( O
+AST O
+) O
+levels O
+were O
+assayed O
+with O
+the O
+commercial O
+kit O
+. O
+
+The O
+inflammation O
+and O
+scaffold O
+structure O
+in O
+liver O
+were O
+stained O
+with O
+hematoxylin O
+and O
+eosin O
+and O
+silver O
+staining O
+respectively O
+. O
+
+The O
+LSECs O
+and O
+sub O
+- O
+endothelial O
+basement O
+membrane O
+were O
+observed O
+with O
+the O
+scanning O
+and O
+transmission O
+electronic O
+microscope O
+. O
+
+The O
+protein O
+expressions O
+of O
+intercellular O
+adhesion O
+molecule O
+- O
+1 O
+( O
+ICAM O
+- O
+1 O
+) O
+and O
+vascular O
+cell O
+adhesion O
+molecule O
+- O
+1 O
+( O
+VCAM O
+- O
+1 O
+) O
+in O
+liver O
+were O
+analyzed O
+with O
+Western O
+blotting O
+. O
+
+Expression O
+of O
+von O
+Willebrand O
+factor O
+( O
+vWF O
+) O
+was O
+investigated O
+with O
+immunofluorescence O
+staining O
+. O
+
+The O
+lipid B
+peroxidation O
+indicators O
+including O
+antisuperoxideanion B
+( O
+ASAFR O
+), O
+hydroxyl O
+free O
+radical O
+(. O
+OH I
+), O
+superoxide O
+dismutase O
+( O
+SOD O
+), O
+malondialdehyde B
+and O
+glutathione O
+S O
+- O
+transferase O
+( O
+GST O
+) O
+were O
+determined O
+with O
+kits O
+, O
+and O
+matrix O
+metalloproteinase O
+- O
+2 O
+and O
+9 O
+( O
+MMP O
+- O
+2 O
+/ O
+9 O
+) O
+activities O
+in O
+liver O
+were O
+analyzed O
+with O
+gelatin O
+zymography O
+and O
+in O
+situ O
+fluorescent O
+zymography O
+respectively O
+. O
+
+The O
+model O
+mice O
+had O
+much O
+higher O
+serum O
+levels O
+of O
+ALT O
+and O
+AST O
+than O
+the O
+normal O
+mice O
+. O
+
+Compared O
+to O
+that O
+in O
+the O
+normal O
+control O
+, O
+more O
+severe O
+liver O
+inflammation O
+and O
+hepatocyte O
+apoptosis O
+, O
+worse O
+hepatic O
+lipid B
+peroxidation O
+demonstrated O
+by O
+the O
+increased O
+ASAFR O
+, O
+. O
+OH I
+and O
+MDA B
+, O
+but O
+decreased O
+SOD O
+and O
+GST O
+, O
+increased O
+MMP O
+- O
+2 O
+/ O
+9 O
+activities O
+and O
+VCAM O
+- O
+1 O
+, O
+ICAM O
+- O
+1 O
+and O
+vWF O
+expressions O
+, O
+which O
+revealed O
+obvious O
+LSEC O
+injury O
+and O
+scaffold O
+structure O
+broken O
+, O
+were O
+shown O
+in O
+the O
+model O
+control O
+. O
+
+Compared O
+with O
+the O
+model O
+group O
+, O
+CMCS O
+and O
+1 B
+, I
+10 I
+- I
+phenanthroline I
+significantly O
+improved O
+serum O
+ALT O
+/ O
+AST O
+, O
+attenuated O
+hepatic O
+inflammation O
+and O
+improved O
+peroxidative O
+injury O
+in O
+liver O
+, O
+decreased O
+MMP O
+- O
+2 O
+/ O
+9 O
+activities O
+in O
+liver O
+tissue O
+, O
+improved O
+integration O
+of O
+scaffold O
+structure O
+, O
+and O
+decreased O
+protein O
+expression O
+of O
+VCAM O
+- O
+1 O
+and O
+ICAM O
+- O
+1 O
+. O
+
+CMCS O
+could O
+protect O
+LSECs O
+from O
+injury O
+and O
+maintain O
+the O
+microvasculature O
+integration O
+in O
+acute O
+injured O
+liver O
+of O
+mice O
+induced O
+by O
+LPS B
+/ O
+D O
+- O
+GalN O
+. O
+
+Its O
+action O
+mechanism O
+was O
+associated O
+with O
+the O
+down O
+- O
+regulation O
+of O
+MMP O
+- O
+2 O
+/ O
+9 O
+activities O
+and O
+inhibition O
+of O
+peroxidation O
+in O
+injured O
+liver O
+. O
+
+
+A O
+Type O
+2 O
+Diabetes O
+- O
+Associated O
+Functional O
+Regulatory O
+Variant O
+in O
+a O
+Pancreatic O
+Islet O
+Enhancer O
+at O
+the O
+ADCY5 O
+Locus O
+. O
+
+Molecular O
+mechanisms O
+remain O
+unknown O
+for O
+most O
+type O
+2 O
+diabetes O
+genome O
+- O
+wide O
+association O
+study O
+identified O
+loci O
+. O
+
+Variants O
+associated O
+with O
+type O
+2 O
+diabetes O
+and O
+fasting O
+glucose B
+levels O
+reside O
+in O
+introns O
+of O
+ADCY5 O
+, O
+a O
+gene O
+that O
+encodes O
+adenylate O
+cyclase O
+5 O
+. O
+
+Adenylate O
+cyclase O
+5 O
+catalyzes O
+the O
+production O
+of O
+cyclic B
+AMP I
+, O
+which O
+is O
+a O
+second O
+messenger O
+molecule O
+involved O
+in O
+cell O
+signaling O
+and O
+pancreatic O
+b O
+- O
+cell O
+insulin O
+secretion O
+. O
+
+We O
+demonstrated O
+that O
+type O
+2 O
+diabetes O
+risk O
+alleles O
+are O
+associated O
+with O
+decreased O
+ADCY5 O
+expression O
+in O
+human O
+islets O
+and O
+examined O
+candidate O
+variants O
+for O
+regulatory O
+function O
+. O
+
+rs11708067 O
+overlaps O
+a O
+predicted O
+enhancer O
+region O
+in O
+pancreatic O
+islets O
+. O
+
+The O
+type O
+2 O
+diabetes O
+risk O
+rs11708067 O
+- O
+A O
+allele O
+showed O
+fewer O
+H3K27ac O
+ChIP O
+- O
+seq O
+reads O
+in O
+human O
+islets O
+, O
+lower O
+transcriptional O
+activity O
+in O
+reporter O
+assays O
+in O
+rodent O
+b O
+- O
+cells O
+( O
+rat O
+832 O
+/ O
+13 O
+and O
+mouse O
+MIN6 O
+), O
+and O
+increased O
+nuclear O
+protein O
+binding O
+compared O
+with O
+the O
+rs11708067 O
+- O
+G O
+allele O
+. O
+
+Homozygous O
+deletion O
+of O
+the O
+orthologous O
+enhancer O
+region O
+in O
+832 O
+/ O
+13 O
+cells O
+resulted O
+in O
+a O
+64 O
+% O
+reduction O
+in O
+expression O
+level O
+of O
+Adcy5 O
+, O
+but O
+not O
+adjacent O
+gene O
+Sec22a O
+, O
+and O
+a O
+39 O
+% O
+reduction O
+in O
+insulin O
+secretion O
+. O
+
+Together O
+, O
+these O
+data O
+suggest O
+that O
+rs11708067 O
+- O
+A O
+risk O
+allele O
+contributes O
+to O
+type O
+2 O
+diabetes O
+by O
+disrupting O
+an O
+islet O
+enhancer O
+, O
+which O
+results O
+in O
+reduced O
+ADCY5 O
+expression O
+and O
+impaired O
+insulin O
+secretion O
+. O
+
+
+Homozygously O
+deleted O
+gene O
+DACH1 O
+regulates O
+tumor O
+- O
+initiating O
+activity O
+of O
+glioma O
+cells O
+. O
+
+Loss O
+or O
+reduction O
+in O
+function O
+of O
+tumor O
+suppressor O
+genes O
+contributes O
+to O
+tumorigenesis O
+. O
+
+Here O
+, O
+by O
+allelic O
+DNA O
+copy O
+number O
+analysis O
+using O
+single O
+- O
+nucleotide O
+polymorphism O
+genotyping O
+array O
+and O
+mass O
+spectrometry O
+, O
+we O
+report O
+homozygous O
+deletion O
+in O
+glioblastoma O
+multiformes O
+at O
+chromosome O
+13q21 O
+, O
+where O
+DACH1 O
+gene O
+is O
+located O
+. O
+
+We O
+found O
+decreased O
+cell O
+proliferation O
+of O
+a O
+series O
+of O
+glioma O
+cell O
+lines O
+by O
+forced O
+expression O
+of O
+DACH1 O
+. O
+
+We O
+then O
+generated O
+U87TR O
+- O
+Da O
+glioma O
+cells O
+, O
+where O
+DACH1 O
+expression O
+could O
+be O
+activated O
+by O
+exposure O
+of O
+the O
+cells O
+to O
+doxycycline B
+. O
+
+Both O
+ex O
+vivo O
+cellular O
+proliferation O
+and O
+in O
+vivo O
+growth O
+of O
+s B
+. I
+c I
+. O
+
+transplanted O
+tumors O
+in O
+mice O
+are O
+reduced O
+in O
+U87TR O
+- O
+Da O
+cells O
+with O
+DACH1 O
+expression O
+( O
+U87 O
+- O
+DACH1 O
+- O
+high O
+), O
+compared O
+with O
+DACH1 O
+- O
+nonexpressing O
+U87TR O
+- O
+Da O
+cells O
+( O
+U87 O
+- O
+DACH1 O
+- O
+low O
+). O
+
+U87 O
+- O
+DACH1 O
+- O
+low O
+cells O
+form O
+spheroids O
+with O
+CD133 O
+and O
+Nestin O
+expression O
+in O
+serum O
+- O
+free O
+medium O
+but O
+U87 O
+- O
+DACH1 O
+- O
+high O
+cells O
+do O
+not O
+. O
+
+Compared O
+with O
+spheroid O
+- O
+forming O
+U87 O
+- O
+DACH1 O
+- O
+low O
+cells O
+, O
+adherent O
+U87 O
+- O
+DACH1 O
+- O
+high O
+cells O
+display O
+lower O
+tumorigenicity O
+, O
+indicating O
+DACH1 O
+decreases O
+the O
+number O
+of O
+tumor O
+- O
+initiating O
+cells O
+. O
+
+Gene O
+expression O
+analysis O
+and O
+chromatin O
+immunoprecipitation O
+assay O
+reveal O
+that O
+fibroblast O
+growth O
+factor O
+2 O
+( O
+FGF2 O
+/ O
+bFGF O
+) O
+is O
+transcriptionally O
+repressed O
+by O
+DACH1 O
+, O
+especially O
+in O
+cells O
+cultured O
+in O
+serum O
+- O
+free O
+medium O
+. O
+
+Exogenous O
+bFGF O
+rescues O
+spheroid O
+- O
+forming O
+activity O
+and O
+tumorigenicity O
+of O
+the O
+U87 O
+- O
+DACH1 O
+- O
+high O
+cells O
+, O
+suggesting O
+that O
+loss O
+of O
+DACH1 O
+increases O
+the O
+number O
+of O
+tumor O
+- O
+initiating O
+cells O
+through O
+transcriptional O
+activation O
+of O
+bFGF O
+. O
+
+These O
+results O
+illustrate O
+that O
+DACH1 O
+is O
+a O
+distinctive O
+tumor O
+suppressor O
+, O
+which O
+does O
+not O
+only O
+suppress O
+growth O
+of O
+tumor O
+cells O
+but O
+also O
+regulates O
+bFGF O
+- O
+mediated O
+tumor O
+- O
+initiating O
+activity O
+of O
+glioma O
+cells O
+. O
+
+
+Definition O
+and O
+management O
+of O
+anemia O
+in O
+patients O
+infected O
+with O
+hepatitis O
+C O
+virus O
+. O
+
+Chronic O
+infection O
+with O
+hepatitis O
+C O
+virus O
+( O
+HCV O
+) O
+can O
+progress O
+to O
+cirrhosis O
+, O
+hepatocellular O
+carcinoma O
+, O
+and O
+end O
+- O
+stage O
+liver O
+disease O
+. O
+
+The O
+current O
+best O
+treatment O
+for O
+HCV O
+infection O
+is O
+combination O
+therapy O
+with O
+pegylated B
+interferon I
+and O
+ribavirin B
+. O
+
+Although O
+this O
+regimen O
+produces O
+sustained O
+virologic O
+responses O
+( O
+SVRs O
+) O
+in O
+approximately O
+50 O
+% O
+of O
+patients O
+, O
+it O
+can O
+be O
+associated O
+with O
+a O
+potentially O
+dose O
+- O
+limiting O
+hemolytic O
+anemia O
+. O
+
+Hemoglobin O
+concentrations O
+decrease O
+mainly O
+as O
+a O
+result O
+of O
+ribavirin B
+- O
+induced O
+hemolysis O
+, O
+and O
+this O
+anemia O
+can O
+be O
+problematic O
+in O
+patients O
+with O
+HCV O
+infection O
+, O
+especially O
+those O
+who O
+have O
+comorbid O
+renal O
+or O
+cardiovascular O
+disorders O
+. O
+
+In O
+general O
+, O
+anemia O
+can O
+increase O
+the O
+risk O
+of O
+morbidity O
+and O
+mortality O
+, O
+and O
+may O
+have O
+negative O
+effects O
+on O
+cerebral O
+function O
+and O
+quality O
+of O
+life O
+. O
+
+Although O
+ribavirin B
+- O
+associated O
+anemia O
+can O
+be O
+reversed O
+by O
+dose O
+reduction O
+or O
+discontinuation O
+, O
+this O
+approach O
+compromises O
+outcomes O
+by O
+significantly O
+decreasing O
+SVR O
+rates O
+. O
+
+Recombinant O
+human O
+erythropoietin O
+has O
+been O
+used O
+to O
+manage O
+ribavirin B
+- O
+associated O
+anemia O
+but O
+has O
+other O
+potential O
+disadvantages O
+. O
+
+Viramidine B
+, O
+a O
+liver O
+- O
+targeting O
+prodrug O
+of O
+ribavirin B
+, O
+has O
+the O
+potential O
+to O
+maintain O
+the O
+virologic O
+efficacy O
+of O
+ribavirin B
+while O
+decreasing O
+the O
+risk O
+of O
+hemolytic O
+anemia O
+in O
+patients O
+with O
+chronic O
+hepatitis O
+C O
+. O
+
+
+Association O
+between O
+an O
+endoglin O
+gene O
+polymorphism O
+and O
+systemic O
+sclerosis O
+- O
+related O
+pulmonary O
+arterial O
+hypertension O
+. O
+
+Systemic O
+sclerosis O
+( O
+SSc O
+) O
+is O
+a O
+connective O
+tissue O
+disorder O
+characterized O
+by O
+early O
+generalized O
+microangiopathy O
+with O
+disturbed O
+angiogenesis O
+. O
+
+Endoglin O
+gene O
+( O
+ENG O
+) O
+encodes O
+a O
+transmembrane O
+glycoprotein O
+which O
+acts O
+as O
+an O
+accessory O
+receptor O
+for O
+the O
+transforming O
+growth O
+factor O
+- O
+beta O
+( O
+TGF O
+- O
+beta O
+) O
+superfamily O
+, O
+and O
+is O
+crucial O
+for O
+maintaining O
+vascular O
+integrity O
+. O
+
+A O
+6 O
+- O
+base O
+insertion O
+in O
+intron O
+7 O
+( O
+6bINS O
+) O
+of O
+ENG O
+has O
+been O
+reported O
+to O
+be O
+associated O
+with O
+microvascular O
+disturbance O
+. O
+
+OBJECTIVES O
+: O
+Our O
+objective O
+was O
+to O
+investigate O
+the O
+relationship O
+between O
+6bINS O
+and O
+the O
+vascular O
+complication O
+pulmonary O
+arterial O
+hypertension O
+( O
+PAH O
+) O
+in O
+SSc O
+in O
+a O
+French O
+Caucasian O
+population O
+. O
+
+METHODS O
+: O
+Two O
+hundred O
+eighty O
+SSc O
+cases O
+containing O
+29 O
+/ O
+280 O
+having O
+PAH O
+diagnosed O
+by O
+catheterism O
+were O
+compared O
+with O
+140 O
+patients O
+with O
+osteoarthritis O
+. O
+
+Genotyping O
+was O
+performed O
+by O
+polymerase O
+- O
+chain O
+- O
+reaction O
+- O
+based O
+fluorescence O
+and O
+direct O
+sequencing O
+of O
+genomic O
+DNA O
+. O
+
+RESULTS O
+: O
+The O
+polymorphism O
+was O
+in O
+Hardy O
+- O
+Weinberg O
+equilibrium O
+. O
+
+We O
+observed O
+a O
+significant O
+lower O
+frequency O
+of O
+6bINS O
+allele O
+in O
+SSc O
+patients O
+with O
+associated O
+PAH O
+compared O
+with O
+controls O
+[ O
+10 O
+. O
+3 O
+vs O
+23 O
+. O
+9 O
+%, O
+P O
+= O
+0 O
+. O
+1 O
+; O
+odds O
+ratio O
+( O
+OR O
+) O
+0 O
+. O
+37 O
+, O
+95 O
+% O
+confidence O
+interval O
+( O
+CI O
+) O
+0 O
+. O
+15 O
+- O
+0 O
+. O
+89 O
+], O
+and O
+a O
+trend O
+in O
+comparison O
+with O
+SSc O
+patients O
+without O
+PAH O
+( O
+10 O
+. O
+3 O
+vs O
+20 O
+. O
+3 O
+%, O
+P O
+= O
+0 O
+. O
+5 O
+; O
+OR O
+: O
+0 O
+. O
+45 O
+, O
+95 O
+% O
+CI O
+: O
+0 O
+. O
+19 O
+- O
+1 O
+. O
+8 O
+). O
+
+Genotypes O
+carrying O
+allele O
+6bINS O
+were O
+also O
+less O
+frequent O
+in O
+SSc O
+patients O
+with O
+PAH O
+than O
+in O
+controls O
+( O
+20 O
+. O
+7 O
+vs O
+42 O
+. O
+9 O
+%, O
+P O
+= O
+0 O
+. O
+2 O
+). O
+
+CONCLUSIONS O
+: O
+Thus O
+the O
+frequency O
+of O
+6bINS O
+differs O
+between O
+SSc O
+patients O
+with O
+or O
+without O
+PAH O
+, O
+suggesting O
+the O
+implication O
+of O
+ENG O
+in O
+this O
+devastating O
+vascular O
+complication O
+of O
+SSc O
+. O
+
+
+Assessment O
+of O
+a O
+new O
+non O
+- O
+invasive O
+index O
+of O
+cardiac O
+performance O
+for O
+detection O
+of O
+dobutamine B
+- O
+induced O
+myocardial O
+ischemia O
+. O
+
+BACKGROUND O
+: O
+Electrocardiography O
+has O
+a O
+very O
+low O
+sensitivity O
+in O
+detecting O
+dobutamine B
+- O
+induced O
+myocardial O
+ischemia O
+. O
+
+OBJECTIVES O
+: O
+To O
+assess O
+the O
+added O
+diagnostic O
+value O
+of O
+a O
+new O
+cardiac O
+performance O
+index O
+( O
+dP O
+/ O
+dtejc O
+) O
+measurement O
+, O
+based O
+on O
+brachial O
+artery O
+flow O
+changes O
+, O
+as O
+compared O
+to O
+standard O
+12 O
+- O
+lead O
+ECG O
+, O
+for O
+detecting O
+dobutamine B
+- O
+induced O
+myocardial O
+ischemia O
+, O
+using O
+Tc99m B
+- O
+Sestamibi B
+single O
+- O
+photon O
+emission O
+computed O
+tomography O
+as O
+the O
+gold O
+standard O
+of O
+comparison O
+to O
+assess O
+the O
+presence O
+or O
+absence O
+of O
+ischemia O
+. O
+
+METHODS O
+: O
+The O
+study O
+group O
+comprised O
+40 O
+patients O
+undergoing O
+Sestamibi B
+- O
+SPECT O
+/ O
+dobutamine B
+stress O
+test O
+. O
+
+Simultaneous O
+measurements O
+of O
+ECG O
+and O
+brachial O
+artery O
+dP O
+/ O
+dtejc O
+were O
+performed O
+at O
+each O
+dobutamine B
+level O
+. O
+
+In O
+19 O
+of O
+the O
+40 O
+patients O
+perfusion O
+defects O
+compatible O
+with O
+ischemia O
+were O
+detected O
+on O
+SPECT O
+. O
+
+The O
+increase O
+in O
+dP O
+/ O
+dtejc O
+during O
+infusion O
+of O
+dobutamine B
+in O
+this O
+group O
+was O
+severely O
+impaired O
+as O
+compared O
+to O
+the O
+non O
+- O
+ischemic O
+group O
+. O
+
+dP O
+/ O
+dtejc O
+outcome O
+was O
+combined O
+with O
+the O
+ECG O
+results O
+, O
+giving O
+an O
+ECG O
+- O
+enhanced O
+value O
+, O
+and O
+compared O
+to O
+ECG O
+alone O
+. O
+
+RESULTS O
+: O
+The O
+sensitivity O
+improved O
+dramatically O
+from O
+16 O
+% O
+to O
+79 O
+%, O
+positive O
+predictive O
+value O
+increased O
+from O
+60 O
+% O
+to O
+68 O
+% O
+and O
+negative O
+predictive O
+value O
+from O
+54 O
+% O
+to O
+78 O
+%, O
+and O
+specificity O
+decreased O
+from O
+90 O
+% O
+to O
+67 O
+%. O
+
+CONCLUSIONS O
+: O
+If O
+ECG O
+alone O
+is O
+used O
+for O
+specificity O
+, O
+the O
+combination O
+with O
+dP O
+/ O
+dtejc O
+improved O
+the O
+sensitivity O
+of O
+the O
+test O
+and O
+could O
+be O
+a O
+cost O
+- O
+savings O
+alternative O
+to O
+cardiac O
+imaging O
+or O
+perfusion O
+studies O
+to O
+detect O
+myocardial O
+ischemia O
+, O
+especially O
+in O
+patients O
+unable O
+to O
+exercise O
+. O
+
+
+Effects O
+of O
+common O
+germline O
+genetic O
+variation O
+in O
+cell O
+cycle O
+control O
+genes O
+on O
+breast O
+cancer O
+survival O
+: O
+results O
+from O
+a O
+population O
+- O
+based O
+cohort O
+. O
+
+INTRODUCTION O
+: O
+Somatic O
+alterations O
+have O
+been O
+shown O
+to O
+correlate O
+with O
+breast O
+cancer O
+prognosis O
+and O
+survival O
+, O
+but O
+less O
+is O
+known O
+about O
+the O
+effects O
+of O
+common O
+inherited O
+genetic O
+variation O
+. O
+
+Of O
+particular O
+interest O
+are O
+genes O
+involved O
+in O
+cell O
+cycle O
+pathways O
+, O
+which O
+regulate O
+cell O
+division O
+. O
+
+METHODS O
+: O
+We O
+examined O
+associations O
+between O
+common O
+germline O
+genetic O
+variation O
+in O
+13 O
+genes O
+involved O
+in O
+cell O
+cycle O
+control O
+( O
+CCND1 O
+, O
+CCND2 O
+, O
+CCND3 O
+, O
+CCNE1 O
+, O
+CDK2 O
+[ O
+p33 O
+], O
+CDK4 O
+, O
+CDK6 O
+, O
+CDKN1A O
+[ O
+p21 O
+, O
+Cip1 O
+], O
+CDKN1B O
+[ O
+p27 O
+, O
+Kip1 O
+], O
+CDKN2A O
+[ O
+p16 O
+], O
+CDKN2B O
+[ O
+p15 O
+], O
+CDKN2C O
+[ O
+p18 O
+], O
+and O
+CDKN2D O
+[ O
+p19 O
+]) O
+
+and O
+survival O
+among O
+women O
+diagnosed O
+with O
+invasive O
+breast O
+cancer O
+participating O
+in O
+the O
+SEARCH O
+( O
+Studies O
+of O
+Epidemiology O
+and O
+Risk O
+factors O
+in O
+Cancer O
+Heredity O
+) O
+breast O
+cancer O
+study O
+. O
+
+DNA O
+from O
+up O
+to O
+4 O
+, O
+470 O
+women O
+was O
+genotyped O
+for O
+85 O
+polymorphisms O
+that O
+tag O
+the O
+known O
+common O
+polymorphisms O
+( O
+minor O
+allele O
+frequency O
+> O
+0 O
+. O
+5 O
+) O
+in O
+the O
+genes O
+. O
+
+The O
+genotypes O
+of O
+each O
+polymorphism O
+were O
+tested O
+for O
+association O
+with O
+survival O
+using O
+Cox O
+regression O
+analysis O
+. O
+
+RESULTS O
+: O
+The O
+rare O
+allele O
+of O
+the O
+tagging O
+single O
+nucleotide O
+polymorphism O
+( O
+SNP O
+) O
+rs2479717 O
+is O
+associated O
+with O
+an O
+increased O
+risk O
+of O
+death O
+( O
+hazard O
+ratio O
+= O
+1 O
+. O
+26 O
+per O
+rare O
+allele O
+carried O
+, O
+95 O
+% O
+confidence O
+interval O
+: O
+1 O
+. O
+12 O
+to O
+1 O
+. O
+42 O
+; O
+P O
+= O
+0 O
+. O
+1 O
+), O
+which O
+was O
+not O
+attenuated O
+after O
+adjusting O
+for O
+tumour O
+stage O
+, O
+grade O
+, O
+and O
+treatment O
+. O
+
+This O
+SNP O
+is O
+part O
+of O
+a O
+large O
+linkage O
+disequilibrium O
+block O
+, O
+which O
+contains O
+CCND3 O
+, O
+BYSL O
+, O
+TRFP O
+, O
+USP49 O
+, O
+C6ofr49 O
+, O
+FRS3 O
+, O
+and O
+PGC O
+. O
+
+We O
+evaluated O
+the O
+association O
+of O
+survival O
+and O
+somatic O
+expression O
+of O
+these O
+genes O
+in O
+breast O
+tumours O
+using O
+expression O
+microarray O
+data O
+from O
+seven O
+published O
+datasets O
+. O
+
+Elevated O
+expression O
+of O
+the O
+C6orf49 O
+transcript O
+was O
+associated O
+with O
+breast O
+cancer O
+survival O
+, O
+adding O
+biological O
+interest O
+to O
+the O
+finding O
+. O
+
+CONCLUSION O
+: O
+It O
+is O
+possible O
+that O
+CCND3 O
+rs2479717 O
+, O
+or O
+another O
+variant O
+it O
+tags O
+, O
+is O
+associated O
+with O
+prognosis O
+after O
+a O
+diagnosis O
+of O
+breast O
+cancer O
+. O
+
+Further O
+study O
+is O
+required O
+to O
+validate O
+this O
+finding O
+. O
+
+
+Upregulation O
+of O
+centrosomal O
+protein O
+55 O
+is O
+associated O
+with O
+unfavorable O
+prognosis O
+and O
+tumor O
+invasion O
+in O
+epithelial O
+ovarian O
+carcinoma O
+. O
+
+Centrosomal O
+protein O
+55 O
+( O
+CEP55 O
+) O
+is O
+a O
+cell O
+cycle O
+regulator O
+implicated O
+in O
+development O
+of O
+certain O
+cancers O
+. O
+
+However O
+, O
+characteristics O
+of O
+CEP55 O
+expression O
+and O
+its O
+clinical O
+/ O
+prognostic O
+significance O
+are O
+unclear O
+in O
+human O
+epithelial O
+ovarian O
+carcinoma O
+( O
+EOC O
+). O
+
+Therefore O
+, O
+we O
+investigated O
+the O
+expression O
+and O
+clinicopathological O
+significance O
+of O
+CEP55 O
+in O
+patients O
+with O
+EOC O
+and O
+its O
+role O
+in O
+regulating O
+invasion O
+and O
+metastasis O
+of O
+ovarian O
+cell O
+lines O
+. O
+
+CEP55 O
+mRNA O
+and O
+protein O
+expression O
+levels O
+were O
+detected O
+by O
+quantitative O
+real O
+- O
+time O
+PCR O
+( O
+qRT O
+- O
+PCR O
+), O
+Western O
+blotting O
+, O
+and O
+immunohistochemistry O
+( O
+IHC O
+). O
+
+Potential O
+associations O
+of O
+CEP55 O
+expression O
+scores O
+with O
+clinical O
+parameters O
+and O
+patient O
+survival O
+were O
+evaluated O
+. O
+
+CEP55 O
+function O
+was O
+investigated O
+further O
+using O
+RNA O
+interference O
+, O
+wound O
+healing O
+assay O
+, O
+transwell O
+assay O
+, O
+immunofluorescence O
+analysis O
+, O
+qRT O
+- O
+PCR O
+, O
+and O
+Western O
+blotting O
+. O
+
+CEP55 O
+was O
+significantly O
+upregulated O
+in O
+ovarian O
+cancer O
+cell O
+lines O
+and O
+lesions O
+compared O
+with O
+normal O
+cells O
+and O
+adjacent O
+noncancerous O
+ovarian O
+tissues O
+. O
+
+In O
+the O
+213 O
+EOC O
+samples O
+, O
+CEP55 O
+protein O
+levels O
+were O
+positively O
+correlated O
+with O
+clinical O
+stage O
+( O
+P O
+< O
+0 O
+. O
+1 O
+), O
+lymph O
+node O
+metastasis O
+( O
+P O
+< O
+0 O
+. O
+1 O
+), O
+intraperitoneal O
+metastasis O
+( O
+P O
+< O
+0 O
+. O
+1 O
+), O
+tumor O
+recurrence O
+( O
+P O
+< O
+0 O
+. O
+1 O
+), O
+differentiation O
+grade O
+( O
+P O
+< O
+0 O
+. O
+1 O
+), O
+residual O
+tumor O
+size O
+( O
+P O
+< O
+0 O
+. O
+1 O
+), O
+ascites O
+see O
+tumor O
+cells O
+( O
+P O
+= O
+0 O
+. O
+20 O
+), O
+and O
+serum O
+CA153 O
+level O
+( O
+P O
+< O
+0 O
+. O
+1 O
+). O
+
+Moreover O
+, O
+patients O
+with O
+aberrant O
+CEP55 O
+protein O
+expression O
+showed O
+tendencies O
+to O
+receive O
+neoadjuvant O
+chemotherapy O
+( O
+P O
+< O
+0 O
+. O
+1 O
+) O
+and O
+cytoreductive O
+surgery O
+( O
+P O
+= O
+0 O
+. O
+20 O
+). O
+
+By O
+contrast O
+, O
+no O
+significant O
+correlation O
+was O
+detected O
+between O
+the O
+protein O
+levels O
+and O
+patient O
+age O
+, O
+histological O
+type O
+, O
+or O
+serum O
+CA125 O
+, O
+CA199 O
+, O
+CA724 O
+, O
+NSE O
+, O
+CEA O
+, O
+and O
+b O
+- O
+HCG O
+levels O
+. O
+
+Patients O
+with O
+high O
+CEP55 O
+protein O
+expression O
+had O
+shorter O
+overall O
+survival O
+and O
+disease O
+- O
+free O
+survival O
+compared O
+with O
+those O
+with O
+low O
+CEP55 O
+expression O
+. O
+
+Multivariate O
+analysis O
+implicated O
+CEP55 O
+as O
+an O
+independent O
+prognostic O
+indicator O
+for O
+EOC O
+patients O
+. O
+
+Additionally O
+, O
+downregulation O
+of O
+CEP55 O
+in O
+ovarian O
+cancer O
+cells O
+remarkably O
+inhibited O
+cellular O
+motility O
+and O
+invasion O
+. O
+
+Aberrant O
+CEP55 O
+expression O
+may O
+predict O
+unfavorable O
+clinical O
+outcomes O
+in O
+EOC O
+patients O
+and O
+play O
+an O
+important O
+role O
+in O
+regulating O
+invasion O
+in O
+ovarian O
+cancer O
+cells O
+. O
+
+Thus O
+, O
+CEP55 O
+may O
+serve O
+as O
+a O
+prognostic O
+marker O
+and O
+therapeutic O
+target O
+for O
+EOC O
+. O
+
+
+Male O
+11b O
+- O
+HSD1 O
+Knockout O
+Mice O
+Fed O
+Trans O
+- O
+Fats O
+and O
+Fructose B
+Are O
+Not O
+Protected O
+From O
+Metabolic O
+Syndrome O
+or O
+Nonalcoholic O
+Fatty O
+Liver O
+Disease O
+. O
+
+Nonalcoholic O
+fatty O
+liver O
+disease O
+( O
+NAFLD O
+) O
+defines O
+a O
+spectrum O
+of O
+conditions O
+from O
+simple O
+steatosis O
+to O
+nonalcoholic O
+steatohepatitis O
+( O
+NASH O
+) O
+and O
+cirrhosis O
+and O
+is O
+regarded O
+as O
+the O
+hepatic O
+manifestation O
+of O
+the O
+metabolic O
+syndrome O
+. O
+
+Glucocorticoids B
+can O
+promote O
+steatosis O
+by O
+stimulating O
+lipolysis O
+within O
+adipose O
+tissue O
+, O
+free B
+fatty I
+acid I
+delivery O
+to O
+liver O
+and O
+hepatic O
+de O
+novo O
+lipogenesis O
+. O
+
+Glucocorticoids B
+can O
+be O
+reactivated O
+in O
+liver O
+through O
+11b O
+- O
+hydroxysteroid O
+dehydrogenase O
+type O
+1 O
+( O
+11b O
+- O
+HSD1 O
+) O
+enzyme O
+activity O
+. O
+
+Inhibition O
+of O
+11b O
+- O
+HSD1 O
+has O
+been O
+suggested O
+as O
+a O
+potential O
+treatment O
+for O
+NAFLD O
+. O
+
+To O
+test O
+this O
+, O
+male O
+mice O
+with O
+global O
+( O
+11b O
+- O
+HSD1 O
+knockout O
+[ O
+KO O
+]) O
+and O
+liver O
+- O
+specific O
+( O
+LKO O
+) O
+11b O
+- O
+HSD1 O
+loss O
+of O
+function O
+were O
+fed O
+the O
+American O
+Lifestyle O
+Induced O
+Obesity O
+Syndrome O
+( O
+ALIOS O
+) O
+diet O
+, O
+known O
+to O
+recapitulate O
+the O
+spectrum O
+of O
+NAFLD O
+, O
+and O
+metabolic O
+and O
+liver O
+phenotypes O
+assessed O
+. O
+
+Body O
+weight O
+, O
+muscle O
+and O
+adipose O
+tissue O
+masses O
+, O
+and O
+parameters O
+of O
+glucose B
+homeostasis O
+showed O
+that O
+11b O
+- O
+HSD1KO O
+and O
+LKO O
+mice O
+were O
+not O
+protected O
+from O
+systemic O
+metabolic O
+disease O
+. O
+
+Evaluation O
+of O
+hepatic O
+histology O
+, O
+triglyceride B
+content O
+, O
+and O
+blinded O
+NAFLD O
+activity O
+score O
+assessment O
+indicated O
+that O
+levels O
+of O
+steatosis O
+were O
+similar O
+between O
+11b O
+- O
+HSD1KO O
+, O
+LKO O
+, O
+and O
+control O
+mice O
+. O
+
+Unexpectedly O
+, O
+histological O
+analysis O
+revealed O
+significantly O
+increased O
+levels O
+of O
+immune O
+foci O
+present O
+in O
+livers O
+of O
+11b O
+- O
+HSD1KO O
+but O
+not O
+LKO O
+or O
+control O
+mice O
+, O
+suggestive O
+of O
+a O
+transition O
+to O
+NASH O
+. O
+
+This O
+was O
+endorsed O
+by O
+elevated O
+hepatic O
+expression O
+of O
+key O
+immune O
+cell O
+and O
+inflammatory O
+markers O
+. O
+
+These O
+data O
+indicate O
+that O
+11b O
+- O
+HSD1 O
+- O
+deficient O
+mice O
+are O
+not O
+protected O
+from O
+metabolic O
+disease O
+or O
+hepatosteatosis O
+in O
+the O
+face O
+of O
+a O
+NAFLD O
+- O
+inducing O
+diet O
+. O
+
+However O
+, O
+global O
+deficiency O
+of O
+11b O
+- O
+HSD1 O
+did O
+increase O
+markers O
+of O
+hepatic O
+inflammation O
+and O
+suggests O
+a O
+critical O
+role O
+for O
+11b O
+- O
+HSD1 O
+in O
+restraining O
+the O
+transition O
+to O
+NASH O
+. O
+
+
+Single O
+- O
+strand O
+conformation O
+polymorphism O
+analysis O
+of O
+the O
+FMR1 O
+gene O
+in O
+autistic O
+and O
+mentally O
+retarded O
+children O
+in O
+Japan O
+. O
+
+Fragile O
+X O
+syndrome O
+is O
+one O
+of O
+the O
+most O
+common O
+causes O
+of O
+mental O
+retardation O
+in O
+males O
+, O
+and O
+patients O
+with O
+fragile O
+X O
+syndrome O
+occasionally O
+develop O
+autism O
+. O
+
+It O
+is O
+usually O
+caused O
+by O
+an O
+expansion O
+of O
+the O
+trinucleotide O
+repeat O
+in O
+the O
+5 O
+'- O
+untranslated O
+region O
+of O
+the O
+FMR1 O
+gene O
+, O
+but O
+in O
+a O
+small O
+number O
+of O
+patients O
+deletions O
+and O
+point O
+mutations O
+have O
+been O
+identified O
+. O
+
+We O
+screened O
+all O
+17 O
+exons O
+of O
+the O
+FMR1 O
+gene O
+for O
+mutations O
+in O
+90 O
+autistic O
+or O
+mentally O
+retarded O
+children O
+using O
+polymerase O
+chain O
+reaction O
+( O
+PCR O
+)- O
+single O
+strand O
+conformation O
+polymorphism O
+( O
+SSCP O
+) O
+analysis O
+. O
+
+No O
+mutations O
+were O
+found O
+in O
+76 O
+male O
+patients O
+. O
+
+However O
+, O
+one O
+female O
+patient O
+was O
+heterozygous O
+for O
+a O
+normal O
+allele O
+and O
+a O
+mutant O
+allele O
+with O
+an O
+A O
+to O
+C O
+substitution O
+at O
+nucleotide O
+879 O
+in O
+exon O
+9 O
+. O
+
+This O
+mutation O
+was O
+not O
+found O
+in O
+50 O
+controls O
+. O
+
+Reverse O
+transcription O
+- O
+PCR O
+revealed O
+that O
+a O
+large O
+proportion O
+of O
+the O
+mutant O
+transcripts O
+were O
+spliced O
+aberrantly O
+, O
+causing O
+premature O
+termination O
+of O
+the O
+protein O
+synthesis O
+. O
+
+Although O
+uncommon O
+, O
+point O
+mutations O
+in O
+the O
+FMR1 O
+gene O
+may O
+be O
+a O
+cause O
+of O
+autism O
+and O
+mental O
+retardation O
+in O
+Japanese O
+patients O
+. O
+
+
+Pheochromocytoma O
+unmasked O
+by O
+amisulpride B
+and O
+tiapride B
+. O
+
+OBJECTIVE O
+: O
+To O
+describe O
+the O
+unmasking O
+of O
+pheochromocytoma O
+in O
+a O
+patient O
+treated O
+with O
+amisulpride B
+and O
+tiapride B
+. O
+
+CASE O
+SUMMARY O
+: O
+A O
+42 O
+- O
+year O
+- O
+old O
+white O
+man O
+developed O
+acute O
+hypertension O
+with O
+severe O
+headache O
+and O
+vomiting O
+2 O
+hours O
+after O
+the O
+first O
+doses O
+of O
+amisulpride B
+100 O
+mg O
+and O
+tiapride B
+100 O
+mg O
+. O
+
+Both O
+drugs O
+were O
+immediately O
+discontinued O
+, O
+and O
+the O
+patient O
+recovered O
+after O
+subsequent O
+nicardipine B
+and O
+verapamil B
+treatment O
+. O
+
+Abdominal O
+ultrasound O
+showed O
+an O
+adrenal O
+mass O
+, O
+and O
+postoperative O
+histologic O
+examination O
+confirmed O
+the O
+diagnosis O
+of O
+pheochromocytoma O
+. O
+
+DISCUSSION O
+: O
+Drug O
+- O
+induced O
+symptoms O
+of O
+pheochromocytoma O
+are O
+often O
+associated O
+with O
+the O
+use O
+of O
+substituted B
+benzamide I
+drugs I
+, O
+but O
+the O
+underlying O
+mechanism O
+is O
+unknown O
+. O
+
+In O
+our O
+case O
+, O
+use O
+of O
+the O
+Naranjo O
+probability O
+scale O
+indicated O
+a O
+possible O
+relationship O
+between O
+the O
+hypertensive O
+crisis O
+and O
+amisulpride B
+and O
+tiapride B
+therapy O
+. O
+
+CONCLUSIONS O
+: O
+As O
+of O
+March O
+24 O
+, O
+2005 O
+, O
+this O
+is O
+the O
+first O
+reported O
+case O
+of O
+amisulpride B
+- O
+and O
+tiapride B
+- O
+induced O
+hypertensive O
+crisis O
+in O
+a O
+patient O
+with O
+pheochromocytoma O
+. O
+
+Physicians O
+and O
+other O
+healthcare O
+professionals O
+should O
+be O
+aware O
+of O
+this O
+potential O
+adverse O
+effect O
+of O
+tiapride B
+and O
+amisulpride B
+. O
+
+
+Phenylephrine B
+but O
+not O
+ephedrine B
+reduces O
+frontal O
+lobe O
+oxygenation O
+following O
+anesthesia O
+- O
+induced O
+hypotension O
+. O
+
+BACKGROUND O
+: O
+Vasopressor O
+agents O
+are O
+used O
+to O
+correct O
+anesthesia O
+- O
+induced O
+hypotension O
+. O
+
+We O
+describe O
+the O
+effect O
+of O
+phenylephrine B
+and O
+ephedrine B
+on O
+frontal O
+lobe O
+oxygenation O
+( O
+S O
+( O
+c O
+) O
+O O
+( O
+2 O
+)) O
+following O
+anesthesia O
+- O
+induced O
+hypotension O
+. O
+
+METHODS O
+: O
+Following O
+induction O
+of O
+anesthesia O
+by O
+fentanyl B
+( O
+0 O
+. O
+15 O
+mg O
+kg O
+(- O
+1 O
+)) O
+and O
+propofol B
+( O
+2 O
+. O
+0 O
+mg O
+kg O
+(- O
+1 O
+)), O
+13 O
+patients O
+received O
+phenylephrine B
+( O
+0 O
+. O
+1 O
+mg O
+iv O
+) O
+and O
+12 O
+patients O
+received O
+ephedrine B
+( O
+10 O
+mg O
+iv O
+) O
+to O
+restore O
+mean O
+arterial O
+pressure O
+( O
+MAP O
+). O
+
+Heart O
+rate O
+( O
+HR O
+), O
+MAP O
+, O
+stroke O
+volume O
+( O
+SV O
+), O
+cardiac O
+output O
+( O
+CO O
+), O
+and O
+frontal O
+lobe O
+oxygenation O
+( O
+S O
+( O
+c O
+) O
+O O
+( O
+2 O
+)) O
+were O
+registered O
+. O
+
+RESULTS O
+: O
+Induction O
+of O
+anesthesia O
+was O
+followed O
+by O
+a O
+decrease O
+in O
+MAP O
+, O
+HR O
+, O
+SV O
+, O
+and O
+CO O
+concomitant O
+with O
+an O
+elevation O
+in O
+S O
+( O
+c O
+) O
+O O
+( O
+2 O
+). O
+
+After O
+administration O
+of O
+phenylephrine B
+, O
+MAP O
+increased O
+( O
+51 O
++/- O
+12 O
+to O
+81 O
++/- O
+13 O
+mmHg O
+; O
+P O
+< O
+0 O
+. O
+1 O
+; O
+mean O
++/- O
+SD O
+). O
+
+However O
+, O
+a O
+14 O
+% O
+( O
+from O
+70 O
++/- O
+8 O
+% O
+to O
+60 O
++/- O
+7 O
+%) O
+reduction O
+in O
+S O
+( O
+c O
+) O
+O O
+( O
+2 O
+) O
+( O
+P O
+< O
+0 O
+. O
+5 O
+) O
+followed O
+with O
+no O
+change O
+in O
+CO B
+( O
+3 O
+. O
+7 O
++/- O
+1 O
+. O
+1 O
+to O
+3 O
+. O
+4 O
++/- O
+0 O
+. O
+9 O
+l O
+min O
+(- O
+1 O
+)). O
+
+The O
+administration O
+of O
+ephedrine B
+led O
+to O
+a O
+similar O
+increase O
+in O
+MAP O
+( O
+53 O
++/- O
+9 O
+to O
+79 O
++/- O
+8 O
+mmHg O
+; O
+P O
+< O
+0 O
+. O
+1 O
+), O
+restored O
+CO O
+( O
+3 O
+. O
+2 O
++/- O
+1 O
+. O
+2 O
+to O
+5 O
+. O
+0 O
++/- O
+1 O
+. O
+3 O
+l O
+min O
+(- O
+1 O
+)), O
+and O
+preserved O
+S O
+( O
+c O
+) O
+O O
+( O
+2 O
+). O
+
+CONCLUSIONS O
+: O
+The O
+utilization O
+of O
+phenylephrine B
+to O
+correct O
+hypotension O
+induced O
+by O
+anesthesia O
+has O
+a O
+negative O
+impact O
+on O
+S O
+( O
+c O
+) O
+O O
+( O
+2 O
+) O
+while O
+ephedrine B
+maintains O
+frontal O
+lobe O
+oxygenation O
+potentially O
+related O
+to O
+an O
+increase O
+in O
+CO O
+. O
+
+
+Somatic O
+and O
+gonadal O
+mosaicism O
+in O
+X O
+- O
+linked O
+retinitis O
+pigmentosa O
+. O
+
+The O
+g O
+. O
+ORF15 O
++ O
+652 O
+- O
+653delAG O
+mutation O
+in O
+the O
+RPGR O
+gene O
+is O
+the O
+most O
+frequent O
+mutation O
+in O
+X O
+- O
+linked O
+retinitis O
+pigmentosa O
+( O
+XLRP O
+). O
+
+The O
+objective O
+of O
+this O
+study O
+was O
+to O
+investigate O
+the O
+possibility O
+of O
+mosaicism O
+in O
+an O
+XLRP O
+family O
+. O
+
+Eight O
+subjects O
+in O
+the O
+RP O
+family O
+were O
+recruited O
+. O
+
+Blood O
+samples O
+were O
+collected O
+for O
+DNA O
+extraction O
+. O
+
+Haplotype O
+analysis O
+and O
+mutational O
+screening O
+on O
+the O
+RPGR O
+gene O
+were O
+performed O
+. O
+
+Additionally O
+, O
+samples O
+of O
+hair O
+follicles O
+and O
+buccal O
+cells O
+from O
+the O
+mother O
+of O
+the O
+proband O
+were O
+acquired O
+for O
+DNA O
+extraction O
+and O
+molecular O
+analysis O
+. O
+
+Phenotype O
+was O
+characterized O
+with O
+routine O
+ophthalmic O
+examination O
+, O
+Goldmann O
+perimetry O
+, O
+electroretinography O
+, O
+and O
+color O
+fundus O
+photography O
+. O
+
+A O
+g O
+. O
+ORF15 O
++ O
+652 O
+- O
+653delAG O
+mutation O
+was O
+identified O
+in O
+second O
+- O
+and O
+third O
+- O
+generation O
+patients O
+/ O
+carriers O
+. O
+
+A O
+first O
+- O
+generation O
+female O
+, O
+who O
+was O
+considered O
+to O
+be O
+an O
+obligate O
+carrier O
+, O
+demonstrated O
+a O
+normal O
+phenotype O
+as O
+well O
+as O
+a O
+normal O
+genotype O
+in O
+lymphocytic O
+DNA O
+, O
+indicating O
+the O
+gonadal O
+mosaicism O
+; O
+however O
+, O
+a O
+heterozygous O
+AG O
+- O
+deletion O
+at O
+nucleotide O
+652 O
+and O
+653 O
+was O
+identified O
+in O
+the O
+genomic O
+DNA O
+of O
+hair O
+follicles O
+, O
+hair O
+shaft O
+, O
+and O
+buccal O
+cells O
+, O
+indicating O
+that O
+the O
+mutation O
+is O
+somatic O
+. O
+
+In O
+conclusion O
+, O
+we O
+reported O
+on O
+a O
+family O
+in O
+which O
+an O
+asymptomatic O
+woman O
+with O
+somatic O
+- O
+gonadal O
+mosaicism O
+for O
+a O
+RPGR O
+gene O
+mutation O
+transmitted O
+the O
+mutation O
+to O
+an O
+asymptomatic O
+daughter O
+and O
+to O
+a O
+son O
+with O
+XLRP O
+. O
+
+Gonadal O
+mosaicism O
+may O
+be O
+responsible O
+for O
+a O
+proportion O
+of O
+multiplex O
+or O
+simplex O
+RP O
+families O
+, O
+in O
+which O
+more O
+than O
+50 O
+% O
+of O
+all O
+cases O
+of O
+RP O
+are O
+found O
+. O
+
+( O
+c O
+) O
+2007 O
+Wiley O
+- O
+Liss O
+, O
+Inc O
+. O
+
+
+Complete O
+atrioventricular O
+block O
+secondary O
+to O
+lithium B
+therapy O
+. O
+
+Sinus O
+node O
+dysfunction O
+has O
+been O
+reported O
+most O
+frequently O
+among O
+the O
+adverse O
+cardiovascular O
+effects O
+of O
+lithium B
+. O
+
+In O
+the O
+present O
+case O
+, O
+complete O
+atrioventricular O
+( O
+AV O
+) O
+block O
+with O
+syncopal O
+attacks O
+developed O
+secondary O
+to O
+lithium B
+therapy O
+, O
+necessitating O
+permanent O
+pacemaker O
+implantation O
+. O
+
+Serum O
+lithium B
+levels O
+remained O
+under O
+or O
+within O
+the O
+therapeutic O
+range O
+during O
+the O
+syncopal O
+attacks O
+. O
+
+Lithium B
+should O
+be O
+used O
+with O
+extreme O
+caution O
+, O
+especially O
+in O
+patients O
+with O
+mild O
+disturbance O
+of O
+AV O
+conduction O
+. O
+
+
+Organophosphate B
+- O
+induced O
+convulsions O
+and O
+prevention O
+of O
+neuropathological O
+damages O
+. O
+
+Such O
+organophosphorus B
+( O
+OP B
+) O
+compounds O
+as O
+diisopropylfluorophosphate B
+( O
+DFP B
+), O
+sarin B
+and O
+soman B
+are O
+potent O
+inhibitors O
+of O
+acetylcholinesterases O
+( O
+AChEs O
+) O
+and O
+butyrylcholinesterases O
+( O
+BChEs O
+). O
+
+The O
+acute O
+toxicity O
+of O
+OPs B
+is O
+the O
+result O
+of O
+their O
+irreversible O
+binding O
+with O
+AChEs O
+in O
+the O
+central O
+nervous O
+system O
+( O
+CNS O
+), O
+which O
+elevates O
+acetylcholine B
+( O
+ACh B
+) O
+levels O
+. O
+
+The O
+protective O
+action O
+of O
+subcutaneously O
+( O
+SC O
+) O
+administered O
+antidotes O
+or O
+their O
+combinations O
+in O
+DFP B
+( O
+2 O
+. O
+0 O
+mg O
+/ O
+kg O
+BW O
+) O
+intoxication O
+was O
+studied O
+in O
+9 O
+- O
+10 O
+- O
+weeks O
+- O
+old O
+Han O
+- O
+Wistar O
+male O
+rats O
+. O
+
+The O
+rats O
+received O
+AChE O
+reactivator O
+pralidoxime B
+- I
+2 I
+- I
+chloride I
+( O
+2PAM B
+) O
+( O
+30 O
+. O
+0 O
+mg O
+/ O
+kg O
+BW O
+), O
+anticonvulsant O
+diazepam B
+( O
+2 O
+. O
+0 O
+mg O
+/ O
+kg O
+BW O
+), O
+A O
+( O
+1 O
+)- O
+adenosine O
+receptor O
+agonist O
+N B
+( I
+6 I
+)- I
+cyclopentyl I
+adenosine I
+( O
+CPA B
+) O
+( O
+2 O
+. O
+0 O
+mg O
+/ O
+kg O
+BW O
+), O
+NMDA O
+- O
+receptor O
+antagonist O
+dizocilpine B
+maleate I
+(+- O
+MK801 B
+hydrogen I
+maleate I
+) O
+( O
+2 O
+. O
+0 O
+mg O
+/ O
+
+kg O
+BW O
+) O
+or O
+their O
+combinations O
+with O
+cholinolytic O
+drug O
+atropine B
+sulfate I
+( O
+50 O
+. O
+0 O
+mg O
+/ O
+kg O
+BW O
+) O
+immediately O
+or O
+30 O
+min O
+after O
+the O
+single O
+SC O
+injection O
+of O
+DFP B
+. O
+
+The O
+control O
+rats O
+received O
+atropine B
+sulfate I
+, O
+but O
+also O
+saline O
+and O
+olive B
+oil I
+instead O
+of O
+other O
+antidotes O
+and O
+DFP B
+, O
+respectively O
+. O
+
+All O
+rats O
+were O
+terminated O
+either O
+24 O
+h O
+or O
+3 O
+weeks O
+after O
+the O
+DFP B
+injection O
+. O
+
+The O
+rats O
+treated O
+with O
+DFP B
+- O
+atropine B
+showed O
+severe O
+typical O
+OP B
+- O
+induced O
+toxicity O
+signs O
+. O
+
+When O
+CPA B
+, O
+diazepam B
+or O
+2PAM B
+was O
+given O
+immediately O
+after O
+DFP B
+- O
+atropine B
+, O
+these O
+treatments O
+prevented O
+, O
+delayed O
+or O
+shortened O
+the O
+occurrence O
+of O
+serious O
+signs O
+of O
+poisoning O
+. O
+
+Atropine B
+- O
+MK801 B
+did O
+not O
+offer O
+any O
+additional O
+protection O
+against O
+DFP B
+toxicity O
+. O
+
+In O
+conclusion O
+, O
+CPA B
+, O
+diazepam B
+and O
+2PAM B
+in O
+combination O
+with O
+atropine B
+prevented O
+the O
+occurrence O
+of O
+serious O
+signs O
+of O
+poisoning O
+and O
+thus O
+reduced O
+the O
+toxicity O
+of O
+DFP B
+in O
+rat O
+. O
+
+
+The O
+activation O
+of O
+spinal O
+N O
+- O
+methyl O
+- O
+D O
+- O
+aspartate O
+receptors O
+may O
+contribute O
+to O
+degeneration O
+of O
+spinal O
+motor O
+neurons O
+induced O
+by O
+neuraxial O
+morphine B
+after O
+a O
+noninjurious O
+interval O
+of O
+spinal O
+cord O
+ischemia O
+. O
+
+We O
+investigated O
+the O
+relationship O
+between O
+the O
+degeneration O
+of O
+spinal O
+motor O
+neurons O
+and O
+activation O
+of O
+N O
+- O
+methyl O
+- O
+d O
+- O
+aspartate O
+( O
+NMDA O
+) O
+receptors O
+after O
+neuraxial O
+morphine B
+following O
+a O
+noninjurious O
+interval O
+of O
+aortic O
+occlusion O
+in O
+rats O
+. O
+
+Spinal O
+cord O
+ischemia O
+was O
+induced O
+by O
+aortic O
+occlusion O
+for O
+6 O
+min O
+with O
+a O
+balloon O
+catheter O
+. O
+
+In O
+a O
+microdialysis O
+study O
+, O
+10 O
+muL O
+of O
+saline O
+( O
+group O
+C O
+; O
+n O
+= O
+8 O
+) O
+or O
+30 O
+mug O
+of O
+morphine B
+( O
+group O
+M O
+; O
+n O
+= O
+8 O
+) O
+was O
+injected O
+intrathecally O
+( O
+IT O
+) O
+0 O
+. O
+5 O
+h O
+after O
+reflow O
+, O
+and O
+30 O
+mug O
+of O
+morphine B
+( O
+group O
+SM O
+; O
+n O
+= O
+8 O
+) O
+or O
+10 O
+muL O
+of O
+saline O
+( O
+group O
+SC O
+; O
+n O
+= O
+8 O
+) O
+was O
+injected O
+IT O
+0 O
+. O
+5 O
+h O
+after O
+sham O
+operation O
+. O
+
+Microdialysis O
+samples O
+were O
+collected O
+preischemia O
+, O
+before O
+IT O
+injection O
+, O
+and O
+at O
+2 O
+, O
+4 O
+, O
+8 O
+, O
+24 O
+, O
+and O
+48 O
+h O
+of O
+reperfusion O
+( O
+after O
+IT O
+injection O
+). O
+
+Second O
+, O
+we O
+investigated O
+the O
+effect O
+of O
+IT O
+MK I
+- I
+801 I
+( O
+30 O
+mug O
+) O
+on O
+the O
+histopathologic O
+changes O
+in O
+the O
+spinal O
+cord O
+after O
+morphine B
+- O
+induced O
+spastic O
+paraparesis O
+. O
+
+After O
+IT O
+morphine B
+, O
+the O
+cerebrospinal O
+fluid O
+( O
+CSF O
+) O
+glutamate B
+concentration O
+was O
+increased O
+in O
+group O
+M O
+relative O
+to O
+both O
+baseline O
+and O
+group O
+C O
+( O
+P O
+< O
+0 O
+. O
+5 O
+). O
+
+This O
+increase O
+persisted O
+for O
+8 O
+hrs O
+. O
+
+IT O
+MK B
+- I
+801 I
+significantly O
+reduced O
+the O
+number O
+of O
+dark O
+- O
+stained O
+alpha O
+- O
+motoneurons O
+after O
+morphine B
+- O
+induced O
+spastic O
+paraparesis O
+compared O
+with O
+the O
+saline O
+group O
+. O
+
+These O
+data O
+indicate O
+that O
+IT O
+morphine B
+induces O
+spastic O
+paraparesis O
+with O
+a O
+concomitant O
+increase O
+in O
+CSF O
+glutamate B
+, O
+which O
+is O
+involved O
+in O
+NMDA O
+receptor O
+activation O
+. O
+
+We O
+suggest O
+that O
+opioids B
+may O
+be O
+neurotoxic O
+in O
+the O
+setting O
+of O
+spinal O
+cord O
+ischemia O
+via O
+NMDA O
+receptor O
+activation O
+. O
+
+
+Growth O
+- O
+associated O
+protein O
+43 O
+expression O
+in O
+hippocampal O
+molecular O
+layer O
+of O
+chronic O
+epileptic O
+rats O
+treated O
+with O
+cycloheximide B
+. O
+
+PURPOSE O
+: O
+GAP43 O
+has O
+been O
+thought O
+to O
+be O
+linked O
+with O
+mossy O
+fiber O
+sprouting O
+( O
+MFS O
+) O
+in O
+various O
+experimental O
+models O
+of O
+epilepsy O
+. O
+
+To O
+investigate O
+how O
+GAP43 O
+expression O
+( O
+GAP43 O
+- O
+ir O
+) O
+correlates O
+with O
+MFS O
+, O
+we O
+assessed O
+the O
+intensity O
+( O
+densitometry O
+) O
+and O
+extension O
+( O
+width O
+) O
+of O
+GAP43 O
+- O
+ir O
+in O
+the O
+inner O
+molecular O
+layer O
+of O
+the O
+dentate O
+gyrus O
+( O
+IML O
+) O
+of O
+rats O
+subject O
+to O
+status O
+epilepticus O
+induced O
+by O
+pilocarpine B
+( O
+Pilo B
+), O
+previously O
+injected O
+or O
+not O
+with O
+cycloheximide B
+( O
+CHX B
+), O
+which O
+has O
+been O
+shown O
+to O
+inhibit O
+MFS O
+. O
+
+METHODS O
+: O
+CHX B
+was O
+injected O
+before O
+the O
+Pilo B
+injection O
+in O
+adult O
+Wistar O
+rats O
+. O
+
+The O
+Pilo B
+group O
+was O
+injected O
+with O
+the O
+same O
+drugs O
+, O
+except O
+for O
+CHX O
+. O
+
+Animals O
+were O
+killed O
+between O
+30 O
+and O
+60 O
+days O
+later O
+, O
+and O
+brain O
+sections O
+were O
+processed O
+for O
+GAP43 O
+immunohistochemistry O
+. O
+
+RESULTS O
+: O
+Densitometry O
+showed O
+no O
+significant O
+difference O
+regarding O
+GAP43 O
+- O
+ir O
+in O
+the O
+IML O
+between O
+Pilo O
+, O
+CHX O
++ O
+Pilo O
+, O
+and O
+control O
+groups O
+. O
+
+However O
+, O
+the O
+results O
+of O
+the O
+width O
+of O
+the O
+GAP43 O
+- O
+ir O
+band O
+in O
+the O
+IML O
+showed O
+that O
+CHX B
++ O
+Pilo B
+and O
+control O
+animals O
+had O
+a O
+significantly O
+larger O
+band O
+( O
+p O
+= O
+0 O
+. O
+3 O
+) O
+as O
+compared O
+with O
+that O
+in O
+the O
+Pilo B
+group O
+. O
+
+CONCLUSIONS O
+: O
+Our O
+current O
+finding O
+that O
+animals O
+in O
+the O
+CHX O
++ O
+Pilo B
+group O
+have O
+a O
+GAP43 O
+- O
+ir O
+band O
+in O
+the O
+IML O
+, O
+similar O
+to O
+that O
+of O
+controls O
+, O
+reinforces O
+prior O
+data O
+on O
+the O
+blockade O
+of O
+MFS O
+in O
+these O
+animals O
+. O
+
+The O
+change O
+in O
+GAP43 O
+- O
+ir O
+present O
+in O
+Pilo O
+- O
+treated O
+animals O
+was O
+a O
+thinning O
+of O
+the O
+band O
+to O
+a O
+very O
+narrow O
+layer O
+just O
+above O
+the O
+granule O
+cell O
+layer O
+that O
+is O
+likely O
+to O
+be O
+associated O
+with O
+the O
+loss O
+of O
+hilar O
+cell O
+projections O
+that O
+express O
+GAP O
+- O
+43 O
+. O
+
+
+Daidzein B
+activates O
+choline O
+acetyltransferase O
+from O
+MC O
+- O
+IXC O
+cells O
+and O
+improves O
+drug O
+- O
+induced O
+amnesia O
+. O
+
+The O
+choline O
+acetyltransferase O
+( O
+ChAT O
+) O
+activator O
+, O
+which O
+enhances O
+cholinergic O
+transmission O
+via O
+an O
+augmentation O
+of O
+the O
+enzymatic O
+production O
+of O
+acetylcholine B
+( O
+ACh B
+), O
+is O
+an O
+important O
+factor O
+in O
+the O
+treatment O
+of O
+Alzheimer O
+' O
+s O
+disease O
+( O
+AD O
+). O
+
+Methanolic O
+extracts O
+from O
+Pueraria O
+thunbergiana O
+exhibited O
+an O
+activation O
+effect O
+( O
+46 O
+%) O
+on O
+ChAT O
+in O
+vitro O
+. O
+
+Via O
+the O
+sequential O
+isolation O
+of O
+Pueraria O
+thunbergiana O
+, O
+the O
+active O
+component O
+was O
+ultimately O
+identified O
+as O
+daidzein B
+( O
+4 B
+', I
+7 I
+- I
+dihydroxy I
+- I
+isoflavone I
+). O
+
+In O
+order O
+to O
+investigate O
+the O
+effects O
+of O
+daidzein B
+from I
+Pueraria O
+thunbergiana I
+on O
+scopolamine B
+- O
+induced O
+impairments O
+of O
+learning O
+and O
+memory O
+, O
+we O
+conducted O
+a O
+series O
+of O
+in O
+vivo O
+tests O
+. O
+
+Administration O
+of O
+daidzein B
+( O
+4 O
+. O
+5 O
+mg O
+/ O
+kg O
+body O
+weight O
+) O
+to O
+mice O
+was O
+shown O
+significantly O
+to O
+reverse O
+scopolamine B
+- O
+induced O
+amnesia O
+, O
+according O
+to O
+the O
+results O
+of O
+a O
+Y O
+- O
+maze O
+test O
+. O
+
+Injections O
+of O
+scopolamine B
+into O
+mice O
+resulted O
+in O
+impaired O
+performance O
+on O
+Y O
+- O
+maze O
+tests O
+( O
+a O
+37 O
+% O
+decreases O
+in O
+alternation O
+behavior O
+). O
+
+By O
+way O
+of O
+contrast O
+, O
+mice O
+treated O
+with O
+daidzein B
+prior O
+to O
+the O
+scopolamine B
+injections O
+were O
+noticeably O
+protected O
+from O
+this O
+performance O
+impairment O
+( O
+an O
+approximately O
+12 O
+%- O
+21 O
+% O
+decrease O
+in O
+alternation O
+behavior O
+). O
+
+These O
+results O
+indicate O
+that O
+daidzein B
+might O
+play O
+a O
+role O
+in O
+acetylcholine B
+biosynthesis O
+as O
+a O
+ChAT O
+activator O
+, O
+and O
+that O
+it O
+also O
+ameliorates O
+scopolamine B
+- O
+induced O
+amnesia O
+. O
+
+
+Effect O
+of O
+alpha B
+- I
+tocopherol I
+and O
+deferoxamine B
+on O
+methamphetamine B
+- O
+induced O
+neurotoxicity O
+. O
+
+Methamphetamine B
+( O
+MA B
+)- O
+induced O
+dopaminergic O
+neurotoxicity O
+is O
+believed O
+to O
+be O
+associated O
+with O
+the O
+increased O
+formation O
+of O
+free O
+radicals O
+. O
+
+This O
+study O
+examined O
+the O
+effect O
+of O
+alpha B
+- I
+tocopherol I
+( O
+alpha B
+- I
+TC I
+), O
+a O
+scavenger O
+of O
+reactive B
+oxygen I
+species I
+, O
+and O
+deferoxamine B
+( O
+DFO B
+), O
+an O
+iron B
+chelator O
+, O
+on O
+the O
+MA B
+- O
+induced O
+neurotoxicity O
+. O
+
+Male O
+rats O
+were O
+treated O
+with O
+MA B
+( O
+10 O
+mg O
+/ O
+kg O
+, O
+every O
+2 O
+h O
+for O
+four O
+injections O
+). O
+
+The O
+rat O
+received O
+either O
+alpha B
+- I
+TC I
+( O
+20 O
+mg O
+/ O
+kg O
+) O
+intraperitoneally O
+for O
+3 O
+days O
+and O
+30 O
+min O
+prior O
+to O
+MA B
+administration O
+or O
+DFO B
+( O
+50 O
+mg O
+/ O
+kg O
+) O
+subcutaneously O
+30 O
+min O
+before O
+MA B
+administration O
+. O
+
+The O
+concentrations O
+of O
+dopamine B
+( O
+DA B
+), O
+serotonin B
+and O
+their O
+metabolites O
+decreased O
+significantly O
+after O
+MA B
+administration O
+, O
+which O
+was O
+inhibited O
+by O
+the O
+alpha B
+- I
+TC I
+and O
+DFO B
+pretreatment O
+. O
+
+alpha B
+- I
+TC I
+and O
+DFO B
+attenuated O
+the O
+MA B
+- O
+induced O
+hyperthermia O
+as O
+well O
+as O
+the O
+alterations O
+in O
+the O
+locomotor O
+activity O
+. O
+
+The O
+level O
+of O
+lipid B
+peroxidation O
+was O
+higher O
+and O
+the O
+reduced O
+glutathione B
+concentration O
+was O
+lower O
+in O
+the O
+MA B
+- O
+treated O
+rats O
+. O
+
+These O
+changes O
+were O
+significantly O
+attenuated O
+by O
+alpha B
+- I
+TC I
+and O
+DFO B
+. O
+
+This O
+suggests O
+that O
+alpha B
+- I
+TC I
+and O
+DFO B
+ameliorate O
+the O
+MA B
+- O
+induced O
+neuronal O
+damage O
+by O
+decreasing O
+the O
+level O
+of O
+oxidative O
+stress O
+. O
+
+
+Cardiac O
+Angiography O
+in O
+Renally O
+Impaired O
+Patients O
+( O
+CARE O
+) O
+study O
+: O
+a O
+randomized O
+double O
+- O
+blind O
+trial O
+of O
+contrast B
+- O
+induced O
+nephropathy O
+in O
+patients O
+with O
+chronic O
+kidney O
+disease O
+. O
+
+BACKGROUND O
+: O
+No O
+direct O
+comparisons O
+exist O
+of O
+the O
+renal O
+tolerability O
+of O
+the O
+low O
+- O
+osmolality O
+contrast O
+medium O
+iopamidol B
+with O
+that O
+of O
+the O
+iso O
+- O
+osmolality O
+contrast O
+medium O
+iodixanol B
+in O
+high O
+- O
+risk O
+patients O
+. O
+
+METHODS O
+AND O
+RESULTS O
+: O
+The O
+present O
+study O
+is O
+a O
+multicenter O
+, O
+randomized O
+, O
+double O
+- O
+blind O
+comparison O
+of O
+iopamidol B
+and O
+iodixanol B
+in O
+patients O
+with O
+chronic O
+kidney O
+disease O
+( O
+estimated O
+glomerular O
+filtration O
+rate O
+, O
+20 O
+to O
+59 O
+mL O
+/ O
+min O
+) O
+who O
+underwent O
+cardiac O
+angiography O
+or O
+percutaneous O
+coronary O
+interventions O
+. O
+
+Serum O
+creatinine B
+( O
+SCr O
+) O
+levels O
+and O
+estimated O
+glomerular O
+filtration O
+rate O
+were O
+assessed O
+at O
+baseline O
+and O
+2 O
+to O
+5 O
+days O
+after O
+receiving O
+medications O
+. O
+
+The O
+primary O
+outcome O
+was O
+a O
+postdose O
+SCr O
+increase O
+> O
+or O
+= O
+0 O
+. O
+5 O
+mg O
+/ O
+dL O
+( O
+44 O
+. O
+2 O
+micromol O
+/ O
+L O
+) O
+over O
+baseline O
+. O
+
+Secondary O
+outcomes O
+were O
+a O
+postdose O
+SCr O
+increase O
+> O
+or O
+= O
+25 O
+%, O
+a O
+postdose O
+estimated O
+glomerular O
+filtration O
+rate O
+decrease O
+of O
+> O
+or O
+= O
+25 O
+%, O
+and O
+the O
+mean O
+peak O
+change O
+in O
+SCr O
+. O
+
+In O
+414 O
+patients O
+, O
+contrast B
+volume O
+, O
+presence O
+of O
+diabetes O
+mellitus O
+, O
+use O
+of O
+N B
+- I
+acetylcysteine I
+, O
+mean O
+baseline O
+SCr O
+, O
+and O
+estimated O
+glomerular O
+filtration O
+rate O
+were O
+comparable O
+in O
+the O
+2 O
+groups O
+. O
+
+SCr O
+increases O
+> O
+or O
+= O
+0 O
+. O
+5 O
+mg O
+/ O
+dL O
+occurred O
+in O
+4 O
+. O
+4 O
+% O
+( O
+9 O
+of O
+204 O
+patients O
+) O
+after O
+iopamidol B
+and O
+6 O
+. O
+7 O
+% O
+( O
+14 O
+of O
+210 O
+patients O
+) O
+after O
+iodixanol B
+( O
+P O
+= O
+0 O
+. O
+39 O
+), O
+whereas O
+rates O
+of O
+SCr O
+increases O
+> O
+or O
+= O
+25 O
+% O
+were O
+9 O
+. O
+8 O
+% O
+and O
+12 O
+. O
+4 O
+%, O
+respectively O
+( O
+P O
+= O
+0 O
+. O
+44 O
+). O
+
+In O
+patients O
+with O
+diabetes O
+, O
+SCr O
+increases O
+> O
+or O
+= O
+0 O
+. O
+5 O
+mg O
+/ O
+dL O
+were O
+5 O
+. O
+1 O
+% O
+( O
+4 O
+of O
+78 O
+patients O
+) O
+with O
+iopamidol B
+and O
+13 O
+. O
+0 O
+% O
+( O
+12 O
+of O
+92 O
+patients O
+) O
+with O
+iodixanol B
+( O
+P O
+= O
+0 O
+. O
+11 O
+), O
+whereas O
+SCr O
+increases O
+> O
+or O
+= O
+25 O
+% O
+were O
+10 O
+. O
+3 O
+% O
+and O
+15 O
+. O
+2 O
+%, O
+respectively O
+( O
+P O
+= O
+0 O
+. O
+37 O
+). O
+
+Mean O
+post O
+- O
+SCr O
+increases O
+were O
+significantly O
+less O
+with O
+iopamidol B
+( O
+all O
+patients O
+: O
+0 O
+. O
+7 O
+versus O
+0 O
+. O
+12 O
+mg O
+/ O
+dL O
+, O
+6 O
+. O
+2 O
+versus O
+10 O
+. O
+6 O
+micromol O
+/ O
+L O
+, O
+P O
+= O
+0 O
+. O
+3 O
+; O
+patients O
+with O
+diabetes O
+: O
+0 O
+. O
+7 O
+versus O
+0 O
+. O
+16 O
+mg O
+/ O
+dL O
+, O
+6 O
+. O
+2 O
+versus O
+14 O
+. O
+1 O
+micromol O
+/ O
+L O
+, O
+P O
+= O
+0 O
+. O
+1 O
+). O
+
+CONCLUSIONS O
+: O
+The O
+rate O
+of O
+contrast B
+- O
+induced O
+nephropathy O
+, O
+defined O
+by O
+multiple O
+end O
+points O
+, O
+is O
+not O
+statistically O
+different O
+after O
+the O
+intraarterial O
+administration O
+of O
+iopamidol B
+or O
+iodixanol B
+to O
+high O
+- O
+risk O
+patients O
+, O
+with O
+or O
+without O
+diabetes O
+mellitus O
+. O
+
+Any O
+TRUE O
+difference O
+between O
+the O
+agents O
+is O
+small O
+and O
+not O
+likely O
+to O
+be O
+clinically O
+significant O
+. O
+
+
+Estrogen B
+prevents O
+cholesteryl B
+ester I
+accumulation O
+in O
+macrophages O
+induced O
+by O
+the O
+HIV O
+protease O
+inhibitor O
+ritonavir B
+. O
+
+Individuals O
+with O
+HIV O
+can O
+now O
+live O
+long O
+lives O
+with O
+drug O
+therapy O
+that O
+often O
+includes O
+protease B
+inhibitors I
+such O
+as O
+ritonavir B
+. O
+
+Many O
+patients O
+, O
+however O
+, O
+develop O
+negative O
+long O
+- O
+term O
+side O
+effects O
+such O
+as O
+premature O
+atherosclerosis O
+. O
+
+We O
+have O
+previously O
+demonstrated O
+that O
+ritonavir B
+treatment O
+increases O
+atherosclerotic O
+lesion O
+formation O
+in O
+male O
+mice O
+to O
+a O
+greater O
+extent O
+than O
+in O
+female O
+mice O
+. O
+
+Furthermore O
+, O
+peripheral O
+blood O
+monocytes O
+isolated O
+from O
+ritonavir B
+- O
+treated O
+females O
+had O
+less O
+cholesteryl B
+ester I
+accumulation O
+. O
+
+In O
+the O
+present O
+study O
+, O
+we O
+have O
+investigated O
+the O
+molecular O
+mechanisms O
+by O
+which O
+female B
+hormones I
+influence O
+cholesterol B
+metabolism O
+in O
+macrophages O
+in O
+response O
+to O
+the O
+HIV O
+protease O
+inhibitor O
+ritonavir B
+. O
+
+We O
+have O
+utilized O
+the O
+human O
+monocyte O
+cell O
+line O
+, O
+THP O
+- O
+1 O
+as O
+a O
+model O
+to O
+address O
+this O
+question O
+. O
+
+Briefly O
+, O
+cells O
+were O
+differentiated O
+for O
+72 O
+h O
+with O
+100 O
+nM O
+PMA B
+to O
+obtain O
+a O
+macrophage O
+- O
+like O
+phenotype O
+in O
+the O
+presence O
+or O
+absence O
+of O
+1 O
+nM O
+17beta B
+- I
+estradiol I
+( O
+E2 B
+), O
+100 O
+nM O
+progesterone B
+or O
+vehicle O
+( O
+0 O
+. O
+1 O
+% O
+ethanol B
+). O
+
+Cells O
+were O
+then O
+treated O
+with O
+30 O
+ng O
+/ O
+ml O
+ritonavir B
+or O
+vehicle O
+in O
+the O
+presence O
+of O
+aggregated O
+LDL B
+for O
+24 O
+h O
+. O
+Cell O
+extracts O
+were O
+harvested O
+, O
+and O
+lipid B
+or O
+total O
+RNA O
+was O
+isolated O
+. O
+
+E2 B
+decreased O
+the O
+accumulation O
+of O
+cholesteryl B
+esters I
+in O
+macrophages O
+following O
+ritonavir B
+treatment O
+. O
+
+Ritonavir B
+increased O
+the O
+expression O
+of O
+the O
+scavenger O
+receptor O
+, O
+CD36 O
+mRNA O
+, O
+responsible O
+for O
+the O
+uptake O
+of O
+LDL B
+. O
+
+Additionally O
+, O
+ritonavir B
+treatment O
+selectively O
+increased O
+the O
+relative O
+levels O
+of O
+PPARgamma O
+mRNA O
+, O
+a O
+transcription O
+factor O
+responsible O
+for O
+the O
+regulation O
+of O
+CD36 O
+mRNA O
+expression O
+. O
+
+Treatment O
+with O
+E2 B
+, O
+however O
+, O
+failed O
+to O
+prevent O
+these O
+increases O
+at O
+the O
+mRNA O
+level O
+. O
+
+E2 O
+did O
+, O
+however O
+, O
+significantly O
+suppress O
+CD36 O
+protein O
+levels O
+as O
+measured O
+by O
+fluorescent O
+immunocytochemistry O
+. O
+
+This O
+data O
+suggests O
+that O
+E2 O
+modifies O
+the O
+expression O
+of O
+CD36 O
+at O
+the O
+level O
+of O
+protein O
+expression O
+in O
+monocyte O
+- O
+derived O
+macrophages O
+resulting O
+in O
+reduced O
+cholesteryl B
+ester I
+accumulation O
+following O
+ritonavir B
+treatment O
+. O
+
+
+Clinical O
+comparison O
+of O
+cardiorespiratory O
+effects O
+during O
+unilateral O
+and O
+conventional O
+spinal O
+anaesthesia O
+. O
+
+BACKGROUND O
+: O
+Spinal O
+anaesthesia O
+is O
+widely O
+employed O
+in O
+clinical O
+practice O
+but O
+has O
+the O
+main O
+drawback O
+of O
+post O
+- O
+spinal O
+block O
+hypotension O
+. O
+
+Efforts O
+must O
+therefore O
+continue O
+to O
+be O
+made O
+to O
+obviate O
+this O
+setback O
+OBJECTIVE O
+: O
+To O
+evaluate O
+the O
+cardiovascular O
+and O
+respiratory O
+changes O
+during O
+unilateral O
+and O
+conventional O
+spinal O
+anaesthesia O
+. O
+
+METHODS O
+: O
+With O
+ethical O
+approval O
+, O
+we O
+studied O
+74 O
+American O
+Society O
+of O
+Anesthesiologists O
+( O
+ASA O
+), O
+physical O
+status O
+class O
+1 O
+and O
+2 O
+patients O
+scheduled O
+for O
+elective O
+unilateral O
+lower O
+limb O
+surgery O
+. O
+
+Patients O
+were O
+randomly O
+allocated O
+into O
+one O
+of O
+two O
+groups O
+: O
+lateral O
+and O
+conventional O
+spinal O
+anaesthesia O
+groups O
+. O
+
+In O
+the O
+lateral O
+position O
+with O
+operative O
+side O
+down O
+, O
+patients O
+recived O
+10 O
+mg O
+( O
+2mls O
+) O
+of O
+0 O
+. O
+5 O
+% O
+hyperbaric O
+bupivacaine B
+through O
+a O
+25 O
+- O
+gauge O
+spinal O
+needle O
+. O
+
+Patients O
+in O
+the O
+unilateral O
+group O
+were O
+maintained O
+in O
+the O
+lateral O
+position O
+for O
+15 O
+minutes O
+following O
+spinal O
+injection O
+while O
+those O
+in O
+the O
+conventional O
+group O
+were O
+turned O
+supine O
+immediately O
+after O
+injection O
+. O
+
+Blood O
+pressure O
+, O
+heart O
+rate O
+, O
+respiratory O
+rate O
+and O
+oxygen B
+saturation O
+were O
+monitored O
+over O
+1 O
+hour O
+. O
+
+RESULTS O
+: O
+Three O
+patients O
+( O
+8 O
+. O
+1 O
+%) O
+in O
+the O
+unilateral O
+group O
+and O
+5 O
+( O
+13 O
+. O
+5 O
+%) O
+in O
+the O
+conventional O
+group O
+developed O
+hypotension O
+, O
+P O
+= O
+0 O
+. O
+71 O
+. O
+
+Four O
+( O
+10 O
+. O
+8 O
+%) O
+patients O
+in O
+the O
+conventional O
+group O
+and O
+1 O
+( O
+2 O
+. O
+7 O
+%) O
+in O
+the O
+unilateral O
+group O
+, O
+P O
+= O
+0 O
+. O
+17 O
+required O
+epinephrine B
+infusion O
+to O
+treat O
+hypotension O
+. O
+
+Patients O
+in O
+the O
+conventional O
+group O
+had O
+statistically O
+significant O
+greater O
+fall O
+in O
+the O
+systolic O
+blood O
+pressures O
+at O
+15 O
+, O
+30 O
+and O
+45 O
+minutes O
+when O
+compared O
+to O
+the O
+baseline O
+( O
+P O
+= O
+0 O
+. O
+3 O
+, O
+0 O
+. O
+1 O
+and O
+0 O
+. O
+4 O
+). O
+
+The O
+mean O
+respiratory O
+rate O
+and O
+oxygen B
+saturations O
+in O
+the O
+two O
+groups O
+were O
+similar O
+. O
+
+CONCLUSION O
+: O
+Compared O
+to O
+conventional O
+spinal O
+anaesthesia O
+, O
+unilateral O
+spinal O
+anaesthesia O
+was O
+associated O
+with O
+fewer O
+cardiovascular O
+perturbations O
+. O
+
+Also O
+, O
+the O
+type O
+of O
+spinal O
+block O
+instituted O
+affected O
+neither O
+the O
+respiratory O
+rate O
+nor O
+the O
+arterial O
+oxygen B
+saturation O
+. O
+
+
+Acute O
+effects O
+of O
+N B
+-( I
+2 I
+- I
+propylpentanoyl I
+) I
+urea I
+on O
+hippocampal O
+amino B
+acid I
+neurotransmitters I
+in O
+pilocarpine B
+- O
+induced O
+seizure O
+in O
+rats O
+. O
+
+The O
+present O
+study O
+aimed O
+to O
+investigate O
+the O
+anticonvulsant O
+activity O
+as O
+well O
+as O
+the O
+effects O
+on O
+the O
+level O
+of O
+hippocampal O
+amino O
+acid I
+neurotransmitters I
+( O
+glutamate B
+, O
+aspartate B
+, O
+glycine B
+and O
+GABA B
+) O
+of O
+N B
+-( I
+2 I
+- I
+propylpentanoyl I
+) I
+urea I
+( O
+VPU B
+) O
+in O
+comparison O
+to O
+its O
+parent O
+compound O
+, O
+valproic B
+acid I
+( O
+VPA B
+). O
+
+VPU B
+was O
+more O
+potent O
+than O
+VPA B
+, O
+exhibiting O
+the O
+median O
+effective O
+dose O
+( O
+ED O
+( O
+50 O
+)) O
+of O
+49 O
+mg O
+/ O
+kg O
+in O
+protecting O
+rats O
+against O
+pilocarpine B
+- O
+induced O
+seizure O
+whereas O
+the O
+corresponding O
+value O
+for O
+VPA B
+was O
+322 O
+mg O
+/ O
+kg O
+. O
+
+In O
+vivo O
+microdialysis O
+demonstrated O
+that O
+an O
+intraperitoneal O
+administration O
+of O
+pilocarpine B
+induced O
+a O
+pronounced O
+increment O
+of O
+hippocampal O
+glutamate B
+and O
+aspartate B
+whereas O
+no O
+significant O
+change O
+was O
+observed O
+on O
+the O
+level O
+of O
+glycine B
+and O
+GABA B
+. O
+
+Pretreatment O
+with O
+either O
+VPU B
+( O
+50 O
+and O
+100 O
+mg O
+/ O
+kg O
+) O
+or O
+VPA B
+( O
+300 O
+and O
+600 O
+mg O
+/ O
+kg O
+) O
+completely O
+abolished O
+pilocarpine B
+- O
+evoked O
+increases O
+in O
+extracellular O
+glutamate B
+and O
+aspartate B
+. O
+
+In O
+addition O
+, O
+a O
+statistically O
+significant O
+reduction O
+was O
+also O
+observed O
+on O
+the O
+level O
+of O
+GABA B
+and O
+glycine B
+but O
+less O
+than O
+a O
+drastic O
+reduction O
+of O
+glutamate B
+and O
+aspartate B
+level O
+. O
+
+Based O
+on O
+the O
+finding O
+that O
+VPU B
+and O
+VPA B
+could O
+protect O
+the O
+animals O
+against O
+pilocarpine B
+- O
+induced O
+seizure O
+it O
+is O
+suggested O
+that O
+the O
+reduction O
+of O
+inhibitory O
+amino O
+acid I
+neurotransmitters I
+was O
+comparatively O
+minor O
+and O
+offset O
+by O
+a O
+pronounced O
+reduction O
+of O
+glutamate B
+and O
+aspartate B
+. O
+
+Therefore O
+, O
+like O
+VPA B
+, O
+the O
+finding O
+that O
+VPU B
+could O
+drastically O
+reduce O
+pilocarpine B
+- O
+induced O
+increases O
+in O
+glutamate B
+and O
+aspartate B
+should O
+account O
+, O
+at O
+least O
+partly O
+, O
+for O
+its O
+anticonvulsant O
+activity O
+observed O
+in O
+pilocarpine B
+- O
+induced O
+seizure O
+in O
+experimental O
+animals O
+. O
+
+Some O
+other O
+mechanism O
+than O
+those O
+being O
+reported O
+herein O
+should O
+be O
+further O
+investigated O
+. O
+
+
+Delirium O
+in O
+a O
+patient O
+with O
+toxic O
+flecainide B
+plasma O
+concentrations O
+: O
+the O
+role O
+of O
+a O
+pharmacokinetic O
+drug O
+interaction O
+with O
+paroxetine B
+. O
+
+OBJECTIVE O
+: O
+To O
+describe O
+a O
+case O
+of O
+flecainide B
+- O
+induced O
+delirium O
+associated O
+with O
+a O
+pharmacokinetic O
+drug O
+interaction O
+with O
+paroxetine B
+. O
+
+CASE O
+SUMMARY O
+: O
+A O
+69 O
+- O
+year O
+- O
+old O
+white O
+female O
+presented O
+to O
+the O
+emergency O
+department O
+with O
+a O
+history O
+of O
+confusion O
+and O
+paranoia O
+over O
+the O
+past O
+several O
+days O
+. O
+
+On O
+admission O
+the O
+patient O
+was O
+taking O
+carvedilol B
+12 O
+mg O
+twice O
+daily O
+, O
+warfarin B
+2 O
+mg O
+/ O
+day O
+, O
+folic B
+acid I
+1 O
+mg O
+/ O
+day O
+, O
+levothyroxine B
+100 O
+microg O
+/ O
+day O
+, O
+pantoprazole B
+40 O
+mg O
+/ O
+day O
+, O
+paroxetine B
+40 O
+mg O
+/ O
+day O
+, O
+and O
+flecainide B
+100 O
+mg O
+twice O
+daily O
+. O
+
+Flecainide B
+had O
+been O
+started O
+2 O
+weeks O
+prior O
+for O
+atrial O
+fibrillation O
+. O
+
+Laboratory O
+test O
+findings O
+on O
+admission O
+were O
+notable O
+only O
+for O
+a O
+flecainide B
+plasma O
+concentration O
+of O
+1360 O
+microg O
+/ O
+L O
+( O
+reference O
+range O
+200 O
+- O
+1000 O
+). O
+
+A O
+metabolic O
+drug O
+interaction O
+between O
+flecainide B
+and O
+paroxetine B
+, O
+which O
+the O
+patient O
+had O
+been O
+taking O
+for O
+more O
+than O
+5 O
+years O
+, O
+was O
+considered O
+. O
+
+Paroxetine B
+was O
+discontinued O
+and O
+the O
+dose O
+of O
+flecainide B
+was O
+reduced O
+to O
+50 O
+mg O
+twice O
+daily O
+. O
+
+Her O
+delirium O
+resolved O
+3 O
+days O
+later O
+. O
+
+DISCUSSION O
+: O
+Flecainide B
+and O
+pharmacologically O
+similar O
+agents O
+that O
+interact O
+with O
+sodium B
+channels O
+may O
+cause O
+delirium O
+in O
+susceptible O
+patients O
+. O
+
+A O
+MEDLINE O
+search O
+( O
+1966 O
+- O
+January O
+2009 O
+) O
+revealed O
+one O
+in O
+vivo O
+pharmacokinetic O
+study O
+on O
+the O
+interaction O
+between O
+flecainide B
+, O
+a O
+CYP2D6 O
+substrate O
+, O
+and O
+paroxetine B
+, O
+a O
+CYP2D6 O
+inhibitor O
+, O
+as O
+well O
+as O
+3 O
+case O
+reports O
+of O
+flecainide B
+- O
+induced O
+delirium O
+. O
+
+According O
+to O
+the O
+Naranjo O
+probability O
+scale O
+, O
+flecainide B
+was O
+the O
+probable O
+cause O
+of O
+the O
+patient O
+' O
+s O
+delirium O
+; O
+the O
+Horn O
+Drug O
+Interaction O
+Probability O
+Scale O
+indicates O
+a O
+possible O
+pharmacokinetic O
+drug O
+interaction O
+between O
+flecainide B
+and O
+paroxetine B
+. O
+
+CONCLUSIONS O
+: O
+Supratherapeutic O
+flecainide B
+plasma O
+concentrations O
+may O
+cause O
+delirium O
+. O
+
+Because O
+toxicity O
+may O
+occur O
+when O
+flecainide B
+is O
+prescribed O
+with O
+paroxetine B
+and O
+other O
+potent O
+CYP2D6 O
+inhibitors O
+, O
+flecainide B
+plasma O
+concentrations O
+should O
+be O
+monitored O
+closely O
+with O
+commencement O
+of O
+CYP2D6 O
+inhibitors O
+. O
+
+
+Depression O
+, O
+impulsiveness O
+, O
+sleep O
+, O
+and O
+memory O
+in O
+past O
+and O
+present O
+polydrug O
+users O
+of O
+3 B
+, I
+4 I
+- I
+methylenedioxymethamphetamine I
+( O
+MDMA B
+, O
+ecstasy B
+). O
+
+RATIONALE O
+: O
+Ecstasy B
+( O
+3 B
+, I
+4 I
+- I
+methylenedioxymethamphetamine I
+, O
+MDMA B
+) O
+is O
+a O
+worldwide O
+recreational O
+drug O
+of O
+abuse O
+. O
+
+Unfortunately O
+, O
+the O
+results O
+from O
+human O
+research O
+investigating O
+its O
+psychological O
+effects O
+have O
+been O
+inconsistent O
+. O
+
+OBJECTIVES O
+: O
+The O
+present O
+study O
+aimed O
+to O
+be O
+the O
+largest O
+to O
+date O
+in O
+sample O
+size O
+and O
+5HT B
+- O
+related O
+behaviors O
+; O
+the O
+first O
+to O
+compare O
+present O
+ecstasy B
+users O
+with O
+past O
+users O
+after O
+an O
+abstinence O
+of O
+4 O
+or O
+more O
+years O
+, O
+and O
+the O
+first O
+to O
+include O
+robust O
+controls O
+for O
+other O
+recreational O
+substances O
+. O
+
+METHODS O
+: O
+A O
+sample O
+of O
+997 O
+participants O
+( O
+52 O
+% O
+male O
+) O
+was O
+recruited O
+to O
+four O
+control O
+groups O
+( O
+non O
+- O
+drug O
+( O
+ND O
+), O
+alcohol B
+/ O
+nicotine B
+( O
+AN O
+), O
+cannabis B
+/ O
+alcohol B
+/ O
+nicotine B
+( O
+CAN O
+), O
+non O
+- O
+ecstasy O
+polydrug O
+( O
+PD O
+)), O
+and O
+two O
+ecstasy O
+polydrug O
+groups O
+( O
+present O
+( O
+MDMA B
+) O
+and O
+past O
+users O
+( O
+EX O
+- O
+MDMA B
+). O
+
+Participants O
+completed O
+a O
+drug O
+history O
+questionnaire O
+, O
+Beck O
+Depression O
+Inventory O
+, O
+Barratt O
+Impulsiveness O
+Scale O
+, O
+Pittsburgh O
+Sleep O
+Quality O
+Index O
+, O
+and O
+Wechsler O
+Memory O
+Scale O
+- O
+Revised O
+which O
+, O
+in O
+total O
+, O
+provided O
+13 O
+psychometric O
+measures O
+. O
+
+RESULTS O
+: O
+While O
+the O
+CAN O
+and O
+PD O
+groups O
+tended O
+to O
+record O
+greater O
+deficits O
+than O
+the O
+non O
+- O
+drug O
+controls O
+, O
+the O
+MDMA B
+and O
+EX O
+- O
+MDMA B
+groups O
+recorded O
+greater O
+deficits O
+than O
+all O
+the O
+control O
+groups O
+on O
+ten O
+of O
+the O
+13 O
+psychometric O
+measures O
+. O
+
+Strikingly O
+, O
+despite O
+prolonged O
+abstinence O
+( O
+mean O
+, O
+4 O
+. O
+98 O
+; O
+range O
+, O
+4 O
+- O
+9 O
+years O
+), O
+past O
+ecstasy B
+users O
+showed O
+few O
+signs O
+of O
+recovery O
+. O
+
+Compared O
+with O
+present O
+ecstasy B
+users O
+, O
+the O
+past O
+users O
+showed O
+no O
+change O
+for O
+ten O
+measures O
+, O
+increased O
+impairment O
+for O
+two O
+measures O
+, O
+and O
+improvement O
+on O
+just O
+one O
+measure O
+. O
+
+CONCLUSIONS O
+: O
+Given O
+this O
+record O
+of O
+impaired O
+memory O
+and O
+clinically O
+significant O
+levels O
+of O
+depression O
+, O
+impulsiveness O
+, O
+and O
+sleep O
+disturbance O
+, O
+the O
+prognosis O
+for O
+the O
+current O
+generation O
+of O
+ecstasy B
+users O
+is O
+a O
+major O
+cause O
+for O
+concern O
+. O
+
+
+A O
+comparison O
+of O
+severe O
+hemodynamic O
+disturbances O
+between O
+dexmedetomidine B
+and O
+propofol B
+for O
+sedation O
+in O
+neurocritical O
+care O
+patients O
+. O
+
+OBJECTIVE O
+: O
+Dexmedetomidine B
+and O
+propofol B
+are O
+commonly O
+used O
+sedatives O
+in O
+neurocritical O
+care O
+as O
+they O
+allow O
+for O
+frequent O
+neurologic O
+examinations O
+. O
+
+However O
+, O
+both O
+agents O
+are O
+associated O
+with O
+significant O
+hemodynamic O
+side O
+effects O
+. O
+
+The O
+primary O
+objective O
+of O
+this O
+study O
+is O
+to O
+compare O
+the O
+prevalence O
+of O
+severe O
+hemodynamic O
+effects O
+in O
+neurocritical O
+care O
+patients O
+receiving O
+dexmedetomidine B
+and O
+propofol B
+. O
+
+DESIGN O
+: O
+Multicenter O
+, O
+retrospective O
+, O
+propensity O
+- O
+matched O
+cohort O
+study O
+. O
+
+SETTING O
+: O
+Neurocritical O
+care O
+units O
+at O
+two O
+academic O
+medical O
+centers O
+with O
+dedicated O
+neurocritical O
+care O
+teams O
+and O
+board O
+- O
+certified O
+neurointensivists O
+. O
+
+PATIENTS O
+: O
+Neurocritical O
+care O
+patients O
+admitted O
+between O
+July O
+2009 O
+and O
+September O
+2012 O
+were O
+evaluated O
+and O
+then O
+matched O
+1 O
+: O
+1 O
+based O
+on O
+propensity O
+scoring O
+of O
+baseline O
+characteristics O
+. O
+
+INTERVENTIONS O
+: O
+Continuous O
+sedation O
+with O
+dexmedetomidine B
+or O
+propofol B
+. O
+
+MEASUREMENTS O
+AND O
+MAIN O
+RESULTS O
+: O
+A O
+total O
+of O
+342 O
+patients O
+( O
+105 O
+dexmedetomidine B
+and O
+237 O
+propofol B
+) O
+were O
+included O
+in O
+the O
+analysis O
+, O
+with O
+190 O
+matched O
+( O
+95 O
+in O
+each O
+group O
+) O
+by O
+propensity O
+score O
+. O
+
+The O
+primary O
+outcome O
+of O
+this O
+study O
+was O
+a O
+composite O
+of O
+severe O
+hypotension O
+( O
+mean O
+arterial O
+pressure O
+< O
+60 O
+mm O
+Hg O
+) O
+and O
+bradycardia O
+( O
+heart O
+rate O
+< O
+50 O
+beats O
+/ O
+min O
+) O
+during O
+sedative O
+infusion O
+. O
+
+No O
+difference O
+in O
+the O
+primary O
+composite O
+outcome O
+in O
+both O
+the O
+unmatched O
+( O
+30 O
+% O
+vs O
+30 O
+%, O
+p O
+= O
+0 O
+. O
+94 O
+) O
+or O
+matched O
+cohorts O
+( O
+28 O
+% O
+vs O
+34 O
+%, O
+p O
+= O
+0 O
+. O
+35 O
+) O
+could O
+be O
+found O
+. O
+
+When O
+analyzed O
+separately O
+, O
+no O
+differences O
+could O
+be O
+found O
+in O
+the O
+prevalence O
+of O
+severe O
+hypotension O
+or O
+bradycardia O
+in O
+either O
+the O
+unmatched O
+or O
+matched O
+cohorts O
+. O
+
+CONCLUSIONS O
+: O
+Severe O
+hypotension O
+and O
+bradycardia O
+occur O
+at O
+similar O
+prevalence O
+in O
+neurocritical O
+care O
+patients O
+who O
+receive O
+dexmedetomidine B
+or O
+propofol B
+. O
+
+Providers O
+should O
+similarly O
+consider O
+the O
+likelihood O
+of O
+hypotension O
+or O
+bradycardia O
+before O
+starting O
+either O
+sedative O
+. O
+
+
+Effects O
+of O
+dehydroepiandrosterone B
+in O
+amphetamine B
+- O
+induced O
+schizophrenia O
+models O
+in O
+mice O
+. O
+
+OBJECTIVE O
+: O
+To O
+examine O
+the O
+effects O
+of O
+dehydroepiandrosterone B
+( O
+DHEA B
+) O
+on O
+animal O
+models O
+of O
+schizophrenia O
+. O
+
+METHODS O
+: O
+Seventy O
+Swiss O
+albino O
+female O
+mice O
+( O
+25 O
+- O
+35 O
+g O
+) O
+were O
+divided O
+into O
+4 O
+groups O
+: O
+amphetamine B
+- O
+free O
+( O
+control O
+), O
+amphetamine B
+, O
+50 O
+, O
+and O
+100 O
+mg O
+/ O
+kg O
+DHEA B
+. O
+
+The O
+DHEA B
+was O
+administered O
+intraperitoneally O
+( O
+ip O
+) O
+for O
+5 O
+days O
+. O
+
+Amphetamine B
+( O
+3 O
+mg O
+/ O
+kg O
+ip O
+) O
+induced O
+hyper O
+locomotion O
+, O
+apomorphine B
+( O
+1 O
+. O
+5 O
+mg O
+/ O
+kg O
+subcutaneously O
+[ O
+sc O
+]) O
+induced O
+climbing O
+, O
+and O
+haloperidol B
+( O
+1 O
+. O
+5 O
+mg O
+/ O
+kg O
+sc O
+) O
+induced O
+catalepsy O
+tests O
+were O
+used O
+as O
+animal O
+models O
+of O
+schizophrenia O
+. O
+
+The O
+study O
+was O
+conducted O
+at O
+the O
+Animal O
+Experiment O
+Laboratories O
+, O
+Department O
+of O
+Pharmacology O
+, O
+Medical O
+School O
+, O
+Eskisehir O
+Osmangazi O
+University O
+, O
+Eskisehir O
+, O
+Turkey O
+between O
+March O
+and O
+May O
+2012 O
+. O
+
+Statistical O
+analysis O
+was O
+carried O
+out O
+using O
+Kruskal O
+- O
+Wallis O
+test O
+for O
+hyper O
+locomotion O
+, O
+and O
+one O
+- O
+way O
+ANOVA O
+for O
+climbing O
+and O
+catalepsy O
+tests O
+. O
+
+RESULTS O
+: O
+In O
+the O
+amphetamine B
+- O
+induced O
+locomotion O
+test O
+, O
+there O
+were O
+significant O
+increases O
+in O
+all O
+movements O
+compared O
+with O
+the O
+amphetamine B
+- O
+free O
+group O
+. O
+
+Both O
+DHEA B
+50 O
+mg O
+/ O
+kg O
+( O
+p O
+< O
+0 O
+. O
+5 O
+), O
+and O
+100 O
+mg O
+/ O
+kg O
+( O
+p O
+< O
+0 O
+. O
+1 O
+) O
+significantly O
+decreased O
+all O
+movements O
+compared O
+with O
+the O
+amphetamine B
+- O
+induced O
+locomotion O
+group O
+. O
+
+There O
+was O
+a O
+significant O
+difference O
+between O
+groups O
+in O
+the O
+haloperidol B
+- O
+induced O
+catalepsy O
+test O
+( O
+p O
+< O
+0 O
+. O
+5 O
+). O
+
+There O
+was O
+no O
+significant O
+difference O
+between O
+groups O
+in O
+terms O
+of O
+total O
+climbing O
+time O
+in O
+the O
+apomorphine B
+- O
+induced O
+climbing O
+test O
+( O
+p O
+> O
+0 O
+. O
+5 O
+). O
+
+CONCLUSION O
+: O
+We O
+observed O
+that O
+DHEA B
+reduced O
+locomotor O
+activity O
+and O
+increased O
+catalepsy O
+at O
+both O
+doses O
+, O
+while O
+it O
+had O
+no O
+effect O
+on O
+climbing O
+behavior O
+. O
+
+We O
+suggest O
+that O
+DHEA B
+displays O
+typical O
+neuroleptic B
+- O
+like O
+effects O
+, O
+and O
+may O
+be O
+used O
+in O
+the O
+treatment O
+of O
+schizophrenia O
+. O
+
+
+Aconitine B
+- O
+induced O
+Ca2 B
++ I
+overload O
+causes O
+arrhythmia O
+and O
+triggers O
+apoptosis O
+through O
+p38 O
+MAPK O
+signaling O
+pathway O
+in O
+rats O
+. O
+
+Aconitine B
+is O
+a O
+major O
+bioactive O
+diterpenoid I
+alkaloid I
+with O
+high O
+content O
+derived O
+from O
+herbal O
+aconitum B
+plants I
+. O
+
+Emerging O
+evidence O
+indicates O
+that O
+voltage O
+- O
+dependent O
+Na B
+(+) I
+channels O
+have O
+pivotal O
+roles O
+in O
+the O
+cardiotoxicity O
+of O
+aconitine B
+. O
+
+However O
+, O
+no O
+reports O
+are O
+available O
+on O
+the O
+role O
+of O
+Ca B
+( I
+2 I
++) I
+in O
+aconitine O
+poisoning O
+. O
+
+In O
+this O
+study O
+, O
+we O
+explored O
+the O
+importance O
+of O
+pathological O
+Ca B
+( I
+2 I
++) I
+signaling O
+in O
+aconitine O
+poisoning O
+in O
+vitro O
+and O
+in O
+vivo O
+. O
+
+We O
+found O
+that O
+Ca B
+( I
+2 I
++) I
+overload O
+lead O
+to O
+accelerated O
+beating O
+rhythm O
+in O
+adult O
+rat O
+ventricular O
+myocytes O
+and O
+caused O
+arrhythmia O
+in O
+conscious O
+freely O
+moving O
+rats O
+. O
+
+To O
+investigate O
+effects O
+of O
+aconitine B
+on O
+myocardial O
+injury O
+, O
+we O
+performed O
+cytotoxicity O
+assay O
+in O
+neonatal O
+rat O
+ventricular O
+myocytes O
+( O
+NRVMs O
+), O
+as O
+well O
+as O
+measured O
+lactate O
+dehydrogenase O
+level O
+in O
+the O
+culture O
+medium O
+of O
+NRVMs O
+and O
+activities O
+of O
+serum O
+cardiac O
+enzymes O
+in O
+rats O
+. O
+
+The O
+results O
+showed O
+that O
+aconitine B
+resulted O
+in O
+myocardial O
+injury O
+and O
+reduced O
+NRVMs O
+viability O
+dose O
+- O
+dependently O
+. O
+
+To O
+confirm O
+the O
+pro O
+- O
+apoptotic O
+effects O
+, O
+we O
+performed O
+flow O
+cytometric O
+detection O
+, O
+cardiac O
+histology O
+, O
+transmission O
+electron O
+microscopy O
+and O
+terminal O
+deoxynucleotidyl O
+transferase O
+- O
+mediated O
+dUTP B
+- O
+biotin O
+nick O
+end O
+labeling O
+assay O
+. O
+
+The O
+results O
+showed O
+that O
+aconitine B
+stimulated O
+apoptosis O
+time O
+- O
+dependently O
+. O
+
+The O
+expression O
+analysis O
+of O
+Ca B
+( I
+2 I
++) I
+handling O
+proteins O
+demonstrated O
+that O
+aconitine B
+promoted O
+Ca B
+( I
+2 I
++) I
+overload O
+through O
+the O
+expression O
+regulation O
+of O
+Ca B
+( I
+2 I
++) I
+handling O
+proteins O
+. O
+
+The O
+expression O
+analysis O
+of O
+apoptosis O
+- O
+related O
+proteins O
+revealed O
+that O
+pro O
+- O
+apoptotic O
+protein O
+expression O
+was O
+upregulated O
+, O
+and O
+anti O
+- O
+apoptotic O
+protein O
+BCL O
+- O
+2 O
+expression O
+was O
+downregulated O
+. O
+
+Furthermore O
+, O
+increased O
+phosphorylation O
+of O
+MAPK O
+family O
+members O
+, O
+especially O
+the O
+P O
+- O
+P38 O
+/ O
+P38 O
+ratio O
+was O
+found O
+in O
+cardiac O
+tissues O
+. O
+
+Hence O
+, O
+our O
+results O
+suggest O
+that O
+aconitine B
+significantly O
+aggravates O
+Ca B
+( I
+2 I
++) I
+overload O
+and O
+causes O
+arrhythmia O
+and O
+finally O
+promotes O
+apoptotic O
+development O
+via O
+phosphorylation O
+of O
+P38 O
+mitogen O
+- O
+activated O
+protein O
+kinase O
+. O
+